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List of definitions 
 
Autologous   transfer of material (cells, tissue) from a donor to him or herself 
Autograft    transplant from a donor to him or herself 
Allograft    transplant from genetically non-identical donor of same species 
Chondrocyte   cell embedded within the cartilage matrix 
Chondrogenesis  cartilage development/differentiation 
Collagen II   main collagen type in cartilage 
Collagen X   collagen type that is produced by hypertrophic chondrocytes in  
     endochondral ossification, in this thesis it is used as a marker for 
     terminal differentiation or hypertrophy 
Differentiation   process by which a cell becomes a more specialized cell type  
     (e.g. chondrocyte) 
Elastin    protein, main component of elastic fiber, present in elastic   
     cartilage 
Endochondral ossification formation of bone through a template of cartilage 
Expansion   proliferation (=cell divisions) of cells in vitro (to obtain sufficient  
     number of cells) 
Gene expression  conversion of the information encoded in a gene first into   
     messenger RNA and later to a protein 
Growth factor   protein that regulates cell growth, proliferation or differentiation 
Growth factor receptor a protein embedded in cell membrane that when bound to a  
     growth factor initiates an intracellular signaling pathway 
Hypertrophy   increase in cell size, often used as synonym for terminal   
     differentiation of chondrocytes as cells become larger during this 
     process 
In vitro    “within glass”, experiment in laboratory controlled environment 
In vivo    “within the living”, experiment in living organism 
Matrix    extracellular molecules surrounding the cells and providing  
     structural support to form the tissue    
Medium    fluid in which cells grow or differentiate in vitro 
Mesenchymal stem cell undifferentiated cell (for instance in bone-marrow), that can  
     differentiate in mesenchymal lineage  (i.e. connective tissue) 
Nude mouse   labarotory mouse with absent thymus, resulting in  inhibited  
     immune response 
Osteoblast   bone-forming cell  
Osteogenesis   bone development/differentiation 
Passage    cycle in in-vitro expansion 
Perichondrium   membrane lining cartilage, supplying cartilage with nutrients and 
     containing progenitor cells important for growth and repair of the 
     cartilage 
Pellet    construct of cells spinned down in a tube 
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Progenitor cell   undifferentiated precursor cell, only capable of differentiation into 
     its “target” cell 
Proteoglycan   a glycosaminoglycan linked to a protein forming a hydrophyllic  
     matrix molecule providing compression strength to cartilage 
Scaffold    porous biomaterial on which cells can be seeded, provides form 
     and biomechanical properties even if no extracellular matrix is yet 
     formed by the cells 
Stem cell    undifferentiated cell, capable of unlimited self-renewal and 
     differentiation into any specialized cell type 
Terminal differentiation final stage in chondrogenesis, characterized by a.o. collagen X,  
     also called hypertrophic differentiation 
Tissue engineering  an interdisciplinary field that applies the principles of engineering 
     and life sciences toward the development of biological substitutes 
     that restore, maintain, or improve tissue function or a whole organ 
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List of abbreviations 
 
BGP  β-glycerophosphate 
BMSC bone-marrow derived mesenchymal stem cell 
ECM  extracellular matrix 
GAG  glycosaminoglycan (an extracellular matrix molecule) 
FGF  fibroblast growth factor 
FGFR fibroblast growth factor receptor 
MMP13 matrix metallo preteinase 13, matrix degradation enzyme 
TGF-β transforming growth factor- β 
VEGF vascular endothelial growth factor 
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Cartilage has a very poor capacity for regeneration in vivo. In head and neck surgery 
cartilage defects are usually reconstructed with autologous cartilage from for instance the 
external ear or the ribs. Cartilage tissue engineering may be a promising alternative to 
supply tissue for cartilage reconstructions in otorhinolaryngology as well as in plastic surgery 
and orthopaedics. The aim of this thesis is to find new tools by which cartilage tissue 
engineering can be better controlled. In head and neck surgery it is important that tissue 
engineered cartilage is stable and does not mineralize when used for cartilage 
reconstructions. Therefore, in this thesis our primary focus was the generation of cartilage of 
a hyaline phenotype that does not mineralize when implanted in vivo. For this purpose we 
studied expanded chondrocytes and adult bone-marrow derived mesenchymal stem cells 
(BMSC). We hypothesize that new insights for cartilage tissue engineering can be gained by 
studying in-vivo cartilage development during embryonic development. As these processes 
may involve similar pathways, understanding these common pathways may lead to 
advances in cartilage tissue engineering. We concentrated on two growth factor signaling 
pathways known to be important for cartilage development: TGF-β and FGF.  
 As a background for the research in this thesis we will discuss the following topics in 
this general introduction: cartilage, cartilage defects in head and neck surgery, cartilage 
tissue engineering, embryonic chondrogenesis, and growth factors influencing 
chondrogenesis. We will conclude the general introduction with the aim and outline of this 
thesis. 
 
Cartilage 
Cartilage is a tissue with unique properties. It is avascular, aneural and alymphatic (1) and 
consists of only one cell type: the chondrocyte. These chondrocytes make up only 1-5% of 
the wet weight of cartilage, as they are embedded in a large amount of extracellular matrix 
(ECM). Nutritional supply of the chondrocytes is provided by the perichondrium, a fibrous 
membrane lining the cartilage, by diffusion through the ECM. The most abundant protein in 
the ECM is collagen II, which provides the tissue with tensile-strength (2). Proteoglycan is 
the second major class of matrix molecules, of which aggrecan is the most common. The 
large, hydrophilic proteoglycan molecules provides the tissue with compressive strength, by 
attracting large amounts of water to the cartilage matrix (2). In fact, water makes up 60-80% 
of the wet weight of cartilage (3). The ECM not only supplies the cartilage its biomechanical 
properties, but also represents the microenvironment of the chondrocytes. Chondrocytes are 
continuously in contact with the ECM through multiple receptors, and thus the ECM 
influences chondrocyte differentiation and function.   
 Classically, cartilage is subdivided in three subtypes based on differential molecular 
characteristics of the ECM: hyaline, elastic and fibrous cartilage. Hyaline cartilage has the 
highest collagen II content, and is found in the nasal septum, larynx, trachea, ventral sites of 
the ribs and the joints. Elastic cartilage, characterized by the presence of elastic fibers in the 
ECM, is found in the auricle and in the epiglottis. Fibrous cartilage contains a large amount 
of collagen I and is located in the menisci and the intervertebral disks.  
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 A fourth cartilage subtype could also be specified, although its presence is by definition 
transient: terminally differentiated or hypertrophic cartilage. It is found during the process of 
endochondral ossification, in which a cartilage template precedes the formation of bone (4; 
5). The skeletal bones as well as the ribs and the perpendicular plate of the nasal septum 
are formed this way. Chondrocytes in this cartilage template become terminally 
differentiated and express specific markers such as collagen X, MMP13, VEGF and alkaline 
phosphatase. This results in mineralization and degradation of the terminally differentiated 
cartilage, and attraction of  vasculature. This vasculature carries bone progenitor cells to the 
mineralized cartilage which results in replacement of the cartilage by bone (4; 5). 
 This classical subdivision based on matrix composition (the presence of collagen I, II, X 
or elastin) is arbitrary. Because of site-specific differences, for instance in mechanical stress 
load and nutritional properties, cartilage from different locations have adjusted to their 
specific physiological requirements. For instance, hyaline cartilage in the joints is built up of 
four zones with distinct characteristics, while hyaline cartilage in the nasal septum is more 
symmetrical.  
 Interestingly in this classical classification of cartilage subtypes an important difference 
is not taken into account:  whether or not a perichondrium is present. While articular hyaline 
cartilage has no perichondrium, both hyaline nasoseptal and elastic auricular cartilage are 
lined by perichondrium on both sides. This presence of a perichondrium is important as it is 
known that in this perichondrium undifferentiated progenitor cells reside that form new 
cartilage (6; 7; 8; 9). 
 An important problem for cartilage tissue is that despite these progenitor cells it has a 
very limited spontaneous healing capacity (10; 11; 12). As chondrocytes are embedded in 
extracellular matrix they are limited in migration to the defect. Furthermore, classic wound 
healing starts with an inflammatory phase in which proteolytic enzymes are produced to 
remove damaged extracellular matrix components so that newly formed tissue can fill in the 
defect. In contrast, in cartilage repair this phase is restricted as no matrix-degrading 
enzymes are produced by death chondrocytes present in the wound edges (13). As a 
consequence cartilage defects are usually repaired by fibrocartilage scar tissue, leading to 
permanent loss of the original structure and function. 
 
Cartilage defects in head and neck  
Cartilage provides flexibility and support to the surrounding tissue. In the head and neck 
area the major function of cartilage is to support the airway and therefore loss of cartilage 
may be a major clinical problem. Furthermore, cartilage is esthetically important as it defines 
the appearance of the face by offering support to the nose and external ear. Cartilaginous 
defects in the head and neck region may be due to congenital malformations, trauma or 
tumor resection. Cartilage has a limited intrinsic regeneration capacity in vivo and therefore 
implants are needed for reconstruction of this tissue.  
 Biomaterial implants are subdivided in autografts and allografts (14). Autografts are 
obtained from the patient and include cartilage or bone. Allografts or homologous grafts are 
derived from tissues donated by members of the same species and include irradiated 
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cartilage. Another option is alloplastic implants, which are synthetic biocompatible polymers 
(15). Autologous cartilage grafts have relatively high biocompatibility and low risk of infection 
and extrusion as compared with homografts and alloplastic implants and are therefore 
preferred (14; 15; 16). In head and neck surgery cartilage defects, for instance of the nose, 
auricle or larynx, are usually reconstructed with autologous cartilage from donor sites, such 
as the auricle and the ribs. A major disadvantage of autologous cartilage is its limited 
availability, especially in large reconstructions or after multiple surgeries. Moreover, donor-
site morbidity, such as pain and contour defects in costal cartilage (17) and hypoesthesia of 
the skin in auricular cartilage (18),  is likely to increase when more cartilage is harvested. An 
extra source of autologous cartilage would be desired. Therefore, autologous tissue-
engineered cartilage for reconstructions is a potential alternative. 
 
Cartilage tissue engineering 
Tissue engineering is an interdisciplinary field that applies the principles of engineering and 
life sciences toward the development of biological substitutes that restore, maintain, or prove 
tissue function or a whole organ As cartilage has a very limited spontaneous healing 
capacity (10; 11; 12) and autologous cartilage supply is limited, cartilage has become an 
important target in tissue-engineering research. As cartilage consists of only one cell type 
and does not contain blood vessels or neural innervations, it seems an easy tissue to 
engineer.  
 In orthopaedic surgery, cartilage tissue engineering has already been used clinically 
since the late 1980’s to treat focal joint defects with autologous chondrocyte implantation 
(19). In otorhinolaryngology and head and neck surgery, cartilage tissue engineering may 
offer a promising alternative for the current use of auricular or costal cartilage to reconstruct 
cartilage defects. Unfortunately, less research has been performed on cartilage tissue 
engineering in this specialty (20; 21). However, recent developments such as the first patient 
receiving a tissue-engineered trachea (22) underline the future possibilities of cartilage 
regenerative medicine. 
 A major drawback in head and neck surgery is the well-vascularized subcutaneous 
transplant site, which, in contrast to the immune-privileged region of the joint, poses the risk 
of a strong inflammatory response and resorption of the bioartificial cartilage (21). Therefore, 
not surprisingly, the use of (degradable) scaffolds to create a tissue-engineered cartilage 
construct has proved unsuccessful in the head and neck region (23; 24). It seems necessary 
to tissue engineer a construct of cartilage in vitro that consists of only cells and their ECM 
that has sufficient mechanical properties to support the surrounding tissues from the 
moment of implantation. 
 Different cell sources could be used to engineer cartilage. The most obvious choice for 
an autologous cell source is cartilage itself. Chondrocytes are isolated from the cartilage by 
degrading the matrix, and can then be expanded in vitro until a sufficient cell number is 
obtained. Chondrocytes are known to lose their cartilage phenotype during expansion, a 
process called dedifferentiation (25). However, these cells can be redifferentiated with 
growth factors, even after extensive cell-population doublings (26; 27; 28; 29). For research 
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purposes chondrocytes can be harvested as left-over material from patients undergoing 
surgery (for instance total knee replacement, protruding ear reconstruction or nose 
reconstruction). In this way chondrocytes isolated from for instance hyaline articular 
cartilage, hyaline nasoseptal cartilage or elastic auricular cartilage can be studied. 
 Another popular candidate cell source is adult mesenchymal stem cells (MSC), which 
can be isolated from different tissues such as bone marrow and adipose tissue (30; 31; 32). 
In this thesis we studied bone-marrow derived mesenchymal stem cells (BMSC). These 
cells are isolated from bone-marrow biopsies performed on patients undergoing total hip 
replacement. Like chondrocytes they can be expanded in vitro until a sufficient number is 
obtained. BMSC can undergo a lot more population doublings than chondrocytes without 
losing their chondrogenic potential. BMSC can be differentiated towards many other tissues 
besides cartilage (such as bone or fat) depending on which medium and  growth factors are 
used. Finally, BMSC can be harvested without creating a new (cartilaginous) defect. 
Therefore, BMSC are generally considered a popular cell source for tissue engineering.  
 An important requirement for tissue-engineered cartilage is that it is stable and will not 
mineralize when implanted in the body for reconstruction. Therefore, recent studies 
comparing different cell sources or culture systems did not only evaluate chondrogenic 
capacity, but also took the stability of the tissue-engineered cartilage in consideration. These 
studies demonstrated that, while articular chondrocytes produced hyaline cartilage that did 
not mineralize (33; 34), BMSC displayed signs of chondrocyte hypertrophy such as 
production of collagen X (33; 35; 36). Furthermore, cartilage that was produced by BMSCs 
mineralized in vivo (33; 37). Therefore, more research is warranted to tissue engineer 
hyaline cartilage from BMSC that does not mineralize when implanted in vivo.  
 Though articular chondrocytes produce hyaline cartilage, they are not a likely cell 
source for cartilage reconstructions in the head and neck. Chondrocytes isolated from 
auricular or nasal septum cartilage on the other hand have not been studied as extensively 
as articular chondrocytes, in particular it has not been investigated whether the cartilage 
produced by these chondrocytes mineralizes. In contrast to articular cartilage, auricular and 
nasoseptal cartilage is lined by a perichondrium. The inner layer of this perichondrium (the 
cambium) contains progenitor cells and is difficult to remove from the cartilage. As these 
progenitor cells are thus likely to be isolated alongside auricular and nasoseptal 
chondrocytes, one should not simply translate results from studies with articular 
chondrocytes to expanded auricular and nasoseptal chondrocytes.   
 
Embryonic chondrogenesis 
In vivo, cartilage is only formed during embryology. As cartilage tissue engineering and in-
vivo cartilage development during embryology may involve similar pathways, understanding 
these common pathways may lead to advances in cartilage tissue engineering. Embryonic 
cartilage development is primarily studied during the development of the limb (endochondral 
ossification). This means that the development of terminally differentiated cartilage is studied 
mostly.  
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 One important characteristic of embryonic chondrogenesis is that it is regulated 
through different stages. The first stage in embryonic limb development is the formation of a 
central mesenchymal condensation. This mesenchymal condensation results from an active 
cell movement towards the centre of the outgrowing limb bud and is characterized by 
expression of adhesion molecules, such as N-cadherin (38). As the cells in this 
condensation differentiate to chondrocytes, expression of the cell adhesion molecules is 
downregulated, while collagen II and SOX9 expression is upregulated and a cartilage 
template is formed that consists of a proteoglycan- and collagen II-rich matrix. Next, this 
cartilage becomes hypertrophic, characterized by a collagen X production, and ultimately it 
ossifies (5; 39). 
 Tissue engineering and embryonic development may involve similar signaling 
pathways. Therefore, combining these different fields in research and understanding 
common signaling pathways may lead to advances in tissue engineering. However, there 
are also fundamental differences in these models. Chondrogenically differentiating cells in 
the embryonic limb bud get signals from other cell types surrounding these cells, such as in 
the future perichondrium and the loose mesenchyme. The signals to these cells are hugely 
complex and involve pathways such as TGF-β, BMP, FGF, IHh, PTHrP and Wnt/ β-catenin 
(4). In cartilage tissue engineering on the other hand, generally only one cell population is 
present and the exogenous signals provided to these cells through the medium are 
simplified compared to the signaling in embryonic development. However, studying 
embryonic chondrogenesis may shed light into the possibilities to enhance the exogenous 
signal to better control chondrogenic differentiation.  
 
Growth factors influencing chondrogenesis 
In cartilage tissue engineering the exogenous signals provided to the cells through the 
medium are simplified compared to the signaling in embryonic cartilage development. For 
the redifferentiation of chondrocytes as well as for the differentiation of BMSC growth factors 
are used. Growth factors bind to receptors on the cell membrane and thereby start 
intracellular signaling pathways resulting in a change in gene expression of the cell: 
information encoded in the gene is conversed into messenger RNA and then into a protein. 
In cartilage tissue engineering growth factors are generally added to the chondrogenic 
medium throughout the culture period to study their effects. In embryonic chondrogenesis on 
the other hand a broad array of signaling pathways is produced by the surrounding cells 
depending on the stage of development. Still, studying embryonic chondrogenesis may shed 
light into the possibilities to enhance the exogenous signal in cartilage tissue engineering. 
 Transforming Growth Factor- β (TGF-β) is commonly used for chondrogenic 
differentiation of expanded chondrocyten and BMSC (40; 41), and the standard 
chondrogenic differentiation medium used in this thesis also contains TGF-β. Other growth 
factors are known for an additive effect on chondrogenic differentiation and cartilage matrix 
production, such as BMP and IGF (42). But growth factors are also important in regulating 
terminal differentiation of cartilage. As in cartilage tissue engineering, TGF- β plays an 
essential role in different stages of embryonic chondrogenesis (4).  
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 Fibroblast Growth Factor (FGF) signaling is also important for embryonic cartilage 
development as mutations in the receptors for these growth factors cause syndromes with 
abnormal skeletal development (43). Moreover, FGF2 is added during expansion of BMSC 
to delay loss of chondrogenic potential (44). Therefore, in this thesis we decided to focus on 
TGF-β and FGF signaling pathways.  
 
Aim and outline of this thesis 
The aim of this thesis is to find new tools by which cartilage tissue engineering can be better 
controlled. We hypothesize that new insights to control cartilage tissue engineering can be 
gained by studying in-vivo chondrogenesis during embryonic development. 
 In chapter 2 we studied the potential of expanded chondrocytes isolated from the 
external ear and the nasal septum as cell sources for cartilage tissue engineering. We 
investigated the general performance of these cells, focusing on subtype and stability of 
tissue-engineered constructs. We also performed a microarray study on expanded auricular 
and nasoseptal chondrocytes from the same donors in a first attempt to characterize these 
cells in more detail to evaluate differences as well as potential similarities in phenotype after 
expansion. 
 In the next chapters we focused on the potential of BMSC for cartilage tissue 
engineering. It is known that chondrogenically differentiated BMSC display signs of 
chondrocyte hypertrophy and mineralize in vivo and it has been said that this process 
resembles in-vivo endochondral ossification of the limbs. Therefore, in chapter 3 we 
compared chondrogenesis of in-vitro differentiated BMSC with embryonic limb development. 
First, we studied whether in-vitro chondrogenic differentiation of BMSC consist of the same 
three developmental stages as in-vivo embryonic chondrogenesis: condensation, 
differentiation and hypertrophy. As Fibroblast Growth Factor Receptors (FGFR) are known 
to play an important role in chondrogenic differentiation in embryonic limb development, we 
next investigated and compared FGFR expression in in-vivo embryonic limb development 
and in-vitro chondrogenesis of BMSC. Finally, to evaluate stage-specific modulation of 
chondrogenic differentiation of BMSC with different subtypes of FGF, we studied the effect 
of addition of FGF2 and FGF9 to the chondrogenic medium during different stages in the 
culture process.  
 Another important growth factor in chondrogenesis is TGF-β. TGF- β is commonly 
used to induce chondrogenic differentiation of BMSCs. Intra-cellular signaling of members of 
the TGF-β superfamily involves phosphorylation of Smads. In chapter 4 we investigated 
whether Smad2/3 and/or Smad1/5/8 are phosporylated in hyaline and terminally 
differentiated cartilage both in vivo and in vitro. Next, we evaluated the effect of blocking 
Smad2/3 or Smad1/5/8 phosphorylation on chondrogenic and terminal differentiation, as 
well as on mineralization by addition of blocking agents during different stages of 
chondrogenic differentiation of BMSC. 
 Three mammalian subtypes of TGF-β (TGF-β1, -β2, -β3) exist and all are commonly 
used in different laboratories. More importantly, results with one TGF-β subtype are often 
extrapolated to the other subtypes. In chapter 5 we studied the chondrogenic differentiation 
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induced by all three TGF-β subtypes, focusing on the amount of cartilage produced as well 
as the subtype and stability of the cartilage produced. 
 The results of chapter 3-6 indicated that chondrogenic differentiation of BMSC results 
in the formation of hypertrophic cartilage. Furthermore, it seemed that inhibition of 
hypertrophy was possible to a small extent but did not result in a truly hyaline phenotype. 
Therefore, in chapter 6, we aimed to review literature supplemented with own data to 
answer the question whether it is possible to generate stable hyaline cartilage form adult 
mesenchymal stem cells. Furthermore, knowledge from developmental biology about the 
differential development of hyaline and terminally differentiated cartilage was reviewed and 
studied for implications for cartilage tissue engineering. 
 The terminal differentiation and mineralization seen in chondrogenically differentiated 
BMSC is a problem for clinical translation of cartilage tissue engineering. However, as large 
bones are formed through endochondral ossification during in-vivo development, the 
terminal differentiation of BMSC may offer a new route to engineer bone. Standard practice 
to tissue engineer bone is stimulate BMSC in vitro toward the osteogenic lineage, thereby 
aiming at intramembranous bone formation. However, results of this approach have been 
disappointing due to core degradation and necrosis as a result of lack of vascularization. 
Therefore, in chapter 7 we studied the possibility to tissue engineering bone through 
endochondral ossification as an alternative approach. We tested how in-vitro differentiation 
of BMSCs along the osteogenic and chondrogenic lineages influences survival and 
osteogenesis in vivo. 
 Chapters 8-10 summarize and discuss the findings of this thesis. Some directions are 
given for further research with an emphasis on possibilities and difficulties of translating 
cartilage tissue engineering from research to clinical practice. 
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ABSTRACT 
 
The aim of this study was to evaluate the potential of culture-expanded human auricular and 
nasoseptal chondrocytes as cell source for regeneration of stable cartilage and to analyze 
the differences in gene-expression profile of expanded chondrocytes from these specific 
locations. Auricular chondrocytes in monolayer proliferated less and more slowly (two 
passages took 26.7±2.1 days and were reached in 4.37±0.30 population doublings) than 
nasoseptal chondrocytes (19.3±2.5 days; 5.45±0.20 population doublings). However, 
auricular chondrocytes produced larger pellets with more cartilage-like matrix than 
nasoseptal chondrocytes ( 2.2±0.71 vs 1.7±0.13 mm in diameter after 35 days of culture). 
Although the matrix formed by auricular and nasoseptal chondrocytes contained collagen X, 
it did not mineralize in an in-vitro model, nor after in-vivo subcutaneous implantation. A DNA-
microarray study on expanded auricular and nasoseptal chondrocytes from the same donors 
revealed 1090 differentially expressed genes. No difference was observed in the expression 
of known markers of chondrogenic capacity (e.g. collagen II, FGFR3, BMP2 and ALK1). The 
most striking differences were that the auricular chondrocytes had a higher expression of 
anabolic growth factors BMP5 and IGF1, while matrix-degrading enzymes MMP13 and 
ADAMTS5 were higher expressed in nasoseptal chondrocytes. This might offer a possible 
explanation for the observed higher matrix production by auricular chondrocytes. Moreover, 
chondrocytes isolated from auricular or nasoseptal cartilage had specific gene expression 
profiles even after expansion. These differently expressed genes were not restricted to 
known characterization of donor-site subtype (e.g. elastic), but were also related to 
developmental processes. 
Chondrogenic capacity of ear and nose chondrocytes 
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INTRODUCTION 
 
Developments in regenerative medicine offer promise for the reconstruction of damaged 
tissues and organs including cartilage (45). In orthopaedics, cartilage regenerative medicine 
is being used clinically to treat focal joint defects with autologous chondrocyte implantation 
(ACI) since the first study in patients in 1994 (46). For this procedure, expanded articular 
chondrocytes are used. In otorhinolaryngology and head and neck surgery, cartilage 
regenerative medicine may offer a promising alternative to the current use of auricular or 
costal cartilage to reconstruct cartilage defects. Unfortunately, less research has been 
performed on cartilage regenerative medicine in this specialty (20; 21). However, recent 
developments such as the first patient receiving a tissue-engineered trachea (47) and the 
clinical application of cultured autologous auricular chondrocytes to treat craniofacial or 
nasal augmentation (48) and microtia (49) underline the future possibilities of cartilage 
regenerative medicine. Naturally, in otorhinolaryngology and head and neck surgery 
chondrocyte sources other than articular cartilage might be a better choice. 
 To select a cartilage donor source for cell therapy, one should consider at least three 
important things: the amount of cartilage that can be harvested without doing harm to the 
function of the cartilage structure at the donor site, the invasiveness of the biopsy procedure 
and the difference in chondrogenic phenotype (e.g. hyaline vs. elastic) of the original tissue. 
From the first two standpoints nasoseptal and especially auricular cartilage should be 
considered as favorable chondrocytes sources. Although articular chondrocytes have been 
extensively characterized and studied for their chondrogenic regeneration potential, overall 
fewer studies using alternative cell sources have been published (29; 50; 51; 52). 
 Auricular cartilage is elastic from origin and expanded auricular chondrocytes may 
therefore produce a different cartilage matrix than expanded articular chondrocytes. Though 
harvesting nasoseptal cartilage would not be as minimally invasive as auricular cartilage, it 
does have the potential benefit to originate from hyaline cartilage. However, both donor cell 
sources differ from articular cartilage in one other major aspect: the presence of a 
perichondrium.  
 An important requirement for tissue-engineered cartilage is that it is stable and will not 
mineralize upon implantation for reconstruction. Therefore, recent studies comparing 
different cell sources or culture systems did not only evaluate chondrogenic capacity, but 
took the stability of the tissue-engineered cartilage in consideration; while articular 
chondrocytes produced stable hyaline cartilage that did not mineralize (33; 34), bone-
marrow derived mesenchymal stem cells (BMSC) displayed signs of chondrocyte 
hypertrophy, i.e. production of collagen X (33; 35; 36; 53; 54) and mineralized in vivo (33; 
55). In these comparisons auricular and nasoseptal chondrocytes were not taken into 
account. 
 Results from studies on expanded articular chondrocytes cannot be translated to 
expanded auricular or nasoseptal chondrocytes as auricular cartilage is elastic and auricular 
and nasoseptal cartilage differ from the former by their perichondrium.  While the outer 
fibrous perichondrium can be easily removed from cartilage, this is very difficult for the inner 
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layer (i.e. cambium) of the perichondrium. Undifferentiated progenitor cells in this cambium 
layer are responsible for new cartilage formation (6; 7; 8; 9), but it is possible that culturing 
progenitor cells from the cambium layer gives rise to rather unstable cartilage-like 
constructs, similar to those arising from BMSC. Therefore, it is essential to evaluate the 
mineralization potential of auricular and nasoseptal chondrocytes when considering them for 
reconstructions. To our knowledge this was never done before. 
 As expanded articular chondrocytes at the moment are clinically used for ACI, recent 
studies focus on better characterization of the molecular phenotype of the cells (56; 57). In 
fact, some markers are defined that are predictive of the capacity of these expanded 
chondrocytes to form stable cartilage (57; 58). Characterization might lead to more insight 
into the capacity of the cell sources. Furthermore, these types of characterizations before 
use can be expected to become more important in regenerative medicine. If culture-
expanded auricular or nasoseptal chondrocytes are to be used in the future clinically, they 
should also be better characterized. 
 In this study, we demonstrate the potential of human auricular and nasoseptal 
chondrocytes as cell source for cartilage regenerative medicine. We investigate the general 
performance of these cells, focusing on subtype and stability of tissue-engineered 
constructs. Finally, we performed a DNA microarray study on expanded auricular and 
nasoseptal chondrocytes from the same donors in a first attempt to characterize these cells 
in more detail to evaluate differences as well as potential similarities in phenotype after 
expansion.  
 
MATERIALS AND METHODS 
 
Cell sources 
From 4 donors (age 18, 26, 28, 47) undergoing rhinoplasty using ear cartilage, both ear and 
nasoseptal cartilage were obtained (MEC-2005-359). Additionally, auricular cartilage was 
obtained from in total 4 donors (age 5, 7, 9, 13) undergoing protruding ear reconstruction 
(MEC-2006-186). Nasoseptal cartilage was obtained as leftover material from 2 donors (age 
33, 65) undergoing rhinoplasty (MEC-2005-359).  
 The first aim of this study was to evaluate the potential of culture-expanded human 
auricular and nasoseptal chondrocytes as cell source for regeneration of stable cartilage. 
Because it is known from previous studies that articular chondrocytes form stable hyaline 
cartilage, without collagen X expression and mineralization (33; 34), we used these cells as 
negative controls for hypertrophic differentiation. Healthy, articular cartilage was obtained as 
leftover material from 2 donors (age 3, 8) undergoing triple arthrodesis to treat clubfoot 
deformity (MEC-2007-032). Because BMSC are known to become hypertrophically 
differentiated and mineralize in vivo (33; 35; 36; 54; 55) these cells were used as a positive 
control. BMSC were isolated from a femoral shaft biopsy of 4 donors (age 30, 42, 51, 60) 
undergoing total hip replacement, after informed consent had been obtained in accordance 
with the local ethical committee (MEC-2004-142).  
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Cell isolation and expansion 
For isolation of chondrocytes, cartilage slices were rinsed with saline after careful resection 
of the (fibrous) perichondrium, and subsequently digested through incubation for 2 hours at 
37oC with 2 mg/ml Pronase E (Sigma-Aldrich, St. Louis, MO, USA), followed by overnight 
incubation with 1.5 mg/ml Collagenase B (Boehringer Mannheim, Germany) in DMEM 
containing Glutamax (Gibco, Carlsbad, CA, USA) and 10% fetal calf serum (FCS) (Gibco). 
Next, cell suspensions were filtered through a 100 µm filter, centrifuged and washed with 
saline. For expansion, chondrocytes were seeded at a density of 7,500 cells/cm2 in 
“chondrocyte-expansion medium” (DMEM containing glutamax, with 10% FCS and 1.5 µg/ml 
fungizone (Gibco) and 50 µg/ml gentamicin (Gibco)). At subconfluency cells were trypsinized 
and further expanded. Chondrocytes from passage (P) 2 were used for the experiments. 
Small pieces of auricular and nasoseptal cartilage were kept aside for immunohistochemical 
characterization. 
 For isolation of BMSC the heparinized bone-marrow aspirate was seeded at a density 
of 2-5 x 105 cells/cm2 in “BMSC-expansion medium” (DMEM-LG (Gibco), supplemented with 
10% FCS, 1 ng/ml FGF2 (AbD Serotec, Kidlington, UK), 25 μg/ml ascorbic acid-2-phosphate 
(Sigma-Aldrich), 1.5 µg/ml fungizone and 50 µg/ml gentamicin). After 24 hours, nonadherent 
cells were washed off and adherent cells were further expanded. At subconfluency, BMSC 
were trypsinized, seeded at a density of 2,300 cells/cm2 and further expanded. BMSC 
passages 2-4 were used for the experiment.  
  
Chondrogenic differentiation  
Pellet culture  
To study cartilage subtype differentiation and stability in vitro, auricular and nasoseptal 
chondrocytes, as well as articular chondrocytes and BMSC as controls, were 
chondrogenically differentiated in pellet cultures. Cells were cultured in pellets by 
centrifuging aliquots of 2 x105 cells in 0.5 ml medium at 200 xg for 8 minutes in a 
polypropylene tube. Chondrogenic differentiation was induced by “chondrogenic 
differentiation medium” based on previous publications (27; 54; 59), consisting of DMEM 
containing Glutamax, ITS+1 (B&D Bioscience, Bedford, MA, USA), 40 μg/ml L-proline 
(Sigma-Aldrich), 1 mM sodium-pyruvate (Gibco), 5 µg/ml fungizone and 50 µg/ml 
gentamicin, 25 μg/ml ascorbic acid-2-phosphate, 10 ng/mL TGFβ2 (R&D systems, 
Minneapolis, MN, USA) and 10-7M dexamethasone (Sigma-Aldrich). The medium was 
changed two times a week.  
Flat constructs 
To study in-vivo stability of tissue-engineered cartilage from auricular and nasoseptal 
chondrocytes larger and flat constructs were used because these resemble the clinical need 
better than pellets. Auricular and nasoseptal chondrocytes from one donor (age 18) were 
used for this experiment. Aliquots of 5 x105  auricular chondrocytes or nasoseptal 
chondrocytes (suspended in 100 µl “chondrogenic differentiation medium”) were pipetted 
onto a dry 6.5-mm diameter, 0.4-µm pore size polycarbonate Transwell® filters (Corning 
B.V. Life Sciences, Schiphol-Rijk, the Netherlands), precoated with collagen II (Sigma-
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Aldrich), and centrifuged in a 24-well plate for 5 minutes at 200xg (60). Chondrocytes were 
cultured on “chondrogenic differentiation medium” with medium refreshment three times a 
week.   
 
General performance of auricular vs. nasoseptal chondrocytes  
To directly compare the performance of auricular and nasoseptal chondrocytes, ear and 
nasoseptal cartilage from the same donor were used, for a total of three donors (age 26, 28, 
47). The performance was evaluated in monolayer expansion by number of population 
doublings till subconfluency and time to subconfluency. All chondrocytes were expanded 
and trypsinized when subconfluency was reached. Chondrocytes from passage 2 were 
chondrogenically differentiated for 35 days in pellet culture. To measure the size of the 
chondrogenic pellet at day 35, a picture was taken of the intact pellet together with a stage 
micrometer at 10X magnification. Statistical analysis was performed using Microsoft Office 
Excel 2007. Values are represented as mean ± standard deviation (SD). To compare rate of 
expansion in auricular and nasoseptal chondrocytes from the same three donors, a paired t-
test was performed. To compare size of pellets and GAG amount an unpaired t-test was 
performed. The level of significance was set at a p value <0.05. 
 
Cartilage subtype differentiation 
Characterization of subtype differentiation was studied on pellet cultures at day 35 from 
auricular and nasoseptal chondrocytes from all donors. This was compared with pellet 
cultures from articular chondrocytes and BMSC which are known to produce respectively 
hyaline and hypertrophic cartilage, as well as with sections of native auricular and 
nasoseptal cartilage. In the flat constructs the cartilage subtype differentiation was evaluated 
before and after in-vivo implantation. Characterization of cartilage subtype differentiation 
was performed through immunohistochemistry of collagen II, collagen X, and elastin.  
To study the effect of passage number on subtype differentiation, chondrocytes from 2 
auricular, nasoseptal and articular donors were not only differentiated at passage 2 but also 
at passage 4 and 6.  
 
Stability of tissue-engineered cartilage  
To study the ability to mineralize the matrix as a measure of stability, 10 mM β-
glycerophosphate (BGP) was added to the medium of pellets after cartilage formation had 
started. Based on previous studies, BGP was added to the medium of auricular and 
nasoseptal chondrocytes from day 14 on, and these pellets were harvested at day 35. This 
experiment was performed with auricular and nasoseptal chondrocytes from 3 donors 
(auricular donors aged 9, 13 and 26, nasoseptal donors aged 26, 33 and 65). As a positive 
control for this in-vitro mineralization model, pellets of BMSC of 2 donors (age 30, 42) were 
used. Because of a later onset of cartilage differentiation in BMSC, BGP was added to 
medium of these pellets from day 35 on, and pellets were harvested at day 49. 
 To confirm the stable phenotype of auricular- and nasoseptal-derived tissue-
engineered constructs that was seen in the previous in-vitro model, a subsequent 
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experiment was performed implanting tissue-engineered constructs in-vivo. To directly 
compare the auricular and nasoseptal chondrocytes, cartilage from one single donor (age 
18) was used for this experiment and cells were trypsinized simultaneously. Cells were 
cultured on a Transwell filter as flat constructs because these resemble the clinical need 
better than pellets. As in the previous experiment cells were chondrogenically differentiated 
for 14 days. At this time, 6 flat constructs were harvested for histology and biochemistry and 
8 flat constructs were implanted into the back of a nude mouse. Four 6-weeks old, male 
NMRI nu/nu mice (Taconic, Germantown, NY, USA) were used. Two incisions were made 
along the central line of the spine of the mouse, one at the shoulders and one at the hips. 
Per mouse two auricular-chondrocyte constructs and 2 nasoseptal-chondrocyte constructs 
were implanted. Animals were terminated 6 weeks later to harvest the cartilage constructs 
for histology. This procedure was carried out with approval from the animal ethical 
committee (EUR1428).  
 
(Immuno)histochemistry 
Constructs were fixed in 4% formalin in phosphate-buffered saline (PBS), set in 2% agar, 
and embedded in paraffin. 
Immunohistochemistry for collagen II, collagen X, elastin and vimentine 
 Antigen retrieval for collagen II was performed through incubation with 0.1% pronase 
(Sigma-Aldrich) in PBS for 30 minutes, while antigen retrieval for collagen X required 0.1% 
pepsin (Sigma-Aldrich) in 0.5M acetic acid (pH=2.0) for 2 hours. Both collagen II and 
collagen X stainings continued with incubation with 1% hyaluronidase (Sigma-Aldrich) in 
PBS for 30 minutes. Antigen retrieval for elastin was performed through incubation with 
0.25% trypsin (Sigma) in PBS for 20 minutes.   
 Non-specific binding sites were blocked with 10% goat serum in PBS and sections 
were stained overnight with primary antibodies against collagen II (II/II6B3, Developmental 
Studies Hybridoma Bank, 1:100), collagen X (Quartett, Berlin, Germany, 1:10), and elastin 
(BA4, Sigma-Aldrich, 1:1000). To allow the use of monoclonal mouse antibodies on tissue-
engineered cartilage constructs implanted in a nude mouse, we used a method described by 
Hierck et al (61). An alkaline-phosphatase-conjugated secondary antibody was used, 
followed by incubation with Neu Fuchsin substrate (Chroma, Köngen, Germany) to 
demonstrate alkaline-phosphatase activity with a red staining. 
 To study whether the flat constructs harvested after in-vivo implantation were from 
human origin, a monoclonal mouse anti-human vimentin antibody (AMF-17b, Developmental 
Studies Hybridoma Bank, 1:40) was used. To exclude any unspecific binding of the vimentin 
antibody to mouse IgGs, the mouse-on mouse HRP-Polymer Kit (Biocare Medical, Concord, 
CA, USA) was used, according to manufacturer’s instructions with some small modifications. 
In short, slides were incubated in an aqueous 3% solution of hydrogen peroxidase, to inhibit 
any endogenous peroxidase and allow for a peroxidase-antiperoxidase staining method. 
Antigen retrieval for vimentin was performed through incubation in Rodent Decloaker® for 
60 minutes at 95˚C. Non-specific binding sites were blocked with Rodent Block M® and 
sections were stained overnight with vimentin (V6630, Sigma-Aldrich, 1:40). The MM-
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polymer-HRP® secondary antibody  was used, followed by incubation with 3’diamino-
benzidine chromogen solution (Sigma-Aldrich) to demonstrate positivity for the antibody with 
a brown staining. A mouse monoclonal negative control antibody (Dako) was used as an 
isotype control. Slides were counterstained with hematoxylin. 
Von Kossa/Thionin staining 
For evaluation of mineralization, slides were immersed in 5% silver nitrate solution (Sigma, 
St Louis, MO) for 10 minutes, rinsed in ultra pure water and exposed to light for 10 minutes. 
Excess silver nitrate was removed with 5% sodium-thiosulphate (Sigma, St Louis, MO) and 
cells were rinsed in distilled water. Sections were counterstained with 0.4% thionin in 0.01 M 
aqueous sodium acetate, pH 4.5 for 5 min, which aside from staining the nucleus also 
demonstrates glycosaminoglycan (GAG) content. 
  
Biochemistry  
Flat constructs were digested overnight at 56°C in 1mg/ml proteinase K (Sigma-Aldrich) in 
Tris/EDTA buffer (pH 7.6) containing 185 µg/ml iodoacetamide and 1 µg/ml pepstatin A 
(Sigma-Aldrich). GAG amount was quantified using dimethylmethylene blue (DMB) assay 
(62). The metachromatic reaction of GAG with DMB was monitored with a 
spectrophotometer, and the ratio A530:A590 was used to determine the GAG amount, using 
chondroitin sulfate C (Sigma) as a standard. To determine the amount of DNA, each 
proteinase K-digested sample (50 µl) was treated with 100 µl heparin (8.3 IU/ml in PBS) and 
50 µl ribonuclease A (50 µg/ml in PBS) for 30 min at 37°C. This was followed by adding 50 
µl ethidium bromide solution (25 µg/ml in PBS). Samples were analyzed on the Wallac 1420 
victor2 (Perkin-Elmer, Wellesley, MA, USA) using an extinction filter of 340 nm and an 
emission filter of 590 nm. For standards, calf thymus DNA (Sigma-Aldrich) was used. 
 Statistical analysis was conducted with Microsoft Office Excel 2007. Values are 
represented as mean ± standard deviation (SD). An unpaired t-test was performed to 
compare GAG amount. The level of significance was set at a p value of less than 0.05. 
 
Microarray study  
Both auricular and nasoseptal cartilage were harvested from the same donor, two donors in 
total (age 28, 47). Cells were trypsinized at 80% confluency, as judged by the same 
observer. To avoid a bias in gene-expression data by differences in culture procedures, all 
cells from P2, P4 and P6 were plated in 24 wells plate at high cell density (50,000 NC / cm2) 
in “chondrocyte-expansion medium”. After three days the medium was replaced, followed by 
harvesting of the cells exactly 24 hours later. Therefore, from each donor three samples per 
cell source were available, offering the possibility to statistically adjust for between-donor 
differences. Cells from P2, P4 and P6 were also chondrogenically differentiated in pellets to 
determine the chondrogenic capacity after expansion. 
 
RNA isolation and expression profiling 
For total RNA isolation, cells were manually homogenized in RNA-BeeTM (TEL-TEST, 
Friendswood, TX, USA). RNA was extracted with chloroform and purified from the 
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supernatant using the RNAeasy Micro Kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s guidelines with on-column DNA-digestion. Gene expression profiling was 
performed using Affymetrix 1.0 Human Exon ST arrays, representing all known genes 
(Affymetrix Inc., Santa Clara, CA, USA) according to the manufacturer’s instructions. The 
Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay (kit 900652; 1.0 µg of 
total RNA)  was used to generate amplified and biotinylated sense-strands DNA targets from 
the entire expressed genome. The manufacturer’s instruction (version 4, P/N 701880 Rev. 
4) was followed for the hybridization, washing, and scanning steps. Arrays were hybridized 
by rotating them at 60 rpm in the Affymetrix GeneChip hybridization oven at 45 ºC for 17 
hours. After hybridization, the arrays were washed in the Affymetrix GeneChip Fluidics 
station FS 450. Arrays were scanned using the Affymetrix GeneChip scanner 3000 7G 
system. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Pearson correlation matrix and sources of variation graph. A Pearson correlation 
coefficients for every combination of arrays. A high correlation (black) was revealed for each of the two 
tissues. Note that one array on auricular chondrocytes (donor 1, P2) did not show higher correlation to 
the arrays in the cluster of auricular chondrocytes and was therefore considered an outlier. B Sources of 
variation graph demonstrating that the variation in gene expression in the microarray samples was 
primarily due to cell source with an average F ratio of 5.32, and not to donor variation with an F ratio of 
1.76. 
 
 
Data extraction and statistical analyses  
For quality control, the Affymetrix CEL-files were first imported into Affymetrix Expression 
Console version 1.1 where control probes were extracted and normalized using the default 
RMA algorithm. The Area Under the Curve (AUC) of the Receiver Operator Characteristic 
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was calculated using positive and negative control probes. All arrays had an AUC score 
above the empirically defined threshold of 0.85 indicating a good separation of positive and 
negative controls. Pearson correlation coefficients were determined for each and every 
combination of arrays. For each of the two tissues a cluster of high correlation was revealed. 
One of the three auricular samples of one donor did not show higher correlation to the 
arrays in the cluster of its tissue and was therefore considered an outlier and excluded from 
further analysis (fig. 1). Next, the CEL-files were imported into Partek® Genomic Suite 
software (version 6.4, Partek Inc., St. Louis, MO, USA) where only core probe sets were 
extracted and normalized using the RMA algorithm with GC background correction. Core 
transcript summaries were calculated using the mean intensities of the corresponding probe 
sets, representing the quantitative expression levels of 17881 genes. 
 The correspondence of the replicate samples was confirmed using Principle 
Component Analysis (PCA) and Pearson correlation analysis. P-values and fold differences 
for the expression differences between auricular and nasoseptal chondrocytes were 
generated by applying an Anova model. P-values were corrected for multiple testing using 
the Benjamini–Hochberg method. Genes with p-values smaller than 0.05 and fold 
differences higher than 2 were functionally annotated and classified by using the functional 
annotation clustering tool of Database for Annotation, Visualization, and Integrated 
Discovery (DAVID) (http://david.abcc.ncifcrf.gov/) (63). 
 
Quantitative real-time RT-PCR 
To validate the results from the microarray analysis, the three genes with the highest fold 
difference between auricular and nasoseptal chondrocytes and the three genes with a fold 
difference closest to 2 were analyzed by RT-PCR. 
 Complementary DNA (cDNA) was made using RevertAid™ First Strand cDNA 
Synthesis Kit (MBI Fermentas, Germany) and polymerase chain reactions were performed 
using TaqMan® Universal PCR MasterMix (Applied Biosystems, Capelle a/d Ijssel, 
Netherlands) on an ABI PRISM® 7000 (Applied Biosystems, Foster City, CA, USA). Taqman 
gene-expression assays were purchased from Applied Biosystems for STEAP4 
(Hs00226415_m1), ALX1 (Hs00232518_m1), IL31RA (Hs00371172_m1), GRK5 
(Hs00992173_m1) and TMED3 (Hs00201251_m1). Primer sequences for GAPDH and 
PRG4 are described elsewhere (64). 
 Expression was normalized to GAPDH and expressed relatively using the 2-ΔCt 
formula (65). Subsequently, fold differences for each gene were calculated between 
auricular and nasoseptal chondrocytes. 
 
RESULTS 
 
General performance  
To directly compare the performance of auricular and nasoseptal chondrocytes, ear and 
nasoseptal cartilage from the same donor were used for this experiment, for a total of three 
donors (age 26, 28, 47). After isolation, the auricular chondrocytes adhering to the flask 
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varied tremendously in morphology and size while nasoseptal chondrocytes were all round 
and of similar size. Upon culturing the auricular chondrocytes became more and more 
uniform in their appearance. 
 Auricular chondrocytes had gone through 4.37 population doublings (SD ± 0.30) in two 
passages, while nasoseptal chondrocytes had gone through 5.45 population doublings (SD 
± 0.20) (p=0.026). It took 26.7 days (SD ± 2.1) for auricular chondrocytes and 19.3 (SD ± 
2.5) days for nasoseptal chondrocytes to perform 2 passages (p=0.014).   
 Chondrocytes isolated from auricular cartilage produced significantly larger (p=0.023) 
cartilage-like constructs (Fig. 2A-F). The average diameter of an auricular-chondrocyte pellet 
was 2.2 mm (SD ± 0.71), the average diameter of a pellet of nasoseptal chondrocytes was 
1.7 mm (SD ± 0.13).  
 
Cartilage subtype differentiation 
All pellets of expanded auricular and nasoseptal chondrocytes produced cartilage, as was 
evaluated with thionin staining showing proteoglycans and immunohistochemistry for 
collagen type II (Fig. 2A, 2D). Pellets of both auricular and nasoseptal chondrocytes 
expressed collagen X (Fig. 2B, 2E), independent of donor age or passage number, 
indicating hypertrophic differentiation. In comparison, articular chondrocytes produced 
abundant collagen type II but no collagen type X (Fig. 2G-H), as was also demonstrated in 
previous studies. BMSC, known for their potential to generate terminally differentiated 
chondrogenic pellets and the ability to mineralize, did indeed express both collagen II and 
collagen X in our experiment (Fig. 2I-J). Pellets of chondrocytes of all sources produced less 
cartilage-like matrix with increasing passage number (data not shown). 
  No elastin was detected in pellets from any of the cell sources, including auricular 
chondrocytes. Even after prolonged culturing (70 days) or when primary auricular 
chondrocytes were used, no elastin was observed in the matrix. This suggests that either 
the in-vitro model does not support elastin production of these cells, or that mature elastic 
chondrocytes are incapable of elastin synthesis. 
 In comparison, native nasoseptal cartilage stained positively for collagen II, but not for 
collagen X or elastin. Native auricular cartilage (independent of age) on the other hand 
stained positively for elastin, collagen type II, as well as collagen X. Therefore the tissue-
engineered differed molecularly from the native cartilage the chondrocytes were isolated 
from, as in vitro  nasoseptal chondrocytes produced collagen X and auricular chondrocytes 
did not produce any elastin.  
 
Stability of tissue-engineered cartilage  
Since auricular and nasoseptal chondrocytes formed cartilage positive for collagen X, a 
marker for hypertrophic cartilage, we studied the ability to mineralize as a measure of 
stability of the tissue-engineered cartilage formed by auricular and nasoseptal chondrocytes. 
In this in-vitro model chondrocytes from 1 common donor (age 26) as well as with 2 distinct 
donors (auricular donors aged 9 and 13, nasoseptal donors aged 33 and 65) were used. In 
auricular and nasoseptal chondrocyte pellets a collagen-II rich matrix had formed at day 14  
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Figure 2. Subtype differentiation and stability of tissue-engineered cartilage in pellet culture. 
After 35 days of culture on chondrogenicdifferentiation medium, auricular (A,B) and nasoseptal (D,E) 
chondrocytes had produced both collagen II and collagen X. Von Kossa/Thionin staining demonstrates 
a proteoglycan-rich matrix at day 35 without mineralization when BGP was added to the medium for the 
last 3 weeks (C,F). At day 35 articular chondrocytes had produced collagen II (G), but not collagen X 
(H) and BMSC had produced collagen II (I), as well as collagen X (J). Von Kossa/Thionin staining 
demonstrates abundant mineralization in BMSC pellets when BGP was added to the medium from day 
35-49 (K).Pellets of auricular and nasoseptal chondrocytes are from the same donor. Note that pellets 
of auricular chondrocytes (A-C) were larger and contained more cartilage-like matrix than nasoseptal 
chondrocytes (D-F). 
 
 
and collagen X was present at this time in the pellets of all except one nasoseptal 
chondrocyte donor. At the end of the culture period both collagen II and collagen X were 
observed in all pellets. 
Addition of β-glycerophosphate was used to evaluate the capacity to mineralize, 
resulting in a positive Von-Kossa staining in BMSC pellets (donor age 30, 42) which served 
as a positive mineralization control (Fig. 2K). No mineralization was observed in any of the 
pellets of either auricular or nasoseptal chondrocytes (Fig. 2C, 2F). 
 To compare the performance of auricular and nasoseptal chondrocytes in-vivo in an 
application set-up, auricular and nasoseptal cells were harvested from the one donor (age 
18) seeded in monolayer for expansion and trypsinized simultaneously. Nasoseptal 
chondrocytes had gone through 5.4 population doublings and auricular chondrocytes 
through 2.0 population doublings. 
Chondrogenic capacity of ear and nose chondrocytes 
 
 
31 
 After expansion in monolayer, flat constructs were made by seeding the cells in a 
Transwell culture system and culturing for 14 days on chondrogenic differentiation medium. 
Both auricular chondrocytes and nasoseptal chondrocytes had produced a cartilage-like 
matrix consisting of abundant collagen II and scarce collagen X expression. Similar to what 
was seen in the pellet cultures, cartilage constructs from auricular chondrocytes had 
produced more collagen II and were larger than constructs from nasoseptal chondrocytes. 
Moreover, biochemical analysis demonstrated that the matrix of auricular constructs 
contained significantly (p<0.0005) more GAG than matrix of nasoseptal constructs (20.8 ± 
5.2 µg GAG/µg DNA vs 7.8 ± 2.4 µg GAG/µg DNA). Therefore, the difference in size of the 
cartilage constructs was primarily due to matrix production and not proliferation. In 
agreement with these findings, flat constructs from auricular chondrocytes were more solid 
than flat constructs from nasoseptal chondrocytes. However, constructs from both cell 
sources were still very flexible and fragile after 14 days of in-vitro differentiation. 
 After six weeks of implantation in a nude mouse all cartilage constructs, except one 
from nasoseptal chondrocytes, were recognizable and could be harvested. Constructs from 
auricular chondrocytes were larger and therefore better recognizable in vivo than those from  
 
 
 
 
 
 
 
 
  
 
 
Figure 3. In-vivo stability of tissue-engineered 
cartilage in flat constructs. Characterization of tissue-
engineered constructs of auricular and nasoseptal 
chondrocytes after 14 days of in-vitro culture, followed 
by 6 weeks of in-vivo subcutaneous implantation. 
Constructs of both cell sources had produced abundant 
collagen II (A-B) and little collagen X (C-D). Constructs 
of auricular chondrocytes, but not nasoseptal 
chondrocytes, had produced elastin (E-F). Von 
Kossa/Thionin  staining demonstrated a proteoglycan-
rich matrix in constructs of both cell sources, but no 
mineralizations were observed (G-H). A positive 
vimentin-staining, sensitive for human vimentine only, 
demonstrates that the cartilage-like constructs are from 
human origin, while the surrounding fibrous tissue is 
from murine origin (I-J). Positivity for the antibody is 
demonstrated by a red (A-F) or brown (I-J) staining. 
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nasoseptal chondrocytes. Moreover, these constructs were stiff and strong on handling, 
while constructs from nasoseptal chondrocytes were still fragile and also macroscopically 
did not resemble cartilage. Immunohistochemistry demonstrated a rich collagen II and 
collagen X containing matrix in all harvested constructs of both cell sources (Fig. 3A-D). 
Elastin was demonstrated in the matrix of auricular-chondrocyte constructs, but not in 
nasoseptal chondrocytes (Fig. 3E-F). Von Kossa/Thionin staining demonstrated a 
proteoglycan-rich matrix in constructs from both cell sources, while no mineralization was 
present after 6 weeks of subcutaneous implantation (Fig. 3G-H). By means of a vimentin 
staining, the cartilage-like constructs were demonstrated to be of human origin, while 
surrounding fibrous tissue was of murine origin (Fig. 3I-J). 
 Therefore, after in-vivo implantation flat constructs derived from auricular chondrocytes 
did take on their stable native cartilage subtype, including elastin and collagen X production. 
Flat constructs derived from nasoseptal chondrocytes on the other hand did not as collagen 
X was still present in the matrix. However, though collagen X was present in flat constructs 
from both cell sources indicating hypertrophy, a stable cartilage was produced that did not 
mineralize.  
 
Microarray data 
In the two donors (age 28, 47) used for microarray study auricular chondrocytes had gone 
through 4.7 population doublings at P2 and nasoseptal chondrocytes had gone through 5.4 
population doublings. At P6 cells from both origins had gone through respectively 15.5 and 
14.2 population doublings. 
 Variation in gene expression in the microarray samples was primarily due to cell source 
with an average F ratio of 5.32, and not to donor variation with an F ratio of 1.76 (fig. 1). 
Further analysis demonstrated a group of 1090 genes whose expression was significantly 
different in auricular and nasoseptal chondrocytes (out of 17,881 studied genes in total), of 
which 487 genes showed a fold difference of 2 or more. No significant difference was 
observed in the expression of collagen II, FGFR3, BMP2, and ALK1 which were previously 
reported as markers predicting the capacity of expanded articular chondrocytes to produce 
cartilage (57).  
 Of these significantly differentially expressed genes, 58 genes were more than 5 fold 
higher expressed in auricular chondrocytes compared to nasoseptal chondrocytes (table 1). 
This list is headed by proteoglycan 4 (88x), a matrix molecule with a lubrication function. 
Surprisingly, two growth factors with a known anabolic effect on cartilage production were 
observed in this list of genes expressed higher in auricular chondrocytes than in nasoseptal 
chondrocytes: BMP5 (37x) and IGF1 (9x).  
 As expected from the production of elastin in vivo in the previous experiment, 8-times 
more elastin was expressed in auricular chondrocytes. Fibrillin 2, a glycoprotein essential for 
the formation of elastic fibers, was also expressed significantly higher (7x) in auricular 
chondrocytes (table 1). Other components of the elastic fiber, such as fibrillin 1 and 3 or the 
EMILINs (Elastin Microfibril Interface Located Protein), were not significantly differentially 
expressed.    
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Table 1. Genes expressed over 5 fold more in auricular chondrocytes compared to nasoseptal 
chondrocytes. 
Gene 
symbol 
 
Gene assignment 
Benjamini 
Hochberg 
Fold  
difference 
PRG4 proteoglycan 4  1.4E-3 88.0 
BMP5 bone morphogenetic protein 5  3.9E-4 37.0 
FGL2 fibrinogen-like 2  6.5E-3 36.4 
MAB21L2 mab-21-like 2 (C. elegans) 5.3E-4 30.2 
DLX5 distal-less homeobox 5  4.9E-4 25.4 
MEIS1 Meis homeobox 1  1.8E-4 23.4 
SEMA3E sema domain, immunoglobulin domain (Ig), short basic 
domain, secreted, (semaphorin) 3E  
1.9E-3 23.1 
FAM107A family with sequence similarity 107, member A  9.0E-4 22.2 
CCKAR cholecystokinin A receptor  2.3E-2 17.5 
OGN osteoglycin  1.8E-3 16.3 
MEIS2 Meis homeobox 2  1.8E-4 15.9 
CYP24A1 cytochrome P450, family 24, subfamily A, polypeptide 1  4.1E-3 13.1 
PI15 peptidase inhibitor 15  2.2E-3 12.9 
HMCN1 hemicentin 1  2.6E-3 12.4 
EVI1 ecotropic viral integration site 1  3.4E-4 12.2 
GREM2 gremlin 2, cysteine knot superfamily, homolog 
(Xenopus laevis)  
4.8E-3 12.0 
PTGS1 prostaglandin-endoperoxide synthase 1 (prostaglandin 
G/H synthase and cyclooxygenase)  
7.2E-3 10.9 
PCSK1 proprotein convertase subtilisin/kexin type 1  3.1E-3 10.5 
CHODL chondrolectin  3.1E-3 10.2 
AGPAT9 1-acylglycerol-3-phosphate O-acyltransferase 9  3.5E-3 10.1 
MKX mohawk homeobox 3.9E-4 10.1 
IGF1 insulin-like growth factor 1 (somatomedin C)  1.5E-3 9.4 
LRRC17 leucine rich repeat containing 17 1.2E-2 8.7 
NDP Norrie disease (pseudoglioma)  1.2E-3 8.4 
ELN elastin  7.2E-3 8.2 
FLRT2 fibronectin leucine rich transmembrane protein 2  7.2E-4 8.1 
NPTX2 neuronal pentraxin II  1.2E-3 7.9 
CGNL1 cingulin-like 1  1.1E-3 7.8 
LRFN5 leucine rich repeat and fibronectin type III domain 
containing 5 
1.8E-4 7.7 
NTNG1 netrin G1  2.5E-3 7.5 
PODXL podocalyxin-like  2.1E-3 7.3 
ELMO1 engulfment and cell motility 1  2.2E-4 7.3 
FBN2 fibrillin 2  7.9E-3 7.0 
GNG11 guanine nucleotide binding protein (G protein), gamma 
11 
9.8E-4 6.5 
KIAA0746 KIAA0746 protein 6.4E-4 6.5 
SFRP1 secreted frizzled-related protein 1  1.1E-2 6.5 
SAMD9 sterile alpha motif domain containing 9 7.8E-3 6.5 
COLEC12 collectin sub-family member 12 7.1E-4 6.4 
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CRIP1 cysteine-rich protein 1 (intestinal) 5.5E-3 6.4 
NOVA1 neuro-oncological ventral antigen 1  1.2E-3 6.3 
CLGN calmegin  6.4E-3 6.2 
PTPRU protein tyrosine phosphatase, receptor type, U  8.4E-4 6.2 
THBD thrombomodulin  1.5E-2 6.1 
EIF1AX eukaryotic translation initiation factor 1A, X-linked  2.7E-3 6.0 
RPS6KA5 ribosomal protein S6 kinase, 90kDa, polypeptide 5 1.2E-3 6.0 
ETV1 ets variant 1 3.9E-3 6.0 
ERG v-ets erythroblastosis virus E26 oncogene homolog 
(avian) 
7.5E-3 5.9 
HSD11B1 hydroxysteroid (11-beta) dehydrogenase 1  2.6E-2 5.8 
NGEF neuronal guanine nucleotide exchange factor 1.3E-3 5.8 
TIAM1 T-cell lymphoma invasion and metastasis 1 4.7E-3 5.8 
MATN2 matrilin 2 1.6E-3 5.8 
NPTX1 neuronal pentraxin I 1.6E-3 5.6 
CACNB2 calcium channel, voltage-dependent, beta 2 subunit 1.8E-2 5.5 
SPRY2 sprouty homolog 2 (Drosophila) 5.3E-3 5.4 
GALNT6 UDP-N-acetyl-alpha-D-galactosamine: polypeptide N-
acetylgalactosaminyltransferase 6 
1.0E-3 5.4 
DLX6 distal-less homeobox 6 1.6E-2 5.4 
G0S2 G0/G1switch 2 3.0E-3 5.3 
PITPNC1 phosphatidylinositol transfer protein, cytoplasmic 1 3.0E-3 5.1 
 
 
Table 2. Genes expressed over 5 fold more in nasoseptal chondrocytes compared to auricular 
chondrocytes. 
Gene 
symbol 
 
Gene assignment 
Benjamini 
Hochberg 
Fold  
difference 
STEAP4 STEAP (Six Transmembrane Epithelial Antigen of the 
Prostate)  family member 4 
1.5E-3 85.7 
ALX1 ALX homeobox 1  1.7E-4 43.6 
CPA4  carboxypeptidase A4  3.2E-3 41.4 
MMP13 matrix metallopeptidase 13 (collagenase 3) 3.4E-2 39.0 
SLPI secretory leukocyte peptidase inhibitor 2.8E-3 32.3 
BEX1 brain expressed, X-linked 1 1.5E-3 29.0 
ACTG2 actin, gamma 2, smooth muscle, enteric  8.8E-4 27.0 
VCAM1 vascular cell adhesion molecule 1  1.0E-2 24.2 
KIAA1199 KIAA1199  4.4E-2 16.8 
CH25H cholesterol 25-hydroxylase 9.7E-4 16.3 
CHRDL1 chordin-like 1  5.5E-3 14.0 
BAMBI BMP and activin membrane-bound inhibitor homolog  4.7E-3 14.0 
KCNK2 potassium channel, subfamily K, member 2 1.7E-4 13.6 
DSP desmoplakin  2.1E-3 13.2 
CABLES1 Cdk5 and Abl enzyme substrate 1  2.5E-3 11.5 
VAMP8 vesicle-associated membrane protein 8 (endobrevin) 3.6E-3 11.3 
PLK2 polo-like kinase 2 (Drosophila)  1.1E-3 10.5 
TOX thymocyte selection-associated high mobility group box 7.2E-4 10.2 
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COL11A1 collagen, type XI, alpha 1 1.2E-2 9.9 
SERPINB7 serpin peptidase inhibitor, clade B (ovalbumin), member 
7 
1.1E-2 9.0 
PTGS2 prostaglandin-endoperoxide synthase 2 (prostaglandin 
G/H synthase and cyclooxygenase) 
1.4E-2 8.4 
ITM2C integral membrane protein 2C  3.7E-2 8.3 
THBS1 thrombospondin 1  3.3E-2 7.8 
ACTA2 actin, alpha 2, smooth muscle, aorta  1.0E-2 7.7 
ST6GAL1 ST6 beta-galactosamide alpha-2,6-sialyltranferase 1  2.0E-2 7.1 
KRTAP2-2 keratin associated protein 2-2  1.8E-2 7.1 
TFAP2B transcription factor AP-2 beta (activating enhancer 
binding protein 2 beta) 
7.9E-4 6.9 
P4HA3 prolyl 4-hydroxylase, alpha polypeptide III 7.2E-4 6.8 
SEMA3A sema domain, immunoglobulin domain (Ig), short basic 
domain 
2.5E-2 6.7 
GALNT3 UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-
acetylgalactosaminyltransferase 3 (GalNAc-T3)  
6.1E-3 6.7 
PLA1A phospholipase A1 member A  2.4E-2 6.6 
EYA1 eyes absent homolog 1 (Drosophila)  4.8E-3 6.2 
SGIP1 SH3-domain GRB2-like (endophilin) interacting protein 1  1.1E-3 5.9 
KCNE4 potassium voltage-gated channel, Isk-related family, 
member 4 
1.5E-2 5.8 
FZD7 frizzled homolog 7 (Drosophila) 2.3E-3 5.6 
DOCK10 dedicator of cytokinesis 10  1.7E-2 5.6 
TLR4 toll-like receptor 4  2.2E-3 5.5 
EVI2B ecotropic viral integration site 2B  4.7E-3 5.5 
RDH10 retinol dehydrogenase 10 (all-trans)  1.0E-2 5.5 
LRIG1 leucine-rich repeats and immunoglobulin-like domains 1  3.1E-3 5.4 
ADAMTS5 ADAM metallopeptidase with thrombospondin type 1  
motif, 5 
3.4E-2 5.4 
PDE5A phosphodiesterase 5A, cGMP-specific  2.0E-3 5.3 
SULF2 sulfatase 2  2.2E-3 5.2 
F2RL2 coagulation factor II (thrombin) receptor-like 2  1.8E-2 5.2 
RGMB RGM domain family, member B  2.3E-3 5.2 
LEPR leptin receptor  3.9E-3 5.1 
ME1 malic enzyme 1, NADP(+)-dependent, cytosolic  9.5E-4 5.1 
AGT angiotensinogen (serpin peptidase inhibitor, clade A, 
member 8 
1.8E-3 5.0 
PCDH10 protocadherin 10  9.0E-4 5.0 
 
 
Forty-nine genes were more than 5 fold higher expressed in nasoseptal chondrocytes (table 
2). In contrast, no anabolic growth factors were prominent among the genes that were 
higher expressed in nasoseptal chondrocytes than in auricular chondrocytes. In this list 
matrix degrading enzymes MMP13 (39x) and ADAMTS5 (5x) were prominent. 
The 487 genes that were significantly differentially expressed in auricular and naso-  
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Table 3. Results of functional annotation clustering.  
Annotation cluster 1  
Enrichment score 13.3 
 
count 
Benjamini- 
Hochberg 
• developmental process 172 9.9E-16 
• multicellular organismal development 136 1.2E-14 
• anatomical structure development 126 1.9E-13 
• system development 109 7.3E-13 
• nervous system development  59 6.5E-9 
• multicellular organismal process  168 7.1E-9 
• organ development 78 4.9E-8 
• cellular developmental process 96 5.3E-7 
• cell differentiation 96 5.3E-7 
Annotation cluster 2 
Enrichment score 4.83  
 
count 
Benjamini- 
Hochberg 
■ glycoprotein 185 3.4E-14 
■ signal 144 2.0E-10 
Δ signal peptide  135 4.3E-6 
Δ glycosylation site:N-linked (GlcNAc...) 158 7.1E-6 
• extracellular region 75 1.1E-5 
■ secreted 76 1.3E-5 
Δ disulfide bond 113 1.7E-2 
 
Table shows the two annotation clusters with the highest enrichment scores. The individual annotation 
terms are shown ( • Gene Ontology term ■ SP-PIR keyword Δ Uniprot sequence feature) that make up 
the enriched cluster. The number of genes that are involved in the individual term is shown in the next 
column (count). Finally, the Benjamini-Hochberg stepup (p-value) is shown for each individual term. 
 
 
 
septal chondrocytes with a fold difference of ≥2 were analyzed with Functional Annotation 
Clustering in DAVID (Table 3). This analysis indentified “development” as the most important 
process in which these genes are involved (enrichment score: 13.3).  Second in line of 
importance, were processes related to “glycoproteins” (enrichment score: 4.83). 
 To validate the microarray results, RT-PCR was performed on the three genes with the 
highest fold difference (STEAP4, PRG4, ALX1), as well as the three genes with a fold 
difference closest to 2 (TMED3, IL31RA, GRK5). PCR confirmed the trend and order of 
magnitude in fold difference as observed in the microarray data, indicating the reliability of 
the data sets (Table 4). 
 In conclusion, although no difference was observed in mRNA expression of known 
markers correlated with chondrogenic capacity, auricular chondrocytes do seem to be 
characterized by a higher expression of anabolic growth factors, while matrix degrading 
enzymes showed a higher expression in nasoseptal chondrocytes. Moreover, chondrocytes 
from different specific donor sites seem to preserve specific molecular characteristics even 
after expansion. These specific molecular signatures are not only indicative of cartilage 
subtype characteristics (e.g. elastic), but also reflect different developmental processes. 
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Table 4. RT-PCR validation of microarray. Fold 
differences in expression of STEAP4, PRG4, 
ALX1,TMED3, IL31RA and GRK5 are shown for both 
RT-PCR and microarray analysis. + indicates higher 
expression in auricular chondrocytes, while – indicates 
higher expression in nasoseptal chondrocytes. 
 
 
 
DISCUSSION 
 
This study demonstrates that both auricular and nasoseptal chondrocytes are promising 
candidate cell sources to generate cartilage for possible future reconstructions. Both cell 
sources were capable of producing cartilage. Though both produced collagen X, a marker 
for hypertrophic differentiation, tissue-engineered cartilage constructs (both pellets and flat 
constructs) of these cells were stable and did not mineralize. This was demonstrated in an 
in-vitro model, as well as in-vivo after subcutaneous implantation. A microarray study 
characterized these chondrocytes more profoundly, and revealed that chondrocytes from 
ear and nasal septum are different even after expansion and these differences provide 
possible explanations for the observed higher matrix production by auricular compared to 
nasoseptal chondrocytes.   
 This study was the first to examine subtype and stability of tissue-engineered 
constructs of human auricular and nasoseptal chondrocytes. Human cells were used in our 
study, while most other publications have studied chondrocytes from different locations in 
the body in rabbit (51), bovine (52), and porcine samples (66; 67; 68). Another strong point 
of this study was the elimination of donor differences which usually contributes to a lot of 
noise in the data sets. 
 In our study, auricular chondrocytes seemed to produce more cartilage than 
nasoseptal chondrocytes, confirming a previous study (50; 51). Although we cannot exclude 
that this was related to an increased proliferation rate of nasoseptal chondrocytes, a study 
performed by Tay et al (69) indicated that the increased proliferation rate of nasoseptal 
chondrocytes did not influence matrix production. Our microarray study did offer a possible 
explanation for the observed higher matrix production by auricular chondrocytes. It did not 
show a different expression of predictive markers of chondrogenic capacity in auricular or 
nasoseptal chondrocytes (collagen II, BMP2, FGFR3 or ALK1) (57). However, it did 
demonstrate that two growth factors with a known anabolic effect on cartilage matrix 
production, BMP5 (70) and IGF1 (71), were significantly higher expressed in auricular 
chondrocytes. On the other hand, two enzymes involved in cartilage matrix degradation, 
MMP13 and ADAMTS5, were expressed significantly higher in nasoseptal chondrocytes. 
This is in line with recent results of Asawa et al (50) who found a higher expression of 
MMP1, 2, 3 and 13 and cathepsin B in nasal septum chondrocytes compared to auricular 
chondrocytes in 3D conditions. In this study they also demonstrate that the expression of 
Gene Microarray RT-PCR 
STEAP4 -85.7 -259.8 
PRG4 +88.0 +170.9 
ALX1 -43.6 -22.5 
TMED3 -2.0 -1.3 
IL31RA +2.0 +9.8 
GRK5 -2.0 -1.6 
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MMP13 and cathepsin B was already higher in nasal chondrocytes compared to auricular 
chondrocytes in the monolayer condition. Moreover, in our study the cluster “glycoprotein” 
was identified by functional annotation clustering as a main target of the genes expressed 
differently in auricular and nasoseptal chondrocytes. 
 Cells isolated from auricular and nasoseptal cartilage produce collagen X as well as 
collagen II, confirming results of Naumann et al (72). The subtype of the original donor site 
does not influence terminal differentiation, as expanded auricular (elastic) and nasoseptal 
(hyaline) chondrocytes both produced collagen X, while this molecule is only present in 
native auricular cartilage. In addition, collagen X production was not induced by expansion 
and dedifferentiation as even primary auricular chondrocytes produced abundant collagen X. 
The observed difference between chondrocytes from articular joints and the head and neck 
area, could be caused by the presence of the perichondrium in both nasoseptal and 
auricular cartilage. The inner layer of the perichondrium is extremely difficult to separate 
from the underlying cartilage and is therefore likely contaminating cultures. Undifferentiated 
progenitor cells in this cambium layer are known for their capacity for cartilage regeneration 
(6; 7; 8; 9). This may explain why culturing chondrocytes with these progenitor cells from the 
cambium leads to a cartilage matrix which contains collagen X. Since pellets of both 
auricular and nasoseptal chondrocytes demonstrated collagen X in the matrix, we studied 
their tendency to mineralize in an in-vitro model. While BMSC mineralized in this in-vitro 
model, cartilage-like constructs of both auricular and nasoseptal chondrocytes did not and 
were considered stable. The stability of auricular and nasoseptal chondrocytes was further 
confirmed by implanting tissue-engineered constructs in vivo.  
 Although auricular chondrocytes had produced elastin after 6 weeks of in vivo 
implantation, preceded by 2 weeks of in-vitro differentiation, it was not produced after 10 
weeks of in-vitro culture alone, even when primary chondrocytes were used. Other studies 
have demonstrated as well that elastin was produced by expanded auricular chondrocytes 
implanted directly in vivo (29; 52; 73), while it was not demonstrated in in-vitro 
redifferentiated auricular chondrocytes (72). However, de Chalain et al (74) demonstrated 
that elastin production was stimulated in chondrocyte aggregates embedded in hydrogels 
containing alginate, collagen and κ-elastin. Though this study was performed on primary and 
not expanded chondrocytes, this indicates that choosing the appropriate in-vitro model and 
creating a microenvironment that sustains elastin production may be important to tissue-
engineer elastic cartilage although the prerequisites for elastin formation are still largely 
unknown. The presence of elastin in auricular constructs implanted in vivo, but not in 
nasoseptal constructs, indicates that these expanded cells have retained some 
characteristics of their native donor site. This was supported by our microarray study. In fact, 
1090 genes were expressed on a significant different level in auricular and nasoseptal 
chondrocytes, of which 487 genes had a fold difference of 2 or more. Fibrillin 2 and elastin 
were expressed significantly higher in auricular chondrocytes, indicating that a subtype-
specific phenotype was still present after expansion. More subtle differences, mostly in the 
field of developmental processes, were also observed between auricular and nasoseptal 
chondrocytes. Both auricular and nasoseptal cartilage are formed  in the embryo by neural 
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crest-derived cells, thereby differing from articular cartilage (75). But although the 
chondrocytes they derive form are from similar origins, auricular chondrocytes produce 
elastic and nasoseptal chondrocytes hyaline cartilage. Despite this fundamental difference, 
only little is known about the distinct development processes that lead to these different 
cartilage subtypes. From embryonic development, it is known that while hyaline cartilage is 
present in the nose of murine embryos from day 14 on (75), elastic cartilage in the ear does 
not mature until late fetal and early neonatal periods (76), suggesting that developmental 
differences in timing and molecular signaling may attribute to cartilage subtype 
differentiation. More  knowledge about these differential developmental processes may 
reveal clues for engineering specific subtypes of cartilage. For translation to clinical 
application the culture methods might be optimized, for example by using serum-free 
medium to expand the cells (77) or a lower oxygen tension (78). This might affect the gene 
expression profile as well as the amount and type of cartilage produced.   
 Our data indicate that using expanded chondrocytes from a donor-site that is not 
directly related to the host tissue, may result in cartilage regeneration of a different 
molecular character. Whether this may pose a clinical problem is not clear, as it is common 
practice in head and neck surgery to use auricular, elastic cartilage to repair hyaline 
cartilage defects of the nose. However, it does emphasize the importance to characterize 
auricular and nasoseptal chondrocytes and study them in more detail, as these cells seem 
to have great potential for cartilage regenerative medicine as they produce abundant, stable 
cartilage and can be harvested without doing harm to the donor-site in contrast to articular 
chondrocytes. 
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ABSTRACT 
 
Adult bone-marrow derived mesenchymal stem cells (BMSCs) are considered promising 
candidate cells for therapeutic cartilage and bone regeneration. Because tissue regeneration 
and embryonic development may involve similar pathways, understanding common 
pathways may lead to advances in regenerative medicine. In embryonic limb development 
Fibroblast Growth Factor Receptors (FGFR) play a role in chondrogenic differentiation. The 
aim of this study was to investigate and compare FGFR expression in in-vivo embryonic limb 
development and in-vitro chondrogenesis of BMSCs. Our study showed that  in in-vitro 
chondrogenesis of BMSCs three sequential stages can be found, as in embryonic limb 
development. A mesenchymal condensation (indicated by N-cadherin) is followed by 
chondrogenic differentiation (indicated by collagen II), and hypertrophy (indicated by 
collagen X). FGFR1-3 are expressed in a stage-dependent pattern during in-vitro 
differentiation and in-vivo embryonic limb development. In both models FGFR2 is clearly 
expressed by cells in the condensation phase. No FGFR expression was observed in 
differentiating and mature hyaline chondrocytes, while hypertrophic chondrocytes stained 
strongly for all FGFRs. To evaluate whether stage-specific modulation of chondrogenic 
differentiation in BMSCs is possible with different subtypes of FGF, FGF2 and FGF9 were 
added to the chondrogenic medium during different stages in the culture process (early or 
late). FGF2 and FGF9 differentially affected the amount of cartilage formed by BMSCs 
depending on the stage in which it was added. These results will help us understand the role 
of FGF signaling in chondrogenesis and find new tools to monitor and control chondrogenic 
differentiation. 
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INTRODUCTION 
 
The potential of cell therapy to stimulate tissue regeneration is currently under investigation. 
Adult bone-marrow derived mesenchymal stem cells (BMSCs) are a promising candidate 
cell source for this purpose because of the ease with which they can be isolated and 
expanded as well as their capacity for multilineage differentiation (79; 80).The possibility of 
regenerating cartilage with the aid of BMSCs is appealing since cartilage has a very limited 
spontaneous healing capacity (10; 11; 12). As cartilage consists of only one cell type and 
does not contain blood vessels or neural innervations, it seems an uncomplicated tissue to 
engineer. However, to obtain optimal results in reconstruction of cartilage from different 
anatomical locations, it will be crucial to generate cartilage of a specific subtype. Stable 
hyaline cartilage should be regenerated for articular surface regeneration, since (tissue-
engineered) hypertrophic cartilage may mineralize and perhaps even ossify in vivo via the 
endochondral route (33, 53). The generation of hypertrophic cartilage, on the other hand, 
could be advantageous for bone repair (53).  
 High-cell-density culture systems are helpful in the differentiation of BMSCs towards 
the chondrogenic lineage. For that reason, pellet culture is an accepted model to induce 
chondrogenic differentiation. However, BMSCs display signs of chondrocyte hypertrophy, 
such as production of collagen X and matrix mineralization during an in-vitro pellet culture 
period of several weeks (33; 53). Therefore, pellet culture of BMSCs has been claimed to be 
an in-vitro model for endochondral ossification (33). For cartilage regeneration, the 
consistent terminal hypertrophic differentiation of in-vitro differentiated BMSCs represents a 
lack of external control over their differentiation (33).  
 In embryology research, the development of the skeleton is a popular model to study 
chondrogenesis and endochondral ossification. The first stage of embryonic limb 
development is the formation of a mesenchymal condensation, characterized by the 
expression of cell adhesion molecules, such as N-cadherin.  As the cells in this 
condensation differentiate to chondrocytes, expression of the cell adhesion molecules is 
downregulated, while collagen II and SOX9 expression is upregulated and a cartilage 
template is formed that consists of a proteoglycan- and collagen II-rich matrix. Next, this 
cartilage becomes hypertrophic, characterized by a collagen X production, and ultimately it 
ossifies (5; 39). In embryonic limb development, Fibroblast Growth Factor Receptors 
(FGFR) 1-3 have been extensively studied since it was discovered that mutations in these 
receptors cause syndromes with abnormal skeletal development (43). Thus, studies have 
demonstrated that mRNA levels of FGFR2 are upregulated in the mesenchymal 
condensation, while FGFR3 is expressed during differentiation and FGFR1 during 
hypertrophy (43; 82; 83). 
 We hypothesize that the chondrogenic differentiation of BMSCs in pellet culture takes 
place in a similar fashion to embryonic endochondral ossification. The high-cell density that 
is used in this model, suggests that the chondrogenesis in this in-vitro model starts with cell 
condensation, as in embryonic chondrogenesis. This may then be followed by chondrocyte 
differentiation and terminal hypertrophic differentiation. Moreover, similar signaling clues 
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may be involved in in-vitro differentiation and embryonic development. As FGFR activation is 
associated with endochondral ossification during development it is likely that FGFR 
activation is related to the consistent terminal hypertrophic differentiation seen in BMSCs in 
culture. Although studies on mRNA level indicate an important role for FGFRs in embryonic 
endochondral ossification, data on protein level are lacking. Moreover, FGFR expression 
has never been studied extensively in in-vitro chondrogenesis of BMSCs.  
 We therefore analyzed the developmental stages (condensation, differentiation and 
hypertrophy) of in-vivo embryonic endochondral ossification of the limbs and in-vitro 
chondrogenic differentiation of bone-marrow derived BMSCs. We studied the expression of 
FGFR1-3 in these different developmental stages, and compared the expression patterns in 
both models. Finally, we added FGF2 and FGF9 to modulate FGF signaling during specific 
stages in chondrogenesis. Our ultimate goal is to learn from embryonic principles to find new 
tools to monitor and control chondrogenic differentiation in vitro.  
 
MATERIALS AND METHODS 
 
Embryonic chondrogenesis 
C57/BL6 female mice were intercrossed with CBA males (Charles River Laboratories, 
Wilmington, MA, USA). Gestational age was estimated by the vaginal plug method, with the 
day of plug occurrence designated as day 1 (E1). After gravid female mice had been killed 
by isoflurane inhalation, embryos were excised following cervical dilatation on E12, E13, 
E14, E16, E18 and immediately placed into Dulbecco’s phosphate-buffered saline (Gibco, 
Carlsbad, CA, USA). Embryonic age was determined by a combination of external features 
and somite count. 
 
Cell isolation and expansion 
Bone-marrow-derived BMSCs were isolated from femoral shaft biopsies of five patients (4 
females, 1 male, age 32-60) undergoing total hip replacement, after informed consent had 
been obtained in accordance with the local ethical committee (MEC 2004-142). The 
heparinized aspirate was seeded at a density of 2-5 x 105 cells/cm2 in expansion medium 
(Dulbecco’s Modified Eagle Medium (DMEM)- low glucose (Gibco), supplemented with 10% 
fetal calf serum (Gibco), 1 ng/ml FGF2 (AbD Serotec, Kidlington, UK), 25 μg/ml ascorbic 
acid-2-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 1.5 µg/ml fungizone (Gibco) and 50 
µg/ml gentamicin (Gibco)). After 24 hours, nonadherent cells were washed off and adherent 
cells were further expanded. At subconfluency, BMSCs were trypsinized, seeded at a 
density of 2,300 cells/cm2 and further expanded. BMSCs from passage 4 were used for the 
in-vitro differentiation experiment. 
 To examine FGFR expression during expansion, BMSCs from passage 4 were 
expanded in monolayer for another 4 days, followed by immunohistochemistry for FGFR1-3. 
To evaluate the effect of added FGF2 on FGFR expression, BMSCs from passage 3 were 
expanded either in medium containing FGF2 or in medium without FGF2, until 4 days into 
passage 4, when immunohistochemistry for FGFR1-3 was performed. 
FGFR in in-vitro and in-vivo chondrogenesis 
 
45 
In-vitro differentiation  
After expansion, BMSCs were cultured in pellets, formed by centrifuging aliquots of 2 x105 
cells in 0.5 ml medium at 200g for 8 minutes in a polypropylene tube. Pellets were 
differentiated in a humidified 37°C/5% CO2 incubator in DMEM containing Glutamax (Gibco), 
ITS+1 (B&D Bioscience, Bedford, MA, USA), 40 μg/ml L-proline (Sigma-Aldrich), 1 mM 
sodium-pyruvate (Gibco), 5 µg/ml fungizone and 50 µg/ml gentamicin, 25 μg/ml ascorbic 
acid-2-phosphate, 10 ng/mL TGFβ2 (R&D systems, Minneapolis, MN, USA) and 10-7M 
dexamethasone (Sigma-Aldrich).  
 Examination of FGFR expression during chondrogenesis was carried out with cells 
from 4 different donors. Pellets were sequentially harvested on different culture days in 
triplicate, for immunohistochemistry. Pellets from one donor were harvested in duplicate 
only, because of shortage in cell number. Pellets of donor 1 were used for additional gene-
expression analysis.  
 To study whether FGFR expression in our in-vitro model was regulated by culture 
conditions independent of chondrogenic differentiation, we used pellets from 1 donor at all 
experimental time points as a control cell population. These pellets were cultured without 
dexamethasone and did not undergo chondrogenic differentiation as was demonstrated with 
a negative collagen II staining after 35 days of culture. The absence of dexamethasone in 
the culture medium was the only difference with the experimental condition; the rest of the 
medium (including TGF-β) was the same. 
 
Modulation of FGF signaling 
To study whether stage-specific modulation of chondrogenesis is feasible with FGFs, we 
used BMSCs from two donors: donor 1 that was extensively studied in the previous 
experiment, as well as a new donor. Pellets were chondrogenically differentiated in the 
medium mentioned above (including TGF-β2).  5 nM FGF2 or FGF9 (both Peprotech, Rocky 
Hill, NJ, USA) was added to this medium either throughout the culture, during early 
differentiation (day 3-14), or during late differentiation (day 21-35). As a control, pellets were 
differentiated on chondrogenic medium without  FGF. Pellets were harvested in triplicate at 
day 35 for immunohistochemistry and biochemistry. Three control pellets were also 
harvested on day 21, to analyze the amount of matrix produced before FGF was added 
during late differentiation.   
 
Immunohistochemistry 
Embryonic limb specimens and pellets were fixed in 4% formalin in phosphate-buffered 
saline (PBS). Both pellets and limb specimens were embedded in paraffin, after pellets were 
set in 2% agar. BMSCs in monolayer were fixed for 15 minutes in 4% formalin. To reduce 
variability in histochemical results, all pellets were fixed overnight and stained in the same 
procedure. 
 To allow the use of monoclonal mouse antibodies on murine specimens, an earlier 
described method (61) was used to link the antibody with anti-mouse antiserum before 
immunohistochemistry. Antigen retrieval for collagen II was performed through incubation 
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with 0.1% pronase (Sigma-Aldrich) in PBS for 30 minutes, while antigen retrieval for 
collagen X required 0.1% pepsin (Sigma-Aldrich) in 0.5M acetic acid (pH=2.0) for 2 hours. 
Both staining continued with incubation with 1% hyaluronidase (Sigma-Aldrich) in PBS. A 
heat-induced epitope retrieval was performed for N-cadherin with Target Retrieval Solution 
(Dako, Glostrup, Denmark), according to the manufacturer’s guideline. No enzymatic steps 
were performed for FGFR1-3. 
 Non-specific binding sites were blocked with 10% goat serum in PBS and sections 
were incubated overnight with primary antibodies. Monoclonal antibodies directed against 
both murine and human antigens were available for N-cadherin (M3613, Dako), collagen II 
(II/II6B3, Developmental Studies Hybridoma Bank, Oiwa City, IA) and collagen X 
(2031501005, Quartett, Berlin, Germany). For FGFR1-3 only polyclonal antibodies were 
available which were directed to both murine and human tissues (sc-121, sc-122, sc-123, 
Santa Cruz Biotechnology, Santa Cruz, CA, USA). To study the reliability of the use of these 
polyclonal antibodies we immunohistochemically stained pellets (of human BMSCs) with 
both these polyclonal antibodies and with monoclonal antibodies against FGFR1 (ab829, 
Abcam, Cambridge, UK) and FGFR2 (MAB6843, R&D Systems). The staining produced by 
these polyclonal antibodies showed the same specificity as the staining produced by these 
monoclonal antibodies, suggesting that the use of polyclonal antibodies (necessary for 
directly comparing the human and murine model) did not affect the observed FGFR 
expression pattern. 
  An alkaline-phosphatase-conjugated secondary antibody was used, followed by 
incubation with Neu Fuchsin substrate (Chroma, Köngen, Germany) to demonstrate 
alkaline-phosphatase activity with a red stain. 
 In each staining procedure, a mouse monoclonal negative control antibody (Dako) was 
used as an isotype control for the murine antibodies (N-cadherin, collagen II, collagen X and 
the monoclonal FGFR1-2 antibodies). Rabbit immunoglobulin fraction (normal) (Dako) was 
used as a negative control for the polyclonal rabbit antibodies (polyclonal FGFR1-3 
antibodies). Negative controls were subject to the same antigen retrieval methods as the 
corresponding antibody. A staining was considered successful and used for analysis only if 
the control was negative. Slides were counterstained with hematoxylin. 
 To count the percentage of positive cells for FGFR1-3, the largest section of each 
pellet (section from the middle of the pellet) was selected. On this section the centre 
(approximately 50% of the total diameter) and periphery of the pellet were analyzed 
separately. A cell was considered positive when the cytoplasm stained red. To express a 
difference in staining intensity the percentage of positive cells was multiplied by a score of 1-
3, which represented an increasing intensity of the staining. This resulted in a maximum 
score of 300 per pellet, meaning that all cells were strongly stained.  
 N-cadherin was scored by counting the percentage of positive cells in the centre of the 
pellet, as condensation takes place there. 
 Scoring for collagen II and collagen X was done by calculating the percentage of the 
positive-staining surface in at least three different sections throughout a pellet, using a grid 
of 0.1 x 0.1 mm at 10x magnification. To express a difference in staining intensity this 
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percentage was multiplied by a score of 1-3, representing increasing intensity. This resulted 
in a maximum score of 300, representing the whole pellet stained intensively. 
 All scorings were performed blindly by two independent observers, and per pellet their 
scores were averaged. 
 
Gene expression analysis 
For total RNA isolation, pellets were manually homogenised in RNA-BeeTM (TEL-TEST, 
Friendswood, TX, USA). RNA was extracted with chloroform and purified from the 
supernatant using the RNAeasy Micro Kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s guidelines with on-column DNA-digestion.  
 RNA concentration and purity were assessed on a spectrophotometer (NanoDrop® 
ND-1000 UV-Vis Spectrophotometer, Isogen Life Science B.V., de Meern, The 
Netherlands). Complementary DNA (cDNA) was made using RevertAid™ First Strand cDNA 
Synthesis Kit (MBI Fermentas, St. Leon-Rot, Germany) and reverse transcription-
polymerase chain reactions (RT-PCR) were performed using TaqMan® Universal PCR 
MasterMix (Applied Biosystems, Capelle a/d Ijssel, Netherlands), as described earlier (84), 
but on an ABI PRISM® 7000 (Applied Biosystems, Foster City, CA, USA). Real-time RT-
PCR reactions for collagen II and collagen X are reported by de Mos et al (85). 
Oligonucleotide primers for FGFR assays were designed using PrimerExpress 2.0 software 
(Applied Biosystems, Foster City, CA, USA) to meet SYBRGreen I requirements; gene 
specificity was ensured by BLASTN search.  
 Primer sequences for the FGFRs were FGFR1_FwX2 (5’-
GTCTGCTGACTCCAGTGCAT-3’) and FGFR1_RvX2 (5’-GGTCTTCGGGAAGCTCATAC-
3’); FGFR2_Fw (5’- AGCGTTGCCATTCAAGTGACT -3’) and FGFR2_Rv (5’- 
CTACGCGCAATGCCTTCA -3’); FGFR3_FwX (5’- GCTGCCCGTGAAGTGGAT -3’) and 
FGFR3-RvX (5’-AGAGCAGGACCCCAAAGGA -3’). Primers for FGFR2 and FGFR3 were 
designed to detect all currently known isoforms. This was not possible for FGFR1 in a single 
assay and our primer set for FGFR1 detects all currently known splice variants except 
isoforms 5 and 6. This includes, but not discriminates between, the so-called isoforms IIIb 
and IIIc.  
 Amplification efficiencies of all assays were between 90-98% (data not shown). Data 
were normalized to GAPDH, which was stably expressed across all harvest days (data not 
shown), and presented as relative expression (65).  
 
Biochemistry  
Cartilage constructs were digested overnight at 56°C in 1mg/ml proteinase K (Sigma-
Aldrich) in Tris/EDTA buffer (pH 7.6) containing 185 µg/ml iodoacetamide and 1 µg/ml 
pepstatin A (Sigma-Aldrich). Glycosaminoglycan (GAG) content was quantified using 
dimethylmethylene blue (DMB) assay (62). The metachromatic reaction of GAG with DMB 
was monitored with a spectrophotometer, and the ratio A530:A590 was used to determine 
the GAG amount, using chondroitin sulfate C (Sigma-Aldrich) as a standard. To determine 
the amount of DNA, each proteinase K-digested sample was treated with 100 µl heparin (8,3 
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IU/ml in PBS) and 50 µl ribonuclease A (50 µg/ml in PBS) for 30 min at 37°C. This was 
followed by adding 50 µl ethidium bromide solution (25 µg/ml in PBS). Samples were 
analyzed on the Wallac 1420 victor2 (Perkin-Elmer, Wellesley, MA, USA) using an extinction 
filter of 340 nm and an emission filter of 590 nm. For standards, calf thymus DNA (Sigma-
Aldrich) was used. 
 
Statistical analysis 
Statistical analysis was conducted using the GraphPad Prism 5 (San Diego, CA, USA) 
software for Windows. Values are represented as mean ± SEM. To compare histological 
scores and gene expression of FGFRs of the different culture days, statistical analysis was 
performed using one-way ANOVA, followed by a Newman-Keuls test for multiple 
comparisons. To compare the histological score for the centre of the pellets with that in the 
periphery on a specific culture day, an unpaired t-test was performed. The same test was 
used to compare GAG content. The level of significance was set at a p value of less than 
0.05. 
 
RESULTS  
 
Embryonic chondrogenesis 
 
Condensation (E12) 
On embryonic (E) day 12, N-cadherin was observed in the mesenchymal condensation in 
the centre of the limb bud. Collagen II  stained only very weakly in the mesenchymal 
condensation on E12. No collagen X was seen at this stage (data not shown). 
 On E12 expression of FGFR1 was lower in the mesenchymal condensation than in the 
surrounding loose mesenchyme. In contrast, FGFR2 and FGFR3 expression were seen only 
in the mesenchymal condensation, although the staining for FGFR3 was not very strong (fig. 
1A-C). 
 
Differentiation (E13) 
At E13, multiple cartilage-like elements had formed, characterized by a collagen II rich 
matrix. No N-cadherin or collagen X was seen (data not shown). 
 At this stage, no expression of FGFR1-3 was seen in the differentiating chondrocytes 
(fig. 1D-F). FGFR1 and 2 were expressed in the periphery of the cartilage templates, 
outlining the future perichondrium. FGFR2 was also expressed in the mesenchyme located 
between the future skeletal elements. FGFR3 was not expressed anywhere at this stage. 
 
Hypertrophy (E14-18) 
The first signs of hypertrophy were seen at E14, characterized by a collagen X rich matrix 
(data not shown). These hypertrophic chondrocytes expressed FGFR1-3 at a high level, 
while the remaining differentiating chondrocytes showed no expression of FGFRs at all (fig. 
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1G-I). At E18, expression of FGFR1-3 was not only limited to hypertrophic chondrocytes, but 
was also expressed by some differentiating chondrocytes (fig. 1J-L).  
 
Figure 1. FGFR expression in embryonic chondrogenesis. Red staining demonstrates positivity for 
the antibody. A-C On E12, FGFR1 was expressed throughout the limb bud, but its expression was 
lower in the mesenchymal condensation (MC) than in the surrounding loose mesenchyme (L). In 
contrast, FGFR2 and FGFR3 were only expressed in the condensation. D-F Autopod skeletal elements 
of the forelimb are shown. On E13, no expression of FGFR1-3 was seen in the cartilage templates of 
the digits (C). The future perichondrium (P) expressed FGFR1 and 2, while the loose mesenchyme (L) 
between the cartilage templates expressed FGFR2. G-I On E14, hypertrophic chondrocytes (H) in the 
central area of the radius expressed all FGFRs, while differentiating chondrocytes did not express any 
FGFR. J-L On E18, expression of FGFR1-3 extended to differentiating chondrocytes (arrow), while no 
articular chondrocytes (A) expressed any FGFR, as is shown here in the first metacarpal phalangeal 
joint. Negative controls performed with rabbit immunoglobulin fraction (normal) did not show positive 
(red) staining. 
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Figure 2. Gene-expression analysis of chondrogenically differentiated BMSCs. Graphs show 
relative mRNA-expression (determined by RT-PCR) during culture of pellets of donor 1 (homogenous 
cartilage formation) (A) collagen II,(B) collagen X, (C) FGFR1, (D) FGFR2, and (E) FGFR3. Levels were 
calculated relative to GAPDH. All data are presented as mean ± SEM. Data are presented on a 
logarithmic scale. 
 
 
Articular cartilage (E16-E18) 
To evaluate the expression of FGFR1-3 in permanent cartilage the articular cartilage was 
studied. Interphalangeal joint cavitation was noted at E16 and E18. The joint surface of the 
phalanges was covered with a high density layer of differentiated chondrocytes not 
expressing FGFR1-3. No expression of FGFR1-3 was seen in these articular hyaline 
chondrocytes at any time point (fig. 1J-L). 
 
In-vitro chondrogenesis 
 
Differentiation stages 
After 35 days of culture, pellets of all donors had produced both collagen II and X, 
suggesting terminal hypertrophic cartilage differentiation. A large, swollen morphology of the 
BMSCs confirmed their hypertrophic differentiation. Only pellets of donor 1 homogeneously 
differentiated to cartilage. Of the other 3 donors only a limited area within the pellets showed 
collagen II and X production (20-75% of the area), indicating that only a subpopulation of the 
cells in these pellets chondrogenically differentiated during culture. Therefore, gene-
expression was performed on pellets of donor1, supporting the immuohistochemical results. 
mRNA levels of collagen II and collagen X gradually increased over time (fig. 2A-B), 
confirming the hypertrophic differentiation of BMSCs. 
N-cadherin was clearly expressed in the centre of the pellets of all donors on day 7-10, 
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indicating condensation stage. N-cadherin expression decreased before collagen II was 
produced, and increased again mildly during hypertrophy (fig. 3A-D). In donor 1, collagen II 
was observed on day 21 in the periphery of the pellet, whereas collagen X was still absent 
(fig. 3F,I). In pellets of two other donors a similar interval was seen between collagen II and 
X production, while one donor demonstrated the appearance of collagen X together with 
collagen II at day 21.  
 
 
 
Figure 3. Immunohistochemistry: markers of 
development in chondrogenically differentiated BMSCs. 
Red staining demonstrates positivity for the antibody. Pellets 
of donor 1 are shown because of homogenous 
chondrogenesis in these pellets. A,E On day 10, the BMSCs 
are in the condensation stage, indicated by a high amount of 
N-cadherin production in the centre of the pellets and a lack 
of collagen production. B,F,I On day 21, some BMSCs in the periphery of the pellets are 
chondrogenically differentiated, indicated by collagen II, while they are not yet fully hypertrophic, 
indicated by a lack of collagen X production. C,G,J On day 35 BMSCs in the pellets are hypertrophic 
differentiated, characterized by a swollen morphology, and collagen II and collagen X production. D 
Histological score for N-cadherin, collagen II, and collagen X during culture of the pellets, demonstrating 
stages of condensation, differentiation and hypertrophy during chondrogenesis.Note: when agar (a) is 
still present on the slide during the immunohistochemical staining procedure, it stains red in the Neu 
Fuchsin substrate. Negative controls performed with mouse monoclonal negative control antibody did 
not show positive (red) staining. 
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Figure 4. FGFR expression in BMSCs during expansion. Red staining demonstrates positivity for the 
antibody. Cells are not counterstained. During expansion FGFR1 (A) is highly expressed, while FGFR2 
(B) is expressed weakly, and FGFR3 (C) not at all. Negative controls performed with rabbit 
immunoglobulin fraction (normal) did not show positive (red) staining. 
 
 
FGFR expression  
During expansion, before differentiation in pellet cultures, all BMSCs stained brightly positive 
for FGFR1. No positive staining was seen for FGFR3 and only a very weak staining for 
FGFR2 (fig. 4). This expression pattern during expansion was not influenced by adding 
FGF2 to the culture medium (data not shown). 
 As BMSCs of donor 1 formed complete cartilaginous pellets, FGFR expression was 
scored semi-quantitatively in these pellets. The response of the BMSCs from the other 
donors were comparable to those of donor 1 within the cartilaginous regions. 
Condensation 
FGFR1 was clearly expressed in pellets of donor 1 at day 3, but was followed by a 
significant decrease during the condensation stage, day 7-10 (fig. 5A,D). In contrast, FGFR2 
showed a significant peak in expression in the centre of the pellets at day 10 (fig. 5E,H). The 
area of positive staining for FGFR2 overlapped the staining for N-cadherin, the marker for 
mesenchymal condensation (fig. 3A, 5E). Staining for FGFR3 was also somewhat positive in 
this condensing centre of the pellet (fig. 5I), but the difference in scores was not statistically 
significant (fig. 5L).  
 The N-cadherin positive centre stained clearly positive for FGFR2 in pellets of all other 
donors as well, and vaguely positive for FGFR3  in 2 of the 3 remaining donors. FGFR1 
staining was almost negative in this area. Thus, during the condensation stage FGFR2 in 
particular showed a peak in the expression in chondrogenically differentiating BMSCs. 
Differentiation 
 Increased positive staining for FGFR1 was seen in donor 1 on day 21 compared with 
previous time point, in the area that overlapped with the staining for collagen II (fig. 3F, fig. 
5B). No collagen X was seen at that timepoint (fig. 3I). Staining for FGFR2 and FGFR3 were 
not abundant and similar to previous days (fig. 5F,J). In the pellets of the other donors where 
a small interval between appearance of collagen II and X was also seen, none of the FGFRs 
were evidently positive in the area where collagen II was present.  
Hypertrophy 
 FGFR1 and FGFR2 stained brightly positive throughout pellets of donor 1 days 28-35 (fig.  
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Figure 5. Immunohistochemistry: FGFR1-3 expression in chondrogenically differentiated 
BMSCs. Red staining demonstrates positivity for the antibody. Pellets of donor 1 are shown. A,E,I 
During condensation, little FGFR1 is expressed, while FGFR2 and FGFR3 are clearly expressed in the 
centre of the pellets. B,F,J BMSCs in the periphery of the pellet, within the cartilage-like matrix, express 
FGFR1. FGFR2 and FGFR3 are only minimally expressed. C,G,K During hypertrophic differentiation, all 
FGFRs are highly expressed. A magnification is added as inlay to highlight the cellular staining, 
because cells in these pellets have become dispersed due to the production of abundant matrix at this 
time point. D,H,L Histological score of FGFR1- 3, discriminating centre or periphery of the pellets.  
 
 
5C-D,G-H). Staining for FGFR3 was less intense but, in general, expression of FGFR3 
increased throughout the culture period (fig. 5K-L).  
In pellets of donors with less homogeneous chondrogenic differentiation, a positive 
staining for FGFR1-3 overlapped the area that stained positive for collagen II and X (fig. 6). 
Cells not producing collagen II or X were almost negative for FGFR1-3. Therefore, all 
FGFRs were specifically expressed by hypertrophic BMSCs. 
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Figure 6. Immunohistochemistry of FGFRs in hypertrophic cartilage of pellets with partial 
cartilaginous morphology. A typical example of pellets from donor 2 with limited cartilage formation is 
presented to demonstrate spatial differences in immunohistochemical staining. FGFR1 (A), FGFR2 (B), 
and FGFR3 (C) expression overlaps with the staining for collagen II (D) and collagen X (E). When agar 
(a) is still present on the slide during the staining procedure, it stains red in the Neu Fuchsin substrate. 
 
 
Gene expression 
On transcriptional level, FGFR1 was constantly expressed abundantly during the first 28 
days of culture, and increased from day 28 till day 35. The reduced expression during 
condensation (day 7-10) and the increased expression from day 21 seen on histology, was 
therefore not observed on a gene-expression level (fig. 2C).  FGFR2 mRNA levels were only 
minimal at the start of the culture period and significantly increased over time (fig. 2D). Thus, 
the peak during condensation followed by a decrease during differentiation, seen on protein 
level, was not seen on mRNA level. This was also the case for mRNA levels of FGFR3 (fig. 
2E). 
Control cell population 
Pellets cultured on medium without dexamethasone, were used as a control cell population 
to assure the observed FGFR expression pattern is related to chondrogenic differentiation. 
No collagen II was produced in these pellets after 35 days of culture. FGFR1 was expressed 
at day 3, as was seen during expansion in monolayer culture and in the chondrogenically 
differentiating pellets at day 3. At all subsequent time-points FGFR1 was hardly expressed. 
FGFR2 and FGFR3 were scarcely expressed at all time points in these pellets.  
 
Modulation of FGF signaling  
Because FGFR1 and FGFR2 in particular seemed to have pronounced stage-specific 
expression patterns in in-vitro chondrogenic differentiation of BMSCs, we studied the 
possibility to modulate chondrogenesis by stimulation with FGF2, which has a higher binding 
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affinity for FGFR1 (86), and FGF9, which has a higher binding affinity for FGFR2 (87). FGF 
was added either throughout the culture (day 0-35), early in the differentiation process (day 
3-14), or during a later stage of differentiation (day 21-35). 
 
FGF addition throughout culture 
Pellets treated with FGF2 or FGF9 contained significantly less GAG at day 35 than control 
pellets cultured in chondrogenic medium without addition of FGF (fig. 7A). No significant 
difference was seen in amount of DNA (data not shown). This was confirmed by histology. 
Control pellets from both donors demonstrated a strong positive staining for collagen II and 
X at day 35. Addition of FGF2 throughout the culture period resulted in a weaker staining 
that was limited to a smaller area. Only a very weak staining was seen in pellets treated with 
FGF9 (data not shown).  
 
FGF addition during early differentiation 
Pellets treated with FGF2 from day 3-14 contained a lower amount of GAG at day 35 than 
control pellets (fig. 7A). Conversely, a trend towards a higher GAG amount was seen when 
FGF9 was added from day 3-14 (p=0.13). The amount of DNA did not significantly differ 
(data not shown). While immunohistochemical staining for collagen II and X was observed in 
all pellets, no clear difference in between the conditions could be observed (data not 
shown). 
 
FGF addition during late differentiation 
In the control condition new GAG was deposited from day 21-35 (fig. 7B). Addition of FGF2 
from day 21-35 prevented the accumulation of new GAG (fig. 7B). Addition of FGF9 resulted 
in a two-fold reduction of the matrix (fig. 7B), indicating that the addition of FGF9 during late 
differentiation stimulated matrix resorption over matrix production. These data were 
confirmed by histology.  
 
 
 
 
 
Figure 7. Modulation of 
chondrogenic differentiation of 
BMSCs with FGF.  
A Glycosaminoglycan (GAG) 
content of pellets at day 35, 
relative to control pellets at day 
35.  B GAG content at day 35, 
relative to day 21, demonstrating 
the effect of FGF, when added 
from day 21 on, on further matrix 
production. 
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At day 21, before addition of FGF, collagen II and collagen X were already clearly 
expressed. An increased staining was seen from day 21 to day 35 in control pellets. When 
FGF2 was added from day 21-35, the stained area for collagen II and X was somewhat 
smaller than in the control pellets at day 35. A very weak staining was seen in pellets treated 
with FGF9.  
 
 
DISCUSSION 
 
This study demonstrates that FGFR1-3 are expressed in a stage-dependent pattern both in 
chondrogenic differentiation of adult BMSCs in vitro and in embryonic limb development. 
 To our knowledge, this study is the first to directly relate embryonic chondrogenesis to 
in-vitro differentiation of BMSCs in pellet culture. In both models three stages can be 
discriminated, condensation, differentiation, and hypertrophy, respectively characterized in 
this paper by N-cadherin, collagen II, and collagen X expression. However, this study 
demonstrates that there is a difference in these models when the relative length of these 
stages is considered. For, example while in embryonic development a differentiation stage is 
clearly discernable, in in-vitro chondrogenic pellet cultures of BMSCs almost no interval 
exists between production of collagen II and X. We have related the expression of different 
FGFR subtypes to the differentiation stage in both models. In embryonic endochondral 
ossification, the mesenchymal condensation expressed FGFR2 and FGFR3. No FGFRs 
were expressed in differentiating and mature hyaline chondrocytes, while all FGFRs were 
expressed during hypertrophy. In comparison, in in-vitro differentiating BMSCs FGFR2, and 
to a lower extent FGFR3, were clearly expressed during condensation day 7-10. During 
differentiation expression of FGFR2 and FGFR3 was low, but FGFR1 was already 
expressed by cells producing collagen II before collagen X was observed. When collagen X 
was expressed, during hypertrophy of BMSCs, all FGFRs were expressed. This relation 
between chondrogenic differentiation stages and FGFR expression was further 
strengthened by low expression of all FGFRs in pellets that did not undergo chondrogenic 
differentiation due to withdrawal of dexamethasone. 
 When trying to relate the in-vitro differentiation of BMSCs to embryonic 
chondrogenesis, it is important to take into account the fundamental differences in these 
models. Most importantly, chondrogenically differentiating cells in the embryonic limb bud 
get signals from other cell types surrounding these cells, such as in the future perichondrium 
and the loose mesenchyme. The signals to these cells are hugely complex and not only 
involve growth factors such as TGF-β and FGF, but include pathways such as BMP, IHh, 
PTHrP, Wnt/ β-catenin and many more (4). In comparison, in pellet cultures of BMSCs only 
one cell population is present, and the exogenous signals provided to these cells are 
simplified compared to the signaling in embryonic development. However, studying 
embryonic chondrogenesis may shed light into the possibilities to enhance the exogenous 
signal to better control chondrogenic differentiation. In this paper we have focused on FGF 
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signaling and the possibility to modulate chondrogenesis stage-specifically rather than 
adding a growth factor throughout the culture period. 
 FGFR expression in embryonic limb development has been studied before but only at 
mRNA level (43; 82; 83; 88; 89). In differentiating BMSCs FGFR expression has not been 
studied extensively. There is only one recently published study that demonstrated 
expression of all FGFRs in terminally differentiated BMSCs (90), confirming the data in the 
presented study. Our study added information on FGFR expression during the entire culture 
time. 
 A potential drawback of our study is the fact that we compared murine embryonic 
development to the differentiation of human BMSCs. We used primary antibodies cross-
reacting with antigens of both species to minimize this problem. We did not perform RT-PCR 
during embryonic chondrogenesis and it was, therefore, not possible to directly relate the 
murine and the human model at mRNA level. Previous studies showed similar FGFR 
expression patterns in murine and human development at mRNA level (43; 82; 83; 88; 89). 
Moreover, the BMSCs we used in our experiment were derived from patients suffering hip 
osteoarthritis. Whether this may have an influence on the chondrogenic differentiation of 
these cells is unclear, as data regarding this subject are contradictory (91; 92; 93). 
 Our study on human BMSCs demonstrated a difference in FGFR expression between 
mRNA level and protein level. This could be due to post-transcriptional regulation. This may 
also explain why our results at protein level regarding FGFR expression in murine 
embryonic endochondral ossification differ from previous results at mRNA level. Another 
explanation for these differences could be the fact that many different isoforms of FGFRs 
exist. For immunohistochemistry we used antibodies directed to all isoforms. Although we 
used a single PCR assay to detect all currently known isoforms of FGFR2 and FGFR3, it 
was not possible to design a single set of primers capable of detecting all isoforms of 
FGFR1. Our PCR primer set for FGFR1 was developed to detect five of the seven currently 
known splice variants, including the so-called isoforms IIIb and IIIc, known to play important 
roles in limb development (94). In addition, to minimize the limitations of 
immunohistochemistry, we had a consistent, methodical protocol to process and stain the 
specimens. We, therefore, feel confident that the differences in FGFR expression patterns 
observed between mRNA level and protein level in the in-vitro model are not subject to the 
experimental procedures. As a consequence, since our data on protein level on FGFR 
expression in embryonic endochondral ossification differ from results from previous studies 
on mRNA level,  further experiments dealing with FGF signaling in the developing skeleton 
should preferentially be based on functional protein expression of the receptors.   
 We demonstrated that FGFR1 was expressed at the protein level in expanding BMSCs 
and in early outgrowth of the limb bud, while it was downregulated during condensation. 
FGF2 has a strong binding affinity for this subtype FGF receptor. When it was added from 
days 3-14, when FGFR1 was still expressed, it inhibited cartilage differentiation. Therefore, it 
seems likely that FGFR1 plays a role in mesenchymal stem cell proliferation and retaining 
pluripotency, and not in (early) chondrogenic differentiation. This is supported by the fact 
that conditional inactivation of FGFR1 identified it as a positive regulator of limb bud 
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outgrowth (95). FGFR2 expression showed a peak during condensation, both in embryology 
and adult BMSC differentiation. Moreover, in BMSC pellets its staining overlapped with the 
staining for N-cadherin. FGF9, which has a high binding affinity for FGFR2, resulted in a 
somewhat increased matrix production when added during early differentiation. This 
suggests that FGFR2 plays a significant role in early chondrogenesis. The importance of 
FGFR2 during early chondrogenesis is supported by a previous study indicating FGFR2 as 
a positive regulator in chondrogenesis, by influencing the size of the cartilage templates and 
the onset of the differentiation (96). The severe syndactyly seen in Apert syndrome, caused 
by a FGFR2 gain-of-function mutation, supports this view (97).  
  Since all FGFRs are expressed in hypertrophic chondrocytes in endochondral 
ossification, while no FGFRs are expressed in hyaline articular chondrocytes, 
downregulation of FGFRs may well be important for stable chondrocyte differentiation and 
FGF signaling may prove to be a tool to better control in-vitro chondrogenesis of BMSCs. 
This is supported by our finding that addition of FGF during hypertrophic differentiation is 
detrimental for cartilage-matrix production. In our in-vitro study, BMSCs undergoing 
differentiation displayed only a minimal interval between collagen II and collagen X 
production, indicating rapid hypertrophic differentiation of these cells. A clear decrease in 
FGFR3 expression did not take place during differentiation of BMSCs in pellet culture. 
Therefore, the lack of FGFR3 downregulation could play a role in rapid progression to 
hypertrophy in pellet culture of BMSCs. Moreover, since FGFR1 was the first receptor 
upregulated in the cells producing a cartilage-like matrix, it may also play an important role 
in the early terminal, hypertrophic differentiation of BMSCs in pellet culture. Although all 
receptors were expressed during hypertrophy, FGF2 and FGF9 had differential effects when 
added day 21-35. While FGF2 inhibited further matrix deposition, FGF9 increased matrix 
resorption. This suggests that the FGFRs have specific effects, even during hypertrophy 
when they are all expressed.  Further research is indicated to study the potential to 
modulate FGF signaling to create stable, hyaline cartilage. In this respect it may be 
important to realize that during embryonic limb development the cells differentiating towards 
hyaline, articular cartilage are most likely derived from a distinct progenitor cell population 
than the cells differentiating towards hypertrophic cartilage in the future bony skeletal 
elements (98; 99). 
 We have not only demonstrated that different stages can be discerned in chondrogenic 
differentiation, but also that the effect of a growth factor depends on the stage in which it is 
added in the medium. This is in accordance with embryonic development. While FGF9 has 
an inhibitory effect when added throughout culture, or during hypertrophy, it does not have a 
negative effect when given during early differentiation and might even be stimulatory when 
given at the right time interval. Therefore, a more specific stimulation of FGFR2 activation 
during condensation may be interesting for cartilage tissue engineering. Moreover, since the 
effects of growth factors and modulation of intracellular signaling are mostly studied 
throughout culture, more attention to stage-specific effects may be warranted.  
 In conclusion, we have demonstrated that in-vitro differentiation of BMSCs takes place 
in stages similar to those in embryonic endochondral ossification. A mesenchymal 
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condensation (indicated by N-cadherin) is followed by chondrogenic differentiation (indicated 
by collagen II), and hypertrophy (indicated by collagen X). FGFRs are differentially 
expressed in these stages, both in chondrogenically differentiating BMSC in vitro and in 
embryonic endochondral ossification, and first data indicate that modulation with FGF 
subtypes during different stages affects the amount of cartilage formed by BMSCs. A better 
knowledge of, and control over, FGF signaling may lead to advances in cartilage tissue 
engineering and regenerative medicine. 
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SMAD SIGNALING DETERMINES 
CHONDROGENIC DIFFERENTIATION OF 
BONE MARROW DERIVED MESENCHYMAL STEM CELLS:
inhibition of Smad 1/5/8P prevents 
terminal differentiation and calcification
Tissue Eng Part A 2011; 17: 1157-67
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ABSTRACT 
 
The aim of this study was to investigate the roles of Smad2/3 and Smad1/5/8 
phosphorylation in TGF-β induced chondrogenic differentiation of bone-marrow derived 
mesenchymal stem cells (BMSC) in order to assess whether specific targeting of different 
Smad signaling pathways offers possibilities to prevent terminal differentiation and 
mineralization of chondrogenically differentiated BMSCs. Terminally differentiated 
chondrocytes produced in-vitro by chondrogenic differentiation of BMSCs or studied ex-vivo 
during murine embryonic limb formation, stained positive for both Smad2/3P and 
Smad1/5/8P. Hyaline-like cartilage produced in vitro by articular chondrocytes or studied in 
ex-vivo articular cartilage samples that lacked expression for MMP13 and collagen X only 
expressed Smad2/3P. When either Smad2/3 or Smad1/5/8 phosphorylation was blocked in 
BMSC culture by addition of SB-505124 or dorsomorphin throughout culture, no collagen II 
expression was observed, indicating that both pathways are involved in early 
chondrogenesis. Distinct functions for these pathways were demonstrated when Smad 
signaling was blocked after the onset of chondrogenesis. Blocking Smad2/3P after the onset 
of chondrogenesis resulted in a halt in collagen II production. On the other hand, blocking 
Smad1/5/8P during this time period resulted in decreased expression of MMP13, collagen X 
and alkaline phosphatase while allowing collagen II production. Moreover, blocking 
Smad1/5/8P prevented mineralization. This indicates that while Smad2/3P is important for 
continuation of collagen II deposition, Smad1/5/8 phosphorylation is associated with terminal 
differentiation and mineralization.  
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INTRODUCTION 
 
Development of axial skeletal elements in vertebrates follows a tight schedule of 
differentiation of mesenchymal stem cells into chondrocytes and finally mineralization and 
ossification of the matrix. This process starts with cellular condensation, and is followed by 
differentiation into chondroblasts, chondrocytes, pre-hypertrophic and terminally 
differentiated chondrocytes (5; 39). Next, the cartilage mineralizes and is replaced by bone. 
 After traumatic injury or in diseases such as osteoarthritis or rheumatoid arthritis, 
cartilage can be damaged and the limited reparative capacity of cartilage is a major problem. 
Therefore, bone-marrow derived mesenchymal stem cells (BMSCs) are widely studied for 
their potential use in cartilage tissue engineering in order to repair cartilage defects. 
Chondrogenic differentiation of BMSCs follows a process similar to embryonic limb 
development. The cells condensate (100), start expressing SOX9 and collagen type II, but 
eventually the cells become terminally differentiated expressing MMP-13, collagen X and 
alkaline phosphatase (ALPL) (33; 35; 53). This terminal differentiation of BMSCs may be 
advantageous for tissue engineering of bone through the endochondral route (53). However, 
for cartilage reconstructions it is highly unwanted as terminally differentiated cartilage 
produced by BMSC mineralizes when implanted in vivo (33). So far inhibition of terminal 
differentiation of BMSCs was only demonstrated through the addition of PTHrP (101; 102). 
Elucidation of the mechanisms regulating chondrocyte differentiation, and especially 
terminal differentiation, are crucial to have a better control over the chondrogenic 
differentiation of BMSCs.  
 For in-vitro chondrogenic differentiation of bone-marrow derived BMSCs, TGF-beta is 
commonly used (40; 41). TGF-beta signaling requires binding to complexes of type II and 
type I serine/threonine kinase receptors, followed by receptor-Smad phosphorylation at their 
C-terminus. The canonical TGF-beta pathway is the Smad2/3 pathway. However, it has 
recently been shown that by use of an alternate type I receptor (ALK1 instead of ALK5)  
Smad1/5/8  is phosporylated instead of Smad2/3 (103; 104; 105). The Smad1/5/8 route is 
commonly known as the route activated by Bone Morphogenetic Proteins (BMPs), also a 
member of the TGF-beta superfamily and a very potent inducer of bone formation (106). 
 The Smad2/3 route has been found to block terminal differentiation (107; 108), 
whereas the Smad1/5/8 route is known to stimulate terminal differentiation in murine 
embryonic endochondral ossification (109). We have recently found that the Smad2/3 route 
is protective for postnatal articular cartilage and that loss thereof is potentially a hallmark of 
cartilage degradation (110; 111). In contrast, in osteoarthritis chondrocytes ALK1 expression 
was related to MMP-13 expression, a marker of terminally differentiated chondrocytes (111).    
 We postulate that Smad2/3 signaling is important during all stages of chondrogenic 
differentiation and that Smad1/5/8 signaling is a crucial factor for terminal differentiation. We 
suggest that blocking Smad1/5/8 signaling is a potential tool to prevent terminal 
differentiation of BMSCs and thereby generating tissue-engineered cartilage that does not 
mineralize and more closely resembles the desired stable hyaline cartilage. 
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 Therefore, we set out to investigate the activation of both the Smad2/3 and the 
Smad1/5/8 pathways in in-vitro chondrogenically differentiated BMSCs, which are known to 
generate terminally differentiated cartilage. We investigated these pathways in in-vitro 
cultured articular chondrocytes, which are known to produce stable hyaline-like cartilage 
(33) and compared Smad signaling in in-vitro cultured  cartilage with in-vivo terminally 
differentiated cartilage in murine embryonic limbs, and in-vivo human healthy articular 
cartilage. Then, we assessed the outcome of blocking either Smad2/3 or Smad1/5/8 
phosphorylation during different stages of in-vitro chondrogenic differentiation of BMSCs. 
Finally, we tested whether blocking Smad1/5/8 phosphorylation not only prevented 
hypertrophic differentiation but also resulted in a more stable cartilage construct that does 
not mineralize.   
 
MATERIALS AND METHODS 
 
Harvesting cartilage samples 
To study Smad signaling in healthy hyaline and terminally differentiated cartilage in vivo, 
cartilage was processed directly for immunohistochemistry. Human healthy articular 
cartilage was harvested from left-over material of an amputated knee of a 19 year-old 
patient. Forelimbs of E16 murine embryo’s were used to study terminal differentiated 
cartilage in the central region of the metacarpal bone. C57/BL6 female mice were 
intercrossed with CBA males (Charles River Laboratories, Wilmington, MA, USA). 
Gestational age was estimated by the vaginal plug method, with the day of plug occurrence 
designated as day 1 (E1). After gravid female mice had been killed by isoflurane inhalation, 
embryos were excised following cervical dilatation on E16  and immediately placed into 
Dulbecco’s phosphate-buffered saline (Gibco, Carlsbad, CA, USA).  
 
Cell isolation and expansion 
BMSCs were isolated from a bone-marrow biopsy from the femoral shaft of five patients 
(age 20-44) undergoing total hip replacement, and articular cartilage was obtained from 2 
donors (age 3-8) undergoing triple arthrodesis to treat clubfoot deformity, after informed 
consent had been obtained in accordance with the local ethical committee of Rotterdam 
(MEC-2007-032 and MEC 2004-142).  
 For isolation of BMSCs, the heparinized aspirate from the femoral shaft biopsy was 
seeded at a density of 2-5 x 105 cells/cm2 in DMEM-LG (Gibco, Carlsbad, CA, USA), 
supplemented with 10% fetal calf serum (Gibco), 1 ng/ml FGF2 (AbD Serotec, Kidlington, 
UK), 25 μg/ml ascorbic acid-2-phosphate (Becton Dickinson), 1.5 µg/ml fungizone (Gibco) 
and 50 µg/ml gentamicin (Gibco). After 24 hours, nonadherent cells were washed off and 
adherent cells were further expanded. At subconfluency, BMSCs were trypsinized, seeded 
at a density of 2,300 cells/cm2 and further expanded. BMSCs from passage 2-4 were used.  
 For isolation of chondrocytes, cartilage slices were rinsed with saline and subsequently 
digested through incubation for 2 hours at 37oC with 2 mg/ml Pronase E (Sigma-Aldrich, St. 
Louis, MO, USA), followed by overnight incubation with 1.5 mg/ml Collagenase B 
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(Boehringer Mannheim, Germany) in DMEM containing Glutamax (Gibco), and 10% fetal 
calf serum (FCS) (Gibco). Next, cell suspensions were filtered through a 100 µm filter, 
centrifuged and washed with saline. For expansion, chondrocytes were seeded at a density 
of 7500 cells/cm2 in DMEM containing glutamax, with 10% FCS and 1.5 µg/ml fungizone 
(Gibco) and 50 µg/ml gentamicin (Gibco). When chondrocytes reached subconfluency they 
were trypsinized and further expanded. Chondrocytes from passage 4 were used for the 
experiments. 
 
In-vitro chondrogenic differentiation  
Cells were cultured in pellets, formed by centrifuging aliquots of 2 x105 cells in 0.5 ml 
medium at 200 xg for 8 minutes in a polypropylene tube. Chondrogenic differentiation was 
induced by DMEM containing Glutamax, ITS+1 (B&D Bioscience, Bedford, MA, USA), 40 
μg/ml L-proline (Sigma-Aldrich), 1 mM sodium-pyruvate (Gibco), 5 µg/ml fungizone and 50 
µg/ml gentamicin, 25 μg/ml ascorbic acid-2-phosphate, 10 ng/mL TGFβ2 (R&D systems, 
Minneapolis, MN, USA) and 10-7M dexamethasone (Sigma-Aldrich). The medium was 
changed two times a week. Pellets were cultured for 35 days in total and harvested in 
triplicates for immunohistochemistry and gene expression.  
 To study differentiation and Smad expression during the course of chondrogenic 
differentiation of BMSC, pellets of donor 2 and 5 were harvested days  7, 14, 21, 28 and 35. 
In addition, pellets of BMSC donors 3 and 4 were harvested days 14, 21 and 35 and 
articular chondrocytes were harvested days 7, 14, 21, 28 and 35. 
 
Modulation of Smad-signaling  
To study the effect of inhibition of Smad2/3 phosphorylation on chondrogenic differentiation 
of BMSCs, 10µM SB-505124 (Sigma-Aldrich) was added to the medium during 
chondrogenic differentiation of BMSC from three different donors (donor 1-3). SB-505124 
blocks the kinase domains of ALK4, -5 and -7, thereby preventing Smad2/3 phosphorylation. 
To study the effect of inhibition of Smad1/5/8 phosphorylation, 10µM dorsomorphin (Biomol 
international, Exeter, United Kingdom) was added to the medium of BMSC from three 
donors (donors 2-4). Dorsomorphin blocks kinase domains of ALK1, -2, -3 and -6, thereby 
preventing Smad1/5/8 phosphorylation. Before using these compounds in the chondrogenic 
differentiation of BMSC their specific inhibitory effect on phosphorylation of either Smad2/3 
or Smad1,5,8 was confirmed by Western Blotting cell cultures in monolayer (data not 
shown).  
 As we have previously demonstrated the importance to modulate chondrogenesis of 
BMSC stage-specifically (112), these compounds were not only added to the medium 
throughout the culture period (day 0-35) but also from day 14-35 and day 21-35. After two or 
three weeks of chondrogenic differentiation of BMSC, some collagen II production is usually 
seen but this is donor dependent. Therefore, we used two different time points for the 
addition of dorsomorphin or SB505124 to study their effect on cartilage production and 
terminal differentiation without influencing the initial onset of chondrogenic differentiation. 
The effect of blocking Smad signaling during onset of differentiation only was not 
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investigated as the aim of our study was to investigate the involvement of different Smad 
pathways in terminal differentiation.  
 In the donor with the best chondrogenic capacity, blocking of Smad1/5/8 
phosphorylation days 14-35 resulted in inhibition of markers of terminal differentiation (donor 
4). To study whether stage-specific blocking of Smad1/5/8 after the onset of chondrogenic 
differentiation results in more stable cartilage construct that does not mineralize, 10µM 
dorsomorphin was added to the culture medium from day 14 on as in the previous 
experiment using cells from the donor with the best chondrogenic capacity (donor 4). In this 
experiment culture continued after 35 days with the addition of β-glycerophosphate to the 
medium (containing TGF-β +/- dorsomorphin) to allow for mineralization. After a total culture 
period of 49 days pellets were harvested for histology.   
 
(Immuno)histochemistry 
Samples were fixed in 4% formalin in phosphate-buffered saline (PBS) and embedded in 
paraffin. Pellets were first set in 2% agar before embedding in paraffin. To enable reliable 
direct comparison of intensity of the staining sections of treated pellets and controls were put 
on the same slide. 
 Antigen retrieval for collagen II was performed through incubation with 0.1% pronase 
(Sigma-Aldrich) in PBS for 30 minutes, while antigen retrieval for collagen X required 0.1% 
pepsin (Sigma-Aldrich) in 0.5M acetic acid (pH=2.0) for 2 hours. Both stainings continued 
with incubation with 1% hyaluronidase (Sigma-Aldrich) in PBS. Sections were incubated 
overnight with primary antibodies for collagen II (II/II6B3, Developmental Studies Hybridoma 
Bank) or collagen X (2031501005, Quartett, Berlin, Germany) after blocking of non-specific 
binding sites with 10% goat serum in PBS. An alkaline-phosphatase-conjugated secondary 
antibody was used for these immunohistochemical stainings, followed by incubation with 
Neu Fuchsin substrate (Chroma, Köngen, Germany) to demonstrate alkaline-phosphatase 
activity with a red stain. To allow the use of these monoclonal mouse antibodies on murine 
specimens, an earlier described method (61) was used to link the antibody with anti-mouse 
antiserum before immunohistochemistry.  
 MMP-13 staining was preceded by incubation of the sections in chondroitinase ABC 
(Sigma-Aldrich) 250 units/ml for 1 hour at 37 ˚C. For Smad2P, Smad1/5/8P and MMP-13 
endogenous peroxide was blocked with 1% hydrogen peroxide in methanol for 30 minutes, 
followed by antigen retrieval through incubation in citrate buffer (0.1M sodium citrate + 0.1M 
citric acid) for two hours at room temperature. Sections were incubated overnight with 
primary antibodies against Smad2P, Smad1/5/8P (both Cell Signaling Technology, Danvers, 
MA, USA) or MMP-13 (Santa Cruz Biotechnology) after blocking of non-specific binding 
sites with 5% goat serum. A biotin labeled secondary antibody was used (DAKO, Glostrup, 
Denmark) for these immunohistochemical stainings, followed by a biotin-streptavidin 
detection system according to manufacturers protocol (Vector Laboratories, Burlingame, CA, 
USA). DAB reagent was used to demonstrate bound complexes with a brown stain. 
 Sections were critically studied for presence or absence of a positive staining. In case 
of collagen II and collagen X immunohistochemistry a red staining was considered positive, 
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while in the case of Smad2P, Smad1/5/8P and MMP-13 a brown staining was positive. As 
the antibody for Smad2P detects Smad3 phosphorylated at equivalent sites according to the 
manufacturer, we considered positivity for this antibody as positivity for Smad2/3P.  
 To evaluate mineralization a Von Kossa staining and a Alizarine Red staining were 
performed. For the Von Kossa staining, slides were immersed in 5% silver nitrate solution 
(Sigma-Aldrich) for 10 minutes, rinsed in ultra pure water and exposed to light for 10 
minutes. Excess silver nitrate was removed with 5% sodium-thiosulphate (Sigma-Aldrich) 
and cells were rinsed in distilled water. For the Alizarine Red staining, slides were immersed 
in a saturated Alizarine Red S solution (Sigma-Aldrich) (5 gr/L) for one minute, and rinsed in 
70% ethanol. 
  All (immuno)histochemical stainings were quantified using Bioquant Osteo 7.2 
(Bioquant Image Analysis Corporation, Nashville, TN, USA). Quantification was performed 
on a section through the middle of the pellet. First colour-definitions were set per staining to 
define a positive staining. In the case of staining for collagen II, collagen X, MMP13, Von 
Kossa and Alizarine Red, the positive staining was then automatically selected and the size 
of the positive staining area was defined. Next, the total area of the pellet was manually 
selected and the size defined. The positive staining fraction over the total pellet area was 
calculated and used for further analysis.  
 Positive staining for Smad2/3P or Smad1/5/8P was observed in the cell, indicating 
active signaling via this pathway. Quantification using Bioquant Osteo was performed on a 
200x magnified image in a collagen II rich area of the pellet. Positive cells were 
automatically selected by the software and the percentage of positive cells was calculated. 
For the aim of this paper we focused on whether active signaling was present or not, and the 
intensity of the staining was not further quantified. 
 We have attempted to perform Western Blots for Smad2/3P and Smad1/5/8P on 
pellets, but unfortunately these were not successful due to lengthy protein extraction 
procedure and the fact that the extraction contained large amounts of matrix constituent. 
Furthermore, baseline Smad-levels were not studied as the aim of this study was to 
investigate the role of altered active Smad signaling, as indicated by phosphorylated Smads. 
We did not study whether altered Smad phosphorylation was caused by alteration in basal 
Smad levels since, although interesting, this will not alter the conclusions of this study. 
 
Gene expression analysis 
For total RNA isolation, pellets were manually homogenized in RNA-BeeTM (TEL-TEST, 
Friendswood, TX, USA). RNA was extracted with chloroform and purified from the 
supernatant using the RNAeasy Micro Kit (Qiagen, Hilden, Germany), according to the 
manufacturer’s guidelines with on-column DNA-digestion.  
 RNA concentration and purity were assessed on a spectrophotometer (NanoDrop® 
ND-1000 UV-Vis Spectrophotometer, Isogen Life Science B.V., Belgium). Complementary 
DNA (cDNA) was made using RevertAid™ First Strand cDNA Synthesis Kit (MBI 
Fermentas, Germany) and polymerase chain reactions were performed using TaqMan® 
Universal PCR MasterMix (Applied Biosystems, Capelle a/d Ijssel, Netherlands), as 
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described earlier (113), but on a ABI PRISM® 7000 (Applied Biosystems, Foster City, CA, 
USA). Primers used for real-time RT-PCR reactions for SOX9, CBFA1, collagen II, collagen 
X and ALPL were reported previously by Farrell et al (53), and for MMP13 by de Mos et al 
(114).  
 Amplification efficiencies of all assays were between 90-98% (data not shown).  After 
testing GAPDH, 18S, HPRT, ACTB, UBC and B2M as housekeeping genes on selected 
samples, GAPDH was chosen to normalize the data to. Relative expression was calculated 
according to the 2-ΔCT formula (65).  
 Since in previous experiments we have seen that undifferentiated BMSCs express the 
genes of interest at a very low or undetectable level (unpublished data) these conditions 
were not included.  
 
Statistical analysis 
Statistical analysis was conducted using SPSS 15.0 and the GraphPad Prism 5 (San Diego, 
CA, USA) software for Windows. Values are represented as mean ± SEM. Mixed model 
analysis and independent sample T-test were performed and the level of significance was 
set at a p value of less than 0.05. 
 
RESULTS 
 
Both Smad2/3 and Smad1/5/8 signaling are active in terminally differentiated 
cartilage, while only Smad2/3 is active in hyaline cartilage  
Pellets of BMSCs of all five donors contained abundant collagen II and collagen X after 35 
days of culture (fig. 1A). Sox-9, CBFA1, collagen II, collagen X and ALPL mRNA increased 
in time with limited variation between donors (fig. 2) and  were highly expressed in all pellets 
at day 35 confirming the chondrogenic and subsequent terminal differentiation of these in-
vitro differentiated BMSCs. Moreover, MMP13 was highly expressed on both protein and 
mRNA level (fig. 1B,2). Staining for both Smad2/3P and Smad1/5/8P demonstrated positive 
cells dispersed throughout the pellets at all time-points (data not shown). A strong positive 
staining for both Smad2/3P and Smad1/5/8P was seen in all terminally differentiated cells 
embedded in collagen II and collagen X matrix (fig. 1C,D). In-vivo terminally differentiated 
cartilage in the central region of embryonic (E16) metacarpal bones, rich in collagen X and 
MMP13,  stained positive for both Smad2/3P and Smad1/5/8P (fig. 3A-C). Therefore both 
Smad signaling pathways are active in terminally differentiated cartilage, both in in-vitro 
differentiated BMSC as well as in-vivo during endochondral ossification.   
 Pellet cultures of expanded articular chondrocytes showed abundant collagen type II at 
day 35 (fig. 1E). Chondrogenic differentiation of these cells was confirmed by a high 
expression of mRNA for sox-9 and collagen II. Articular chondrocytes reached a high 
expression of these chondrogenic markers earlier in culture than BMSCs, but the level of 
expression  was  comparable (fig. 2). Collagen X,  MMP13  and  ALPL expression was only  
  
Smad signaling determines chondrogenic differentiation of BMSC 
 
69 
minimal on protein and mRNA level (fig. 1E-F, 2) indicating that issue-engineered cartilage 
from articular chondrocytes resembles hyaline cartilage. Chondrocytes in these pellets 
stained strongly positive for Smad2/3P while no Smad1/5/8P immunostaining was observed 
(fig. 1G,H). This was similar to the healthy human hyaline articular cartilage samples (fig. 
3E,F).  
 Thus signaling through Smad2/3 seems related to hyaline-like chondrogenic 
differentiation and signaling through Smad 1/5/8 is related to terminal differentiation and 
specifically the upregulation of MMP13 expression. 
 
Figure 1. Immunohistochemistry of tissue-engineered cartilage from BMSC and articular 
chondrocytes. A-H Representative donors are shown of a total of 5 BMSC donors and two articular 
chondrocyte donors. Samples were harvested in triplicates for each donor after 35 days of 
chondrogenic differentiation. A red staining demonstrates positivity for the collagen II and collagen X 
antibody, while a brown staining demonstrates positivity for the MMP13, Smad2/3P and Smad1/5/8P 
antibody. Sections are counterstained with hematoxylin (purple). A-D Pellets of BMSCs of all five 
donors contained abundant collagen II and collagen X (A), and both cells and matrix stained positive for 
MMP13 (B). Cells in this tissue-engineered terminally differentiated cartilage stained positive for 
Smad2/3P (C) as well as Smad1/5/8P (D). E-H Tissue-engineered cartilage of articular chondrocytes 
contained collagen II, but no collagen X immunostaining was observed (E). Only minimal expression of 
MMP13 was observed (F). The cells in this tissue-engineered hyaline-like cartilage were positive for 
Smad2/3P (G), but not for Smad1/5/8P(H). I Percentage of collagen X and MMP13-positive staining 
fraction and percentage of Smad2/3P and Smad1/5/8P positive cells in BMSC pellets and articular 
chondrocytes pellets.  
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Figure 2. Gene expression during time course of chondrogenic differentiation of BMSC and 
articular chondrocytes. Gene expression for sox-9 (A), collagen II (B), CBFA1 (C), collagen X (D), 
ALPL (E) and MMP13 (F) is demonstrated for four donors (donors 2-5) with triplicate samples per donor 
of bone-marrow derived stromal cells (black lines) or and two donors of articular chondrocytes (gray 
lines). Detection levels below 1 x 10-4 are considered as no gene expression. Collagen X expression 
was below detection level in all samples of day 28 and 35 from one articular donor. 
 
 
    
 
 
Figure 3. Immunohistochemistry of healthy terminally differentiated and hyaline cartilage in vivo. 
A brown staining demonstrates positivity for the antibody. A-C Terminally differentiated cartilage in the 
central region of a murine metacarpal bone (E16)  stains positive for MMP13, Smad2/3P and 
Smad1/5/8P. D-F Healthy human articular cartilage shows no immunostaining for MMP13. The articular 
chondrocytes stain strongly positive for Smad2P, while no staining for Smad1/5/8 is seen. 
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Figure 4. Immunohistochemistry and gene-expression of BMSC pellets at day 35 of 
chondrogenic differentiation, with or without blocking Smad2/3 phosphorylation day 14-35.  A-F 
Immunohistochemistry is shown of a representative pellet of donor 1 with or without addition of SB-
505124. A-B Blocking Smad2/3 phosphorylation, through addition of SB-505124, inhibited collagen II 
production. The amount of positive staining seen in treated pellets after 35 days of culture, was similar 
to the amount seen before the addition of SB-505124 at 14 days. C-D SB-505124 exposed pellets 
showed less collagen X positivity than control pellets. E-F MMP13 was expressed in both control and 
SB-505124 treated pellets. G Quantification of collagen II, collagen X, and MMP13 in donor 1-3 
(triplicate samples), with addition of SB-505124 from day 14 on in donor 1 and from day 21 on in donor 
2 and 3. Addition of SB-505124 inhibited collagen II and X production, and had no inhibitory effect on 
MMP13 expression. H Gene-expression data is demonstrated of all three donors with triplicate samples 
per donor. Blocking Smad2/3 phosphorylation by addition of SB-505124 day 14-35 significantly 
downregulated the gene expression of collagen II, collagen X and ALPL. 
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Figure 5. Immunohistochemistry and gene-expression of BMSC pellets at day 35 of 
chondrogenic differentiation, with or without blocking Smad1/5/8 phosphorylation day 14-35. A-F 
Immunohistochemistry is shown of representative pellet of donor 4 with or without addition of 
dorsomorphin. A-B Blocking Smad1/5/8 phosphorylation, through addition of dorsomorphin, did not 
inhibit collagen II production. C-D Addition of dorsomorphin resulted in a less intense staining for 
collagen X. E-F Dorsomorphin inhibited the expression of MMP13. G Quantification of collagen II, 
collagen X, and MMP13 in donor 2-4 (triplicate samples), with addition of SB-505124 from day 14 on in 
donor 4 and from day 21 on in donor 2 and 3. The effect of dorsomorphin on collagen II production 
depended on the amount of collagen II present from the start of the addition. Dorsomorphin significantly 
inhibited collagen X production and MMP13 expression. H Gene-expression data is demonstrated of all 
three donors with triplicate samples per donor. Blocking Smad1/5/8 phosphorylation by addition of 
dorsomorphin day 14-35 significantly upregulated Sox-9 gene expression, while it significantly 
downregulated the expression of ALPL and MMP13. 
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Inhibition of Smad2/3 phosphorylation blocked chondrogenic differentiation of 
BMSCs 
To investigate the importance of Smad2/3 signaling for chondrogenic differentiation, SB-
505124 was added to BMSCs from 3 donors (donor 1-3) in chondrogenic pellet cultures. 
Exposure to SB-505124 from the onset of the culture completely blocked chondrogenic 
differentiation and collagen II production (data not shown). 
 Although no clear donor-to-donor differences were observed in gene-expression of 
collagen II in the time-course experiment, timing of collagen II deposition in the matrix as 
seen on immunohistochemistry differed from donor to donor. Only in donor 1 collagen II was 
already present at day 14. Inhibition of Smad 2/3 phosphorylation with SB-505124 prevented 
further collagen II production. While collagen II was present throughout the pellets in the 
controls, very limited collagen II production was seen in SB-505124 treated pellets after 35 
days of culture (fig. 4A,B). Donor 2 and 3 did not have a collagen II containing matrix at day 
14, and addition of SB-505124 form day 14 on resulted in pellets without collagen II at day 
35 (data not shown). When SB-505124 was added to these donors from day 21 on, when 
the first spots of collagen II depositions were seen in the matrix, further collagen II 
production was completely blocked as was the case in the first donor (fig. 4C). Collagen X 
production was not seen in pellets treated with SB-505124, either from day 14 or day 21 on,  
while no inhibitory effect was seen on MMP13 expression.   
 These protein data were supported by gene-expression analysis. In all three donors, 
the addition of SB-505124 form day 14 on significantly inhibited gene-expression of collagen 
II, while expression of Sox-9 was not significantly influenced (fig. 4G). Collagen X 
expression was inhibited on mRNA level corresponding to protein level in treated pellets of 
all three donors, and so was gene-expression of ALPL. This is most likely due to the 
inhibited chondrogenic differentiation, hence delaying further terminal differentiation. 
Staining for MMP13 was positive in both treated and control pellets (fig. 4E,F), and its gene 
expression was not significantly inhibited by addition of SB-505124 (fig. 4G). In figure 4 
gene-expression is displayed for pellets treated with SB-505124 from day 14 as addition 
from day 21 on resulted in similar trends. 
 Summarizing, we conclude that inhibition of Smad2/3 phosphorylation by the addition 
of SB-505124 prevented further cartilage differentiation and cartilage matrix production after 
the onset of chondrogenic differentiation, while it had no inhibiting effect on MMP13 
expression.  
 
Inhibition of Smad1/5/8 phosphorylation inhibited terminal differentiation and 
mineralization in differentiated chondrocytes but completely blocked early 
chondrogenic differentiation 
To test the hypothesis that Smad1/5/8 signaling is related to terminal differentiation, 
dorsomorphin was added to the chondrogenic differentiation medium of BMSCs of three 
donors (donor 2-4) to prevent phosphorylation of Smad1/5/8. Addition of dorsomorphin 
throughout the culture period completely prevented chondrogenic differentiation of BMSCs. 
Thus, Smad1/5/8P is important during the onset of chondrogenesis. 
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Figure 6. Blocking Smad1/5/8 phosphorylation prevents mineralization. A-B Alizarine Red staining, 
demonstrating calcium-phosphate depositions. When β-glycerophosphate was added to the medium 
day 35-49 mineralization was observed in control pellets (A), while no mineralization was demonstrated 
in pellets in which Smad1/5/8 phosphorylation was blocked through addition of dorsomorphin from day 
14 on (B). (C) Quantification of Von Kossa and Alizarine Red staining. Pellets of donor 4 were 
harvested in triplicate for each condition. 
 
Addition of dorsomorphin from day 14 on had  no evident inhibitory effect on further 
cartilage formation in the donor where cartilage matrix was already deposited at day 14 
(donor 4). In these pellets abundant collagen II was seen on immunohistochemistry in 
treated pellets after 35 days of culture, not differing from the control (fig. 5A,B). In the two 
other donors with less chondrogenic capacity, no collagen II was present at day 14 and only 
small spots at day 21. Although, in these cases addition of dorsomorphin inhibited collagen 
II production compared to the control, the collagen II positive area further increased in time 
and at day 35 more collagen II was seen than after the addition of SB-505124. Collagen X 
production and MMP13 expression were inhibited in dorsomorphin-treated pellets compared 
to the controls. Most importantly, in the donor where an abundant cartilage matrix was 
deposited in the presence of dorsomorphin after the onset of chondrogenesis, this collagen 
II rich matrix was lacking collagen X and MMP13 expression, indicating that this cartilage-
like matrix was not terminally differentiated.      
 This effect of dorsomorphin, inhibiting terminal differentiation while allowing collagen II 
production, was even more evident when studying gene-expression. Sox9 expression was 
significantly higher than in the controls (fig. 5G). Though no significant difference was 
observed in gene-expression of CBFA1 or collagen X at day 35, the intensity of the collagen 
X staining was clearly diminished in the treated pellets compared to the control (5C,D). 
Gene-expression of ALPL was somewhat reduced when dorsomorphin was added to the 
medium, though not significantly (p=0.13)  (fig. 5G). Moreover, both gene-expression and 
immunohistochemistry for MMP13 was significantly reduced in treated pellets compared to 
the control (fig. 5E,F,G). Therefore, inhibiting Smad1/5/8 phosphorylation by addition of 
dorsomorphin after initial chondrogenic differentiation, allowed further cartilage production 
and inhibited terminal differentiation. 
To study whether blocking Smad1/5/8 phosphorylation after initial chondrogenic 
differentiation not only inhibits terminal differentiation but also prevents mineralization, an 
additional experiment was performed with cells from the donor with very good chondrogenic 
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capacity. β-Glycerophosphate was added to the medium from day 35-49 to allow 
mineralization of the matrix. While mineralization was clearly present in control pellets, 
blocking Smad1/5/8 phosphorylation completely prevented mineralization as was 
demonstrated by Von Kossa and Alizarine Red staining (fig. 6). 
 
DISCUSSION 
 
Generation of stable hyaline cartilage from BMSCs is currently still a challenge. Although 
chondrogenesis and cartilage formation are achieved, it eventually leads to terminal 
differentiation of chondrocytes instead of the production of stable hyaline cartilage. 
Furthermore, the tissue-engineered cartilage construct is not stable when it is implanted in 
vivo but mineralizes (33; 53). The process of in-vitro chondrogenic differentiation therefore 
seems a recapitulation of endochondral bone formation. A better knowledge of mechanisms 
determining chondrocyte differentiation and terminal differentiation is therefore crucial to 
control the chondrogenic differentiation of BMSCs. To our knowledge this study is the first 
toshow the possibility to direct chondrogenic differentiation of BMSCs towards a more stable 
hyaline-like phenotype by targeting Smad signaling stage-specifically. 
 Both Smad2/3 and Smad1/5/8 phosphorylation is required for onset of chondrogenic 
differentiation as blocking of either one from the start of culture completely prevented 
chondrogenesis of BMSCs. Our results are supported by a study by Roark et al, 
demonstrating in chick limb mesenchymal cells that both TGF-β and BMP are important for 
early chondrogenesis (115). However, in the present study we demonstrate that the different 
Smad signaling pathways have a very distinct function during later stages of 
chondrogenesis. By affecting Smad signaling in BMSC pellets from day 14-35, it was 
possible to study the function of both pathways after the onset of chondrogenic 
differentiation. Blocking Smad2/3 phosphorylation prevented further increase in collagen II 
expression both on mRNA and histology level, but did not alter MMP13 expression. This 
confirms our previous findings that expression of ALK5, one of the main activators for 
Smad2/3 phosphorylation, correlates with collagen II expression in human articular cartilage, 
but not with MMP13 expression (111). Smad2/3 phosphorylation has been shown to block 
terminal differentiation (107). Thus, besides impairing cartilage formation directly, blocking 
Smad2/3 might release the block on terminal differentiation and via this way may allow 
MMP13 expression. This is also suggested by the enhanced terminal differentiation, in 
addition to the cartilage loss, seen in Smad3 deficient mice (108), and the fact that reduced 
TGF-beta signaling via Smad2/3, by proteosomal degradation of Smad2 and 3 through 
enhanced expression of Smurf2, stimulates endochondral ossification. Smad2/3 signaling is 
not only important for chondrogenesis, but also for the reparative response of cartilage. We 
have previously shown a reduced ALK5 expression and reduced responses to TGF-beta in 
aged mice (116). Moreover, reduced Smad2 phosphorylation was accompanied by an 
impaired repair response of the cartilage.  
 In contrast to Smad2/3, blocking Smad1/5/8 phosphorylation from day 14 on did allow 
further cartilage matrix production. Moreover, it prevented expression of both collagen X and 
Chapter 4 
 
 
76 
MMP-13 on histology and inhibited mineralization. Cbfa1 and Smad1 and 5 have been 
suggested crucial for terminal differentiation (117; 118). We found no effect on cbfa1 mRNA 
level, but cbfa1 requires Smad interaction for induction of an osteogenic signal (118; 119). 
Cbfa1 is required for MMP13 expression and it can be anticipated that the lack of 
Smad1/5/8-Cbfa1 interaction in presence of dorsomorphin is a direct cause for the reduction 
in MMP13 found in these chondrogenic pellets (120; 121).  
 Our findings are in line with the results of Valcourt et al (122) showing the involvement 
of Smad1,5,8 in BMP2-induced terminal differentiation of chondrocytes and our previous 
study that demonstrated that ALK1 correlates with MMP13 expression in articular cartilage 
whereas ALK5 does not (111). Smad1 and 5 are crucial for terminal differentiation during 
embryonic development, as was previously demonstrated in Smad1/5CKO mutants which had 
a disorganized growth plate with loss of terminal chondrocytes and very limited collagen X 
expression (109). 
 The observed Smad1/5/8 signaling in BMSCs may be due to signaling of the 
exogenous TGF-beta to the ALK1 receptor. However, we have seen in a previous study that 
chondrogenically differentiated BMSCs express BMP2 (data not published). Therefore, it is 
possible that the observed Smad signaling is not only due to exogenous but also 
endogenous signaling involving BMP. The precise mechanism of Smad phosphorylation 
would require further research. 
 These experiments confirm the importance of using different donors because of the 
variability in timing of chondrogenic differentiation. Although gene-expression of collagen II 
did not obviously differ from donor to donor, timing of collagen II gene expression and 
deposition in the matrix did differ, thereby influencing the results of blocking Smad-signaling. 
The results of inhibition of Smad1/5/8 phosphorylation by dorsomorphin clearly demonstrate 
the importance of targeting the chondrogenic processes at the exact right moment. BMSCs 
of a donor that had an excellent chondrogenic capacity and formed cartilage within 2 weeks 
performed very well with dorsomorphin. Cartilage was formed, terminal differentiation was 
inhibited and mineralization was prevented. However, chondrogenesis of BMSCs of another 
donor that took 3 weeks to form a small amount of cartilage was prevented by adding 
dorsomorphin from day 14, whereas addition from day 21 did allow further cartilage 
formation and inhibited terminal differentiation. This variation in cultures highlights the stage 
specificity of Smad signaling during chondrogenesis. For future studies it may be interesting 
to study whether a more restricted administration of dorsomorphin upon the onset of 
terminal differentiation will completely block terminal differentiation or will just merely 
temporarily inhibit this process, avoiding any adverse effects the continuous administration 
of dorsomorphin may have. However, the donor-to-donor variation in timing of differentiation 
will make it difficult to indentify during culture the exact timing of the onset of terminal 
differentiation and the administration of inhibitors.   
In conclusion, our data strongly suggest that the role of Smad2/3 and Smad1/5/8 
phosphorylation in chondrogenesis by human BMSCs is stage dependent. Based on our 
experiments the timing of Smad2/3 and Smad1/5/8 phosphorylation, relative to the 
expression of known chondrogenic differentiation markers, is schematically demonstrated in 
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figure 7. Both pathways are crucial for initial chondrogenesis. While Smad2/3 is important for 
ongoing cartilage matrix production, Smad1/5/8 is crucial for terminal differentiation and 
mineralization. Most importantly, our data imply that in-vitro cartilage tissue engineering 
might benefit from blocking the Smad1/5/8 route after chondrogenic differentiation of BMSCs 
is induced, to prevent terminal differentiation and mineralization while sustaining further 
cartilage-matrix production.  
 
 
 
 
 
Figure 7. Schematic figure of probable timing of Smad2/3 and Smad1/5/8 signaling during 
chondrogenic differentiation of BMSCs, relative to some known markers of differentiation. 
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ABSTRACT 
 
Human bone-marrow stromal-derived mesenchymal stem cells (BMSC) will differentiate into 
chondrocytes in response to defined chondrogenic medium containing Transforming Growth 
Factor – beta (TGF-β). Results in literature suggest that the three mammalian subtypes of 
TGF-β (TGF-β1, TGF-β2 and TGF-β3) provoke certain subtype-specific activities. Therefore, 
the aim of our study was to investigate whether the TGF-β subtypes affect chondrogenic 
differentiation of in-vitro cultured BMSC differently. BMSC pellets were cultured for 5 weeks 
in chondrogenic media containing either 2.5, 10 or 25 ng/ml of TGF-β1, TGF-β2 or TGF-β3. 
All TGF-β subtypes showed a comparable dose-response curve, with significantly less 
cartilage when 2.5 ng/ml was used and no differences between 10 and 25 ng/ml. Four 
donors with variable chondrogenic capacity were used to evaluate the effect of 10 ng/ml of 
either TGF-β subtype on cartilage formation. No significant TGF-β subtype-dependent 
differences were observed in total amount of collagen or glycosaminoglycans. Cells from a 
donor with low chondrogenic capacity performed equally bad with all TGF-β subtypes, while 
a good donor overall performed well. After addition of β-glycerophosphate during the last 2 
weeks of culture, the expression of hypertrophy markers was analyzed and mineralization 
was demonstrated by alkaline phosphatase activity and Alizarin Red staining. No significant 
TGF-β subtype-dependent differences were observed in expression collagen X or VEGF 
secretion. Nevertheless, pellets cultured with TGF-β1 had significantly less mineralization 
than pellets cultured with TGF-β3. In conclusion, this study suggests that TGF-β subtypes 
do affect terminal differentiation of in-vitro cultured BMSC differently.  
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INTRODUCTION 
 
Each year, approximately one million patients undergo some type of cartilage reconstruction 
(123). These cartilage reconstructions can be performed due to congenital abnormalities, 
posttraumatic defects or deformities after tumor resection. Cartilage has insufficient capacity 
for regeneration (124) and therefore defects need to be reconstructed with transplants. As 
the amount of autologous cartilage donor tissue is limited, cartilage has become a main 
target in tissue engineering research.  
 Human bone-marrow stromal-derived mesenchymal stem cells (BMSC) obtained from 
the bone marrow, are promising cells for cartilage tissue engineering because of their high 
proliferative capacity and their ability to differentiate along chondrogenic lineages (31). In 
previous studies it was shown that BMSC can differentiate into chondrocytes in response to 
defined chondrogenic medium containing Transforming Growth Factor – beta (TGF-β) (41; 
123; 125). In-vitro chondrogenic differentiation of BMSC, cultured with TGF-β, resembles in-
vivo endochondral ossification (35; 54). After an initial mesenchymal condensation, 
characterized by the expression of cell-adhesion molecules such as N-cadherin (126), the 
cells differentiate into chondrocytes, producing cartilage specific extracellular matrix 
components, such as collagen I and collagen II and glycosaminoglycans (GAG) (31). This 
stage is quickly followed by terminal differentiation, also called hypertrophy, characterized by 
the production of collagen X (127; 128). When a phosphate donor is added to the 
chondrogenic medium, hypertrophy is followed by calcification and mineralization of the 
extracellular matrix, demonstrated by calcium depositions and an increased alkaline 
phosphatase (ALP) activity (127). In-vitro cultured cartilage will be of limited clinical use for 
cartilage reconstructions if it mineralizes or is replaced by bone in vivo. Therefore, in 
cartilage tissue engineering it is not only important to create a large amount of cartilage, but 
also to create a stable construct that does not mineralize when implanted in the body. 
 TGF-β is a multifunctional protein that regulates cell proliferation, differentiation and 
extracellular matrix metabolism. Three mammalian subtypes of TGF-β (TGF-β1, TGF-β2, 
and TGF-β3) are commonly used for chondrogenic differentiation of BMSC in different 
laboratories (33; 35; 41; 53; 129). Despite the fact that the three TGF-β subtypes share 71-
76 % sequence identity and they use the same receptors (130; 131), analysis of their in-vivo 
function by gene knockout mice revealed striking differences. TGF-β1-null mice have an 
auto-immune-like inflammatory disease (132), while TGF-β2-knockout mice exhibit perinatal 
mortality and severe developmental defects (133), and TGF-β3-deficient mice have a cleft 
palate and a defective lung development (134). These differences might indicate that certain 
TGF-β subtype-specific activities exist that may influence the outcome of in-vitro 
chondrogenesis of BMSC. Therefore, the choice of TGF-β subtype to induce 
chondrogenesis may attribute to contradictory results in different studies. As far as we know, 
only one study has directly compared the effect of all three different TGF-β subtypes on in-
vitro chondrogenic differentiation of BMSC. Barry et al (135) concluded that TGF-β2 and 
TGF-β3 are significantly more effective in promoting chondrogenesis than TGF-β1, 
demonstrated by a significantly higher GAG/DNA ratio at day 21 and an earlier and more 
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extensive deposition of type II collagen. Would that than make TGF-β2 and TGF-β3 more 
suitable for cartilage tissue engineering of BMSC? As mentioned before, it is also important 
to create a stable transplant that does not mineralize. In literature many studies investigated 
the effect of TGF-β on hypertrophy and mineralization (31; 33; 35; 53; 41; 129; 136; 137; 
138). Even after comparing studies that use identical cell sources, results were inconsistent. 
To our knowledge the effects of the different TGF-β subtypes on terminal differentiation and 
mineralization of BMSC have never been directly compared and may actually cause these 
previous inconsistent results.  
 Therefore, the aim of our study was to investigate whether TGF-β subtypes affect 
chondrogenic differentiation of in-vitro cultured BMSC differently, concentrating on the 
amount of produced cartilage as well as the degree of terminal differentiation and capacity to 
mineralize.  
 
MATERIALS AND METHODS 
 
Isolation and expansion of BMSC  
BMSC were isolated from femoral shaft biopsies of four female donors (age 32 – 85 years) 
undergoing total hip replacement, after informed consent was obtained and with approval of 
the local medical ethical committee (MEC 2004-142). Culture protocols were adapted from  
previously described procedures (139; 140) as used previously in our laboratory (53; 54; 
141) In short, the heparinized aspirates were seeded at a density of 2-5 x 105 cells/ cm² in 
Dulbeco’s modified Eagle’s medium (DMEM) low glucose (Gibco, Carlsbad, CA, USA), 
supplemented with 10% fetal calf serum (FCS) (Gibco), 50 µg/ml Gentamycin, 1.5 µg/ml 
Fungizone (Gibco), 1 ng/ml Fibroblast Growth Factor type 2 (FGF2) (AbD Serotec, 
Kidlington, UK) and 25 µg/ml L-ascorbic acid 2-phosphate (Sigma – Aldrich) at 37°C under 
humidified condition and 5% CO2. After 24 hours non-adherent cells were washed off and 
adherent cells were further expanded. At subconfluency, BMSC were rinsed with phosphate-
buffered saline (PBS) (100 mM NaCl, 80 mM Na2HPO4, 20 mM Na2H2PO4) and detached 
with 0.05% trypsin (Sigma – Aldrich). The cells were replated at density of 2,300 nucleated 
cells/ cm² and further expanded up to three or four passages in the medium described 
above. Medium was changed twice a week. 
 
In-vitro chondrogenic differentiation 
BMSC were resuspended in a concentration of 0.2 x 106 cells in 0.5 ml chondrogenic 
culture medium and centrifuged at 1000 x g for 8 minutes in polypropylene tubes to form 
pellets. Chondrogenic differentiation was induced by culturing for 35 days in chondrogenic 
medium (31; 53; 54), consisting of DMEM high glucose, containing Glutamax (Gibco), 1:100 
Insuline Transferring Selenic acid (ITS+) (B&D Biosciences, Bedford, MA), 40 µg/ml L-
proline (Sigma – Aldrich), 1 mM sodium pyruvate (Gibco), 1.5 µg/ml Fungizone, 50 μg/ml 
Gentamycine, 25 µg/ml L-ascorbic acid 2-phosphate, 100 nM dexamethasone (Sigma – 
Aldrich), and concentration of TGF-β type 1, type 2 or type 3 (R&D Systems, Minneapolis, 
MN, USA) depending on the experiment as described below. Medium was changed twice a 
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week. A dose-response experiment was performed with BMSC from one donor with good 
chondrogenic capacity, using the three different TGF-β subtypes in concentration of 2.5 
ng/ml, 10 ng/ml or 25 ng/ml throughout the culture period. Because all had equal molecular 
weight (approximately 25 kDa) and the three TGF-β subtypes were able to induce 
chondrogenesis with comparable dose-response curves, subsequent experiments were 
obtained with the commonly used concentration of 10 ng/ml TGF-β. BMSC of four donors 
with different chondrogenic capacity were cultured in this fashion. In the last 2 weeks of 
culture, 10 ng/ml β-glycerophosphate (BGP) was added to the medium of some pellets to 
study the capacity to mineralize. 
 
(Immuno)histochemical staining 
Pellets were fixated in 4% formalin in PBS, set in 2% agar and overnight dehydrated and 
embedded in paraffin. Six-micrometer-thick sections were made, deparaffinized in xylene 
and rehydrated through graded ethanol.  
Collagen II and collagen X 
To analyze collagen II expression, antigen retrieval was performed though incubation with 
0.1% pronase (Sigma – Aldrich) in PBS for 30 minutes at 37°C, while antigen retrieval for 
collagen X required 0.1% pepsin (Sigma – Aldrich) in 0.5 M Acetic Acid at pH 2.0 for 2 hours 
at 37°C. Both procedures continued with a 30 minutes incubation of 1% hyaluronidase 
(Sigma – Aldrich) in PBS. Slides were pre-incubated with 10% normal goat serum (NGS) 
(Sigma – Aldrich) in PBS containing 1% bovine serum albumin (BSA) (Sigma – Aldrich). 
Next, the slides were incubated overnight at 4 – 7°C with respectively mouse monoclonal 
antibody against collagen II (II-II6B3, Developmental Studies Hybridome Bank, Iowa City, 
IA) or against collagen X (Quartett X53, Berlin, Germany) in PBS containing 1% BSA. The 
next day, a biotin-labeled secondary antibody was used (LINK) (Biogenex, HK-325-UK, from 
LINK-LABEL kit ZA-000-UM), in addition of 5% normal human serum (NHS), followed by an 
alkaline-phosphatase-conjugated streptavidine (LABEL) (Biogenex, HK-321-UK). Incubation 
with Neu Fuchsin substrate (Chroma, Kongen, Germany) was performed to demonstrate 
alkaline phosphatase activity with a red stain. Sections were counterstained with Gill’s 
haematoxylin (Sigma – Aldrich).  
Alizarin Red and Von Kossa staining 
For evaluation of mineralization, slides were stained in Alizarin Red S solution (Sigma – 
Aldrich). Sections were immersed in acetone and subsequently in acetone/xylene. Thus, 
calcium depositions were demonstrated with an orange stain. Von Kossa staining was also 
used to demonstrate mineralization. For this staining slides were immersed in 5% silver 
nitrate solution (Sigma-Aldrich) for 10 minutes, rinsed in ultra pure water and exposed to 
light for 10 minutes. Excess silver nitrate was removed with 5% thiosulfate (Sigma-Aldrich) 
and slides were rinsed in distilled water. Sections were counterstained with 0.4% thionine in 
0.01 M of aqueous sodium acetate pH 4.5 for 5 minutes, demonstrating proteoglycan 
content of the matrix with a purple stain. Calcium depositions were demonstrated with a 
black stain. Alizarin Red staining and Von Kossa staining showed similar trends and 
therefore only the Alizarin Red staining is demonstrated in the figures. Quantification of 
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mineralization was determined by measuring the positive calcium-phosphate fraction over 
the total pellet area with the program ImageJ, an image processing program developed at 
the National Institutes of Health (142). An area was appointed as a positive calcium-
phosphate fraction where Alizarin Red and Von Kossa staining stained the same area. This 
resulted in a percentage of mineralized area. Averaged results of three sections per pellet 
were used for further analysis. 
 
Biochemistry  
DNA 
Pellets were digested overnight at 56°C in 1 mg/ml proteinase K (Sigma – Aldrich) in 
TRIS/EDTA buffer (pH 7.6) containing 185 µg/ml iodoacetamide and 1 µg/ml pepstatin A 
(Sigma – Aldrich). To determine the amount of DNA, samples were treated with 100 µl 
heparin (8.3 IU/ml in PBS) and 50 µl ribonuclease A (50 µg/ml in PBS) for 30 minutes at 
37°C. This was followed by adding 50 µl ethidium bromide solution (25 µg/ml in PBS). 
Samples were analyzed on the Wallac 1420 victor2 (Perkin-Elmer, Wellesley, MA, USA) 
using extinction filter of 340 nm and an emission filter of 590 nm. For standards, calf thymus 
DNA (Sigma – Aldrich) was used. 
GAG  
Proteinase K-digested samples were used to quantify the amount of GAG, by using 
dimethylmethylene blue (DMB) assay. The metachromatic reaction of GAG with DMB was 
monitored with a spectrophotometer, and the ration A530 : A590 was used to determine the 
amount of GAG, using chondroitin sulfate C (Sigma – Aldrich) as a standard (62). 
Total collagen 
Cells were suspended in milli-Q, hydrolyzed at 108°C for 18 to 20 hours in 6 M HCl and 
dried and redissolved in 100μL water. Hydroxyproline contents were measured by 
colorimetric method (143) (extinction, 570 nm), with chloramine-T and 
dimethylaminobenzaldehyde as reagents and hydroxyproline as standard (Merck, Damstadt, 
Germany). 
VEGF secretion 
To determine VEGF secretion, 48-hours conditioned culture medium was centrifuged at 
1000 x g for 15 minutes immediately after collection and the supernatant was stored at –
80°C until further use. The concentration of VEGF in the medium was measured using a 
commercially available sandwich ELISA kit (R&D Systems, Minneapolis, MN, USA) 
according to suppliers information. 
ALP  activity 
ALP activity was assayed by determining the release of paranitrophenol from 
paranitrophenylphosphate (20 mM in 1M diethanolamine buffer supplemented with 1 mM 
MgCl2 at pH 9.8) in the digest of medium for 10 min at 37 °C. The reaction was stopped by 
adding 0.06 M NaOH. Absorption was measured at 405 nm. Results were adjusted for DNA 
content of the cell lysates. 
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Statistical analysis 
Analysis of (immuno)histochemistry, biochemistry and VEGF expression were performed on 
three pellets of each condition. Biochemical data of TGF-β1 treated pellets of the second 
donor were lost due to a technical error. Mixed model analysis and an independent sample 
T-test were performed on day 21 and day 35 between culture days and between different 
TGF-β subtypes. A p-value less than 0.05 was considered to indicate statistically significant 
differences. Statistical analysis was conducted with Microsoft Office Excel 2000 and SPSS 
15.0.  
 
RESULTS 
 
Dose-response curves 
To study whether the different TGF-β subtypes can be directly compared using the same 
concentration, dose-response curves were performed of the three TGF-β subtypes on 
BMSC from a donor with good chondrogenic capacity. After 35 days of culture, control 
pellets without TGF-β were small, had no positive collagen II staining and contained only a 
little amount of GAG production per DNA (GAG/DNA) (data not shown). Chondrogenic 
differentiation with 2.5 ng/ml of either TGF-β subtype resulted in less cartilage production, 
than with 10 ng/ml or 25 ng/ml of the same TGF-β subtype, as demonstrated with limited 
localisation of collagen II staining towards the central regions (fig. 1) and a significant lower 
amount of GAG/DNA (p < 0.05) (fig. 2). In contrast, with either 10 ng/ml or 25 ng/ml of any 
TGF-β subtype, a rich collagen II containing matrix was found throughout all pellets. No 
significant difference was seen between those two concentrations in intensity of the collagen 
II staining (fig. 1) or in GAG/DNA content for any TGF-β subtype (fig. 2).  
 
Amount of cartilage production  
Based on the previous experiment, we concluded that TGF-β1, -β2 and -β3 have 
comparable dose-response curves and can be directly compared using the same 
concentration. As 10 ng/ml is commonly used in literature to induce chondrogenesis and the 
higher concentration of 25 ng/ml did not seem to have a superior effect, subsequent 
experiments were performed with 10 ng/ml of TGF-β. To fully evaluate the capacity of the 
TGF-β subtypes, we performed the experiments with cells of four selected donors with 
variable chondrogenic capacity. From previous studies the first donor was known to have a 
very good capacity for chondrogenic differentiation, while the second was qualified as good, 
the third as low-moderate and the last donor hardly differentiated chondrogenically at all.  
Indeed, the first and second donor already had some positive collagen II staining at day 21 
in the peripheral regions of the pellets, and at day 35 these pellets had abundant staining 
throughout the pellet, irrespective of TGF-β subtype. In contrast, the third and fourth donor 
did not show any collagen II production at day 21 and at day 35 only a very limited area 
stained positive (data not shown). Furthermore, GAG/DNA was significantly higher in the 
first two donors, compared to third and fourth donor (p < 0.05). Addition of 25 ng/ml of TGF-  
β did not increase the amount of cartilage production by these donors with low chondrogenic  
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Figure 1.  (Immuno)-histochemical staining of collagen II of BMSC pellets from a donor with 
good chondrogenic capacity. Pellets were cultured for 35 days with 2.5 ng/ml, 10 ng/ml or 25 ng/ml of 
TGF-β1, -β2 or -β3. Photographs were taken at magnification 40x.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Content of GAG/DNA in BMSC pellets from a donor with good chondrogenic capacity. 
Pellets were cultured for 35 days with 2.5 ng/ml, 10 ng/ml or 25 ng/ml of TGF-β1, -β2 or -β3. Each bar 
represents the average and standard error of the mean of three replicates. Asterisk indicates a 
significant difference with a p-value of * < 0.05 or ** <0.01.  
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capacity (data not shown).  
At day 21 and day 35, no clear differences in collagen II staining were observed 
between the TGF-β subtypes (data not shown). After analyzing the amounts of DNA, 
collagen/DNA and GAG/DNA of each donor separately, no significant differences between 
the TGF-β subtypes were found. However, in the first, second and fourth donor a trend was 
seen towards a higher amount of cartilage produced in presence of TGF-β2 (fig. 3). Still, 
when pellets of all four donors were analyzed together this trend was not recognizable (data 
not shown).  
 
 
 
Figure 3.  Content of collagen/DNA and total GAG/DNA in BMSC pellets. Pellets were cultured for 
35 days with 10 ng/ml of TGF-β1, -β2, or -β3. Each bar represents the average and standard error of 
the mean of each of the four donors separately, with three replicates per donor. Biochemical data of 
TGF-β1 treated pellets of the second donor were lost due to a technical error indicated with an asterisk. 
 
 
 
 
Expression of hypertrophy markers 
At day 35 a positive collagen X staining was detected throughout the pellet in all conditions 
of the first and second donor, demonstrating terminal differentiation of the tissue-engineered 
cartilage. The third and fourth donor with low chondrogenic capacity did not show any 
positive collagen X staining. No clear differences were observed in collagen X staining 
between the TGF-β subtypes in all donors (data not shown). Furthermore, VEGF was 
secreted in the medium at day 35, although no significant differences were detected 
between the TGF-β subtypes (data not shown). These data indicate that terminal 
differentiation was induced in chondrogenically differentiated BMSC pellets, irrespective of 
the subtype of TGF-β used for culturing. 
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Figure 4. Alizarin Red staining of BMSC pellets. Pellets were cultured for 35 days with 10 ng/ml TGF-
β1, -β2 or -β3 with addition of BGP in the last 2 weeks of culture. Positive staining, demonstrating 
calcium-phosphate depositions, is demonstrated with an orange stain. Results of all individual pellets 
from 4 donors with varying chondrogenic capacity are shown. Photographs were taken at magnification 
40x. 
 
 
 
 
Capacity to mineralize 
Alizarin Red and Von Kossa staining showed similar patterns, therefore Alizarin Red staining 
was used to further evaluate mineralization. As expected no calcium-phosphate depositions 
were observed in pellets cultured on chondrogenic medium in the absence of BGP as a 
phosphate donor. If BGP was added to the medium during the last 2 weeks of culture, 
mineralization was clearly observed at day 35 in good chondrogenic donors indicating that 
the tissue-engineered cartilage was not only terminally differentiated but also had a 
tendency towards matrix mineralization. In the first donor with good chondrogenic capacity, 
mineralization was observed in three out of three pellets cultured with TGF-β3 (fig. 4G-4I). 
All three pellets cultured with TGF-β2 were also mineralized (fig. 4D-4F), however the 
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mineralized area was smaller compared to TGF-β3. In comparison, only one pellet cultured 
with TGF-β1 had a very small amount of mineralization, the others were negative (fig. 4A-
4C). The second donor with good chondrogenic capacity showed abundant mineralization 
throughout all three pellets with TGF-β3 (fig. 4P-4R) and slightly less mineralization with 
TGF-β2 and TGF-β1 (fig. 4J-4O). Pellets of the other donors with less chondrogenic 
capacity contained significantly less cartilaginous matrix and consequently almost no 
mineralization in any of the TGF-β subtypes (fig. 4S-4AJ). Addition of a higher concentration 
of TGF-β (25 ng/ml) did not increase either cartilage matrix production or mineralization 
(data not shown). Quantification of mineralization was determined as a percentage of the 
area that stained positive with Alizarin Red, over total pellet area of all four donors. The 
percentage of mineralization was significantly larger in TGF-β3 pellets, compared to TGF-β1 
(fig. 5).  
 To further investigate TGF-β subtype-specific effects on mineralization, ALP activity 
was measured in chondrogenically differentiated pellets at day 35. Because differences in 
mineralization were more prominent in a donor with good chondrogenic capacity, pellets of 
the second donor were used for this additional analysis. In line with the histology, 
significantly more ALP activity/DNA was present in TGF-β3 pellets, compared to TGF-β1 
pellets (fig. 6).   
 
 
 
 
 Figure 5.  Percentage of mineralized area 
over total pellet area. Quantification was 
performed on Alizarin Red and Von Kossa 
staining of BMSC pellets from all four donors 
cultured for 35 days with 10 ng/ml of TGF-β1, 
-β2, or -β3 with addition of BGP in the last 2 
weeks of culture.  Each bar represents the 
average and standard error of the mean of 
four donors with three replicates per donor. 
Asterisk indicates a significant difference with 
a p-value of * < 0.05. 
 
 
 
 
Figure 6. Alkaline Phosphate (ALP) activity 
in BMSC pellets from a donor with good 
chondrogenic capacity. Pellets were cultured 
for 35 days with 10 ng/ml TGF-β1, -β2 or -β3 
with addition of BGP in the last 2 weeks of 
culture. Each bar represents the average and 
standard error of three replicates. Asterisk 
indicates a significant difference with a p-value 
of * < 0.05.  
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DISCUSSION 
 
To induce chondrogenic differentiation of BMSC, all three mammalian TGF-β subtypes are 
commonly used in different laboratories in varying concentrations (31; 33; 35; 53; 54; 129). 
In this study we demonstrate that all three subtypes are able to induce chondrogenic 
differentiation with comparable dose-response curves. A variation in degree of chondrogenic 
differentiation between samples cultured under same conditions is often described as a 
general issue in BMSC cultures (41; 53) and was also noticed in all conditions in our study. 
Although the smaller variation which was seen in pellets that were cultured with 25 ng/ml of 
TGF-β, 10 ng/ml can be used as an affordable and suitable dosage to induce chondrogenic 
differentiation in BMSC with all three TGF-β subtypes. Despite the fact that the three TGF-β 
subtypes share 71-76 % sequence identity and they use the same receptors (130), we 
demonstrated in this study that TGF-β subtypes do affect chondrogenic differentiation 
differently in in-vitro pellet cultures of BMSC. Although no TGF-β subtype-dependent 
differences were found in cartilage production, a striking difference was seen in the capacity 
of the tissue-engineered cartilage to mineralize. TGF-β3 treated pellets had significantly 
more mineralized extracellular matrix than TGF-β1 treated pellets.  
 Only one other previous study (135) has directly compared the effect of all three 
different TGF-β subtypes on in-vitro chondrogenic differentiation of BMSC. However, this 
study only studied the amount of cartilage production and they performed their experiment 
on BMSC from one single donor only. They concluded that the use of TGF-β3 and TGF-β2 
resulted in significantly more cartilage production than TGF-β1. In a study comparing two 
TGF-β subtypes, TGF-β1 and TGF-β3, no differences were found after comparison of 
BMSC pellets of three donors (144). Those results support our study in which we did not see 
significant TGF-β subtype-dependent differences in cartilage matrix production. 
Nevertheless, pellets treated with TGF-β2 did produce more cartilage matrix than TGF-β1 
and TGF-β3, in three out of four donors after 35 days of culture. Because culture methods of 
these studies were similar, donor-dependent differences might play a role in these 
inconsistent results. Even when cultured in the same fashion, BMSC from different donors 
vary in chondrogenic capacity, as was clearly demonstrated in our study. In our experiments 
an association with donor-age and amount of produced cartilage matrix is obvious; the first 
and second donor (respectively 35 and 32 years old) performed equally well with all TGF-β 
subtypes, while the third and fourth donor (respectively 84 and 68 years old) performed 
equally bad. An explanation for the limited chondrogenic differentiation capacity of older 
donors might be found in a decreased expression of the TGF-β receptors with age (116; 
145). However, a study with 60 donors did not found a correlation between donor age and 
extent of chondrogenic differentiation (41). This may be explained by the lower age range 
(14 – 55 years old) in this previous study, compared to our study (32 – 84 years old).  
 The effects of the different TGF-β subtypes on maintenance of the chondrocytes 
phenotype of chondrogenically differentiated BMSC have never been directly compared. 
Nevertheless, collagen X production and as a consequence terminal differentiation were 
previously demonstrated in chondrogenically differentiated BMSC pellet cultures, in the 
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presence of TGF-β1 (125; 129), TGF-β2 (53; 54) and TGF-β3 (33; 35; 41). This suggests 
that terminal differentiation of BMSC occurs in the presence of all TGF-β subtypes, which is 
supported by our results. VEGF, a proangiogenic factor produced by hypertrophic 
chondrocytes (35; 146) was secreted in our pellet cultures, and no significant differences 
were observed between the TGF-β subtypes. Thus concentrating on two important markers 
of terminal differentiation, hypertrophic alterations occurred similarly in the presence of any 
of the three TGF-β subtypes. Conversely, in literature TGF-β1 was used in studies 
demonstrating an inhibitory effect on terminal differentiation of in-vitro cultured epiphyseal 
chondrocytes (136), rabbit costal chondrocytes (137) and chick embryonic limb 
mesenchymal cells (138). As for clinical application it is required to tissue engineer a 
cartilage construct that is stable and does not mineralize in vivo, direct comparison of the 
effects of TGF-β subtypes on terminal differentiation and the relation to mineralization is 
important. 
 Despite the finding that all TGF-β subtypes induce terminal differentiation to a similar 
degree, TGF-β subtype-dependent differences were observed in the capacity of the tissue-
engineered construct to mineralize. After addition of a phosphate donor to the medium, 
pellets cultured with TGF-β3 showed significantly more cartilage matrix mineralization than 
pellets cultured with TGF-β1. Furthermore, significantly more ALP activity/DNA was seen in 
TGF-β3 treated pellets, compared to TGF-β1. Although in their study, Mueller et al 
concluded that TGF-β3 and TGF-β1 were not different, a closer look at the data indicates a 
higher ALP activity with TGF-β3 than with TGF-β1 (144). The finding that TGF-β1 seems to 
inhibit extracellular matrix calcification is supported by the earlier mentioned previous 
studies (136; 137; 138). Besides the conclusion that TGF-β subtype-dependent effects exist 
on mineralization, our results also indicate that expression of collagen X and VEGF as 
markers of terminal differentiation do not predict mineralization. This is in contrast with 
previous statements (136). For future purposes, it is interesting to analyze the expression of 
a broad spectrum of genes to study which genes are related to terminal differentiation and 
which are related specifically to mineralization. Moreover, when tissue-engineered cartilage 
is developed for cartilage reconstruction, the capacity to mineralize should be included in the 
study. The in-vitro pellet culture system is a suitable model to study terminal differentiation in 
BMSC (137). In-vitro testing of mineralization capacity can be performed on pellets by 
histological and biochemical analysis of calcium depositions and ALP activity, after addition 
of a phosphate donor to the medium.  
 In our study we demonstrated that effects of TGF-β subtypes on in-vitro 
chondrogenesis differ. Questions that arise due to our observations regarding the different 
mechanisms of TGF-β1 and TGF-β3 involved in terminal chondrogenic differentiation and 
matrix mineralization are still unanswered. A recent study suggested that the differences in 
TGF-β subtype actions might be caused by their distinct interactions with the TGF-β receptor 
type I (TβRI) and type II (TβRII) (131). They showed that although all three TGF-β subtypes 
form their receptor complexes (TGF-β subtype·TβRI·TβRII) equally well, the variations in the 
receptor type I and type II preferences among the TGF-β subtypes, likely modulate the 
kinetics of the complex assembly and can explain the functional variation between TGF-β 
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subtypes (131). In future, it might be interesting to study gene expression, as well as focus 
on the differences in receptor-binding as well as intra-cellular signalling in in-vitro cultured 
chondrocytes, to get a closer look at which factors are responsibly for controlling terminal 
differentiation and which factors are related to mineralization.  
 We believe this study contributes to the field of cartilage tissue engineering, because 
TGF-β subtypes differ in their effect on in-vitro chondrogenesis of BMSC cultures. 
Summarizing, tissue-engineered cartilage would be a promising solution for the limited 
availability of autologous cartilage for reconstructions of defects. Therefore, we need a large 
and stable cartilage construct without signs of mineralization. Our experiments show that 
although no significant differences were found between TGF-β1, -β2 and -β3 cultured 
pellets, in the quantity of cartilage production or in the expression of hypertrophic markers, 
the presence of mineralization was significantly higher when TGF-β3 was used, compared to 
TGF-β1. TGF-β1 is therefore preferred for use in cartilage tissue engineering. Since TGF-
β3, and to a lesser extent TGF-β2 show signs of matrix-mineralization, those subtypes might 
be better to tissue engineer bone through endochondral ossification.   
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ABSTRACT 
 
Chondrogenically differentiating bone-marrow derived mesenchymal stem cells (BMSC) 
display signs of chondrocyte hypertrophy, such as production of collagen type X, MMP13, 
alkaline phosphatase (ALPL). For cartilage reconstructions this is undesirable as terminally 
differentiated cartilage produced by BMSC mineralizes when implanted in vivo. Terminal 
differentiation is not restricted to BMSC, but is also encountered in chondrogenic 
differentiation of adipose-derived MSC as well as embryonic stem cells which by definition 
should be able to generate all types of tissues including stable cartilage. Therefore we 
propose that the currently used culture conditions may drive the cells towards terminal 
differentiation. In this manuscript we aim to review the literature supplemented with our own 
data to answer the question: Is it possible to generate stable hyaline cartilage from adult 
mesenchymal stem cells? We demonstrate that recently published methods to inhibit 
terminal differentiation (through PTHrP, MMP13 or blocking phosphorylation of Smad1/5/8) 
result in cartilage formation with reduction of hypertrophic markers, though this does not 
reach the low level of stable chondrocytes. A set of hypertrophy markers should be included 
in future studies to characterize the phenotype more precisely. Finally, we used what is 
currently known in developmental biology about the differential development of hyaline and 
terminally differentiated cartilage to provide thought and insights to change current culture 
models to create hyaline cartilage. Inhibiting terminal differentiation may not result in stable 
hyaline cartilage, if the right balance of signals has not been created from the start of culture 
on. 
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INTRODUCTION 
 
Cartilage tissue has a limited capacity for regeneration. As cartilage lesions can lead to 
progressive clinical problems, the potential of cell therapy to stimulate cartilage regeneration 
is currently being investigated (11; 147; 148). Bone-marrow derived mesenchymal stem 
cells (BMSC) are a promising candidate cell source for this purpose because of the ease 
with which they can be isolated and expanded and because of their capacities for 
chondrogenic differentiation (40; 125). However, chondrogenically differentiating BMSCs 
display signs of chondrocyte hypertrophy, such as production of collagen X, MMP13, 
alkaline phosphatase (ALPL) (33; 35; 36; 53; 135). This terminal differentiation of BMSC 
may be advantageous for tissue engineering of bone through the endochondral route (53; 
149). However, for cartilage reconstructions it is undesirable as terminally differentiated 
cartilage produced by BMSC mineralizes and becomes bone when implanted in vivo (33; 
150).  
 Terminal differentiation is not restricted to BMSC. Mesenchymal stem cells isolated 
from adipose tissue also demonstrated collagen X production and ALPL activity upon 
chondrogenic differentiation and mineralized after in-vivo implantation (151). This indicates 
that a predisposition to endochondral ossification of BMSC is not primarily due to their origin 
from the long bones. Moreover, embryonic stem cells (ESC) which by definition are able to 
generate all different types of tissue in the body including stable hyaline cartilage, produce 
hypertrophic cartilage and not stable cartilage after in-vitro chondrogenic differentiation 
(152). The chondrogenic differentiation protocol for ESCs are based on already established 
protocols for adult stem cells and chondrocytes (153). This suggests that the current culture 
conditions drive the cells towards a more terminal differentiation. Recently published 
methods to inhibit terminal differentiation (through PTHrP (101; 102; 154), MMP13 (155) or 
blocking phosphorylation of Smad1/5/8 (156) result in cartilage formation with reduction of 
hypertrophic markers. However, when compared to stable chondrocytes this is only a limited 
improvement. Therefore we aimed to review the literature supplemented with own data to 
answer the question: Is it possible to generate stable hyaline cartilage from adult 
mesenchymal stem cells such as BMSCs? We used what is currently know in 
developmental biology about the differential development of hyaline and terminally 
differentiated cartilage to provide thought and insights to change current culture models to 
create hyaline cartilage. 
 
MATERIALS AND METHODS 
 
Cell isolation and expansion 
BMSC were isolated from a femoral shaft biopsy of 4 donors (age 30-44) undergoing total 
hip replacement, after informed consent had been obtained in accordance with the local 
ethical committee (MEC-2004-142). BMSC were expanded in DMEM-LG (Gibco, Carlsbad, 
CA, USA), supplemented with 10% fetal calf serum (FCS), 1 ng/ml FGF2 (AbD Serotec, 
Kidlington, UK), 25 μg/ml ascorbic acid-2-phosphate (Sigma-Aldrich, St. Louis, MO, USA), 
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1.5 µg/ml fungizone (Gibco)  and 50 µg/ml gentamicin (Gibco). BMSC form passage (P) 2-4 
were used for the experiments. 
 Articular cartilage was obtained as leftover material from 2 donors (age 3-8) 
undergoing triple arthrodesis (MEC-2007-032). These children were treated for clubfoot 
deformity and therefore this cartilage was considered normal, as was confirmed by 
histology. Auricular cartilage was obtained from a patient undergoing rhinoplasty using ear 
cartilage (age 26) (MEC-2005-359) and a patient (age 12) undergoing protruding ear 
reconstruction (MEC-2006-186). After resection of the perichondrium cartilage slices were 
digested through incubation with 2 mg/ml Pronase E (Sigma-Aldrich) and 1.5 mg/ml 
Collagenase B (Boehringer Mannheim, Germany). Chondrocytes were expanded in DMEM 
containing Glutamax with 10% FCS and 1.5 µg/ml fungizone and 50 µg/ml gentamicin. 
Chondrocytes from P2 were used for the experiments.  
  
Chondrogenic differentiation  
Cells were differentiated in pellet cultures of 2 x105 cells in DMEM containing Glutamax, 
ITS+1 (B&D Bioscience, Bedford, MA, USA), 40 μg/ml L-proline (Sigma-Aldrich), 1 mM 
sodium-pyruvate (Gibco), 5 µg/ml fungizone and 50 µg/ml gentamicin, 25 μg/ml ascorbic 
acid-2-phosphate, 10 ng/mL TGFβ2 (R&D systems, Minneapolis, MN, USA) and 10-7M 
dexamethasone (Sigma-Aldrich). 10µM Dorsomorphin (Biomol international, Exeter, United 
Kingdom) or 10 ng/ml PTHrP (Peprotech, Rocky Hill, NJ, USA)  was added to the medium of 
BMSC from three donors from day 14 on to inhibit terminal differentiation. To test the ability 
of the tissue-engineered constructs to mineralize, β-glycerophosphate was added 
additionally to the medium day 35-49 (156). Pellets were harvested in triplicate for 
(immune)histochemistry and gene-expression analysis.  
  
(Immuno)histochemistry 
Samples were fixed in 4% formalin and embedded in paraffin. Antigen retrieval for collagen 
II was performed through incubation with 0.1% pronase (Sigma-Aldrich) in PBS for 30 
minutes, while antigen retrieval for collagen X required 0.1% pepsin (Sigma-Aldrich) in 0.5M 
acetic acid (pH=2.0) for 2 hours. Both stainings continued with incubation with 1% 
hyaluronidase (Sigma-Aldrich) in PBS. Sections were incubated overnight with primary 
antibodies for collagen II (II/II6B3, Developmental Studies Hybridoma Bank) or collagen X 
(2031501005, Quartett, Berlin, Germany) after blocking of non-specific binding sites with 
10% goat serum in PBS. An alkaline-phosphatase-conjugated secondary antibody was used 
for these stainings, followed by incubation with Neu Fuchsin substrate (Chroma, Köngen, 
Germany) to demonstrate alkaline-phosphatase activity with a red stain. 
 To evaluate mineralization an Alizarin Red staining was performed. Slides were 
immersed in a saturated Alizarin Red S solution (Sigma-Aldrich) (5 gr/L) for one minute, and 
rinsed in 70% ethanol. 
 
Gene-expression analysis 
Pellets were manually homogenized in RNA-BeeTM (TEL-TEST, Friendswood, TX, USA)  
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and RNA was extracted with chloroform and purified from the supernatant using the 
RNAeasy Micro Kit (Qiagen, Hilden, Germany).  
 RNA concentration and purity were assessed on a spectrophotometer (NanoDrop® 
ND-1000 UV-Vis Spectrophotometer, Isogen Life Science B.V., Belgium). Complementary 
DNA (cDNA) was made using RevertAid™ First Strand cDNA Synthesis Kit (MBI 
Fermentas, Germany) and polymerase chain reactions were performed using TaqMan® 
Universal PCR MasterMix (Applied Biosystems, Capelle a/d Ijssel, Netherlands), as 
described earlier (53; 113), but on a ABI PRISM® 7000 (Applied Biosystems, Foster City, 
CA, USA). Primers used for real-time RT-PCR reactions for GAPDH, SOX9, CBFA1, 
collagen II, collagen X and ALPL were reported previously by Farrell et al (53), for SSP1, 
BGLAP and IBSP by Jansen et al (157), for VEGF by Verseijden et al (158),  and for 
MMP13 by de Mos et al (159).  
 After testing GAPDH, 18S, HPRT, ACTB, UBC and B2M as housekeeping genes on 
selected samples, GAPDH was chosen to normalize the data to. Relative expression was 
calculated according to the 2-ΔCT formula (160).  
 
Statistical analysis 
Statistical analysis was conducted using SPSS 15.0 and the GraphPad Prism 5 (San Diego, 
CA, USA) software for Windows. Values are represented as mean ± SEM. Mixed model 
analysis and independent sample T-tests were performed and the level of significance was 
set at a p value of less than 0.05. 
 
Literature review 
A literature search was performed in order to do a narrative review in Pubmed from 1948 
until march 2010 using the following key words: Mesenchymal Stem Cell, Embryonic Stem 
Cell, chondrogenesis, cartilage, hypertrophy, hypertrophic differentiation, terminal 
differentiation, collagen X, MMP13, mineralization, endochondral ossification, development, 
hyaline, growth plate or synovial joint.  We excluded papers that were not written in English. 
 
RESULTS AND DISCUSSION 
 
Characterization of terminal differentiation 
While BMSC display signs of terminal differentiation, i.e. production of collagen X (33; 35; 
53) and mineralization in vivo (33), expanded articular chondrocytes produce stable hyaline 
cartilage that is negative for collagen X and does not mineralize (33; 34). This confirms a 
vast amount of research reports that lead to the general acceptation of collagen X as a key 
marker for hypertrophy. However, we have previously demonstrated that expanded auricular 
chondrocytes cultured under the same conditions produce a cartilage matrix rich in collagen 
X that does not mineralize when implanted in vivo for 6 weeks (161). This may suggest that 
terminal differentiation is not easily characterized by the expression of one marker, but a set 
of markers is required. We studied gene expression of a set of hypertrophic markers by 
BMSC, auricular chondrocytes and articular chondrocytes that were chondrogenically 
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differentiated for 35 days in pellet cultures. On histology all three cell types produced 
cartilaginous matrix and collagen II and SOX9 were expressed in all three cell types 
indicating chondrogenic differentiation. Collagen X expression was significantly higher in 
BMSCs than in auricular chondrocytes, and was hardly expressed by articular chondrocytes 
(fig. 1). Expression of two other hypertrophy markers, MMP13 and SSP1 (osteopontin), were   
 
 
Figure 1. Gene expression of chondrogenic and hypertrophic markers in BMSC, auricular 
chondrocytes and articular chondrocytes. Cells were chondrogenically differentiated for 35 days. 
Data are shown of 12 samples from 3 BMSC donors and of 6 samples from 2 donors of articular or 
auricular chondrocytes. Collagen II and SOX9 were expressed in all three cell types indicating 
chondrogenic differentiation. Expression of Collagen X, MMP13 and SSP1 was highest in BMSC and 
lowest in articular chondrocytes with auricular chondrocytes in between. ALPL and IBSP were 
expressed high in BMSCs compared to both articular and auricular chondrocytes, suggesting a 
correlation between these genes and matrix mineralization. No clear distinct expression pattern was 
seen in the other markers associated with terminal differentiation: CBFA1, VEGF, and BGLAP. 
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also highest in BMSC and lowest in articular chondrocytes with auricular chondrocytes in 
between. ALPL and IBSP (bone sialoprotein II) were expressed high in BMSCs compared to 
both articular and auricular chondrocytes suggesting a correlation between these genes and 
matrix mineralization. Finally, no clear distinct expression pattern was seen in the other 
markers associated with terminal differentiation: CBFA1, VEGF, and BGLAP (osteocalcin).  
The high expression of these genes may indicate that even in articular chondrocytes 
terminal differentiation is initiated to some extent in vitro. In future studies these gene-
expression data should be confirmed on a protein level, to determine whether these proteins 
are in fact translated. However, these gene-expression data do inform us on the phenotype 
of these cells in different stages of chondrogenesis and hypertrophy.    
 In summary, these data indicate that gene expression of collagen X, MMP13 and SSP1 
are markers for increasing hypertrophic phenotype, while ALPL and IBSP gene expression 
correlate well to the ability to mineralize the matrix (fig. 2). Therefore, a set of hypertrophy 
markers should be used in future studies to characterize the progress of terminal 
differentiation more profoundly. 
 
 
 
 
 
 
 
 
 
 
Figure 2. Schematic figure of the gradual progression of chondrogenic differentiation and 
terminal differentiation towards cartilage that can mineralize.  Gene expression of collagen X, 
MMP13 and SSP1 are markers for increasing hypertrophic phenotype, while ALPL and IBSP gene 
expression correlate well to the ability to mineralize the matrix. CBFA1, VEGF an BGLAP are non-
specific markers. 
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Molecular inhibition of terminal differentiation and mineralization in BMSCs   
Recently, a small number of papers have been published on methods to inhibit terminal 
differentiation of BMSC. 
 
PTHrP 
In the growth plate, the negative feedback loop of parathyroid hormone-related peptide 
(PTHrP) and Indian hedgehox (Ihh) determines the moment when the chondrocytes leave 
the proliferative zone and enter the transition to hypertrophic zone (162). PTHrP is produced 
by perichondral cells and chondrocytes at the end of the growing bone, diffuses away and 
binds to PTH/PTHrP receptors on chondrocytes in the growth plate delaying their conversion 
into prehypertrophic and then hypertrophic chondrocytes. Chondrocytes sufficiently far away 
from the source of PTHrP stop proliferating and only then synthesize Ihh. This Ihh then 
stimulates the synthesis of PTHrP by perichondrial cells thereby creating a feedback loop. 
The function of PTHrP in delaying mineralization was demonstrated using PTHrP knock-out 
mice (163). The use of PTHrP addition to BMSCs in culture is therefore very logical. PTHrP 
added throughout the culture period of BMSCs resulted in a significant 5-fold reduction of 
collagen X expression and a two-fold reduction in ALPL activity (101). In another study no 
significant reduction of collagen X mRNA expression was seen when PTHrP was given 
merely from day 14 on, while a reduction in immunostaining for collagen X, collagen I and 
CBFA1 was observed (102; 154). The data of these studies were very promising but since a 
wide range of hypertrophy markers was not taken into account in these studies and the 
effect on mineralization was not evaluated, we repeated this experiment in our lab. Addition 
of PTHrP to chondrogenic differentiation medium from day 14 on confirmed an evident 
reduction of immunostaining for collagen X at day 35 (fig. 3). When β-glycerophosphate was 
added to the medium from day 35-49  Alizarin Red staining demonstrated a clearly 
diminished mineralization potential compared to the control without PTHrP. Although gene-
expression of collagen X, SSP1 and IBSP was significantly reduced in pellets treated with 
PTHrP (fig. 3), the absolute level of expression was still high compared to the cartilage 
constructs produced by auricular or articular chondrocytes (fig. 1). Moreover, no significant 
reduction was observed in gene expression of the other hypertrophic markers (fig. 3), 
including MMP13 and ALPL that were related to terminal differentiation and mineralization in 
the previous experiment. Therefore, it seems unlikely that adding PTHrP during 
chondrogenic differentiation on its own is sufficient to produce a cartilage construct that is 
stable and does not mineralize in vitro. However, in combination with other factors it may 
direct BMSC towards a more stable hyaline phenotype. For further studies on PTHrP and 
inhibition of terminal differentiation of BMSC, it is advisable to study a large array of 
hypertrophic markers and to include in-vivo experiments to study stability and mineralization 
of the cartilage construct when used for cartilage reconstruction.  
 
Blocking Smad1/5/8 phosphorylation 
The Smad1/5/8 route is commonly known as the route activated by Bone Morphogenetic 
Proteins (BMPs), a member of the TGF-beta superfamily and a very potent inducer of bone 
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formation (106). Next to the canonical TGF-β signaling pathway via Smad2/3, it has recently 
been shown that an alternative type I receptor (ALK1 instead of ALK5) can be used by TGF-
β that signals via Smad1/5/8 (104; 103; 105). Smad1/5/8 phosphorylation is known to 
stimulate terminal differentiation in murine embryonic endochondral ossification (109) and 
we have demonstrated previously that this route is activated in in-vitro tissue-engineered 
cartilage constructs derived from BMSCs (156). In contrast, this pathway is not activated in 
hyaline cartilage. The Smad1/5/8 pathway may be activated by either the exogenous TGF-β 
in the chondrogenic differentiation medium or BMP or TGF-β subtypes that are expressed 
endogenously during culturing of BMSCs. 
 Blocking Smad1/5/8 phosphorylation by adding dorsomorphin to the differentiation 
medium from day 14-35 resulted in reduced immunostaining for collagen X and a reduction 
in gene expression of MMP13, SSP1, ALPL and IBSP, markers that we have previously 
characterized to be important for terminal differentiation and mineralization (fig. 3), while 
sustaining further collagen II production. Therefore, dorsomorphin seems to inhibit terminal 
differentiation on a broader scale than PTHrP. Moreover, when β-glycerophosphate was 
added to the medium mineralization was inhibited. However, reduction of hypertrophic 
markers did not reach the low level of expression seen in hyaline cartilage produced by 
articular chondrocytes. It is likely that dorsomorphin inhibits terminal differentiation and 
mineralization temporarily to some extent, but the cartilage construct may become terminally 
differentiated and mineralized when implanted in an in-vivo environment where 
dorsomorphin is not added. Further studies on in-vivo stability of cartilage constructs 
cultured in the presence of dorsomorphin is therefore warranted.   
 
Matrix Metalloprotease Inhibitors 
Endochondral ossification is dependent upon proteolysis of the extracellular matrix and 
MMP13 activity is required for terminal differentiation of bovine fetal epiphyseal 
chondrocytes (164). A recent study demonstrated that addition of a pan-MMP13 inhibitor 
prevented chondrogenic differentiation of bone-marrow and adipose-derived MSC (155). A 
selective MMP13 inhibitor allowed chondrogenesis and reduced ALPL activity two-fold. 
However, it did not significantly reduce gene expression of collagen X and other markers of 
hypertrophy were not evaluated. 
 
Other approaches to reduce terminal differentiation and mineralization of BMSC 
Cells may be sensitive to subtle differences in surface chemistry. Therefore coating the 
surface of a scaffold material can have an effect on cell differentiation, as can the creation of 
functional groups (-CH3, -NH2, SH, -OH, and -COOH). Changing the chemical composition 
of the surface may be an alternative approach to prevent terminal differentiation and create 
hyaline cartilage. 
 BMSCs cultured on nitrogen-rich plasma polymer coating demonstrated a decreased 
gene expression for collagen X, ALPL, bone sialoprotein, osteocalcin, and CBFA1 (Runx2) 
compared to control BMSCs cultured on commercial polysterene (165). However, collagen II 
expression did not reach detectable levels and chondrogenic differentiation was thus not 
Chapter 6 
 
102 
achieved in this experiment with medium containing 10% fetal bovine serum without addition 
of growth factors. As a consequence it is hard to draw conclusions from this study regarding 
the potential to inhibit terminal differentiation and create hyaline cartilage. 
 Coating with cartilaginous extra cellular matrix components creates a 
microenvironment that better resembles natural hyaline cartilage and may favor hyaline 
differentiation. Microbeads coated with collagen II or chondroitin sulfate (CS) led to 
increased glycosaminoglycan and collagen II production compared to pellet culture (166). 
Collagen X expression was reduced on protein level as well as on mRNA level in 
microbeads coated with hyaluronic acid or chondroitin sulfate, compared to collagen II-
coated microbeads or pellets (166). However, collagen X was still upregulated compared to 
undifferentiated BMSC and terminal differentiation was not completely prevented. Other 
hypertrophic markers such as CBFA1 and MMP13 were unfortunately not studied.  
 An alternative hypothesis why mineralization of chondrogenically differentiated BMSC 
occurs in vivo is that differentiation of the in-vitro tissue-engineered constructs is not yet fully 
induced and therefore the cells tend to lose their phenotype after implantation into ectopic 
sites, such as implantation subcutaneously. Indeed extended in-vitro culture of 12 weeks 
with TGF-β and IGF1 on PGA scaffolds resulted in stable cartilage that did not mineralize 
even after 24 weeks of in-vivo implantation, while constructs cultured in vitro for 4 or 8 
weeks demonstrated mineralization and vascular invasion after in-vivo implantation (42). 
Unfortunately, investigation of chondrogenic differentiation was not extended beyond 
collagen II immunohistochemistry and Safranin O staining and hypertrophic markers were 
not studied. Hence, it is impossible to say whether extended differentiation results in the 
production of stable hyaline cartilage. One can only conclude from this study that extended 
culture using the model performed in this study seems to prevent mineralization upon in vivo 
implantation. Moreover, this study should be repeated and extended to other models beside 
PGA and the role of the addition of IGF1 in this study should be further evaluated.    
 
 
 
Figure 3 (next page). (Immuno)histochemistry and gene-expression of BMSC pellets with or 
without addition of dorsomorphin or PTHrP. BMSC were chondrogenically differentiated with or 
without addition of dorsomorphin or PTHrP day 14-35. A-B Immunohistochemistry for collagen II and 
collagen X at day 35. While collagen X was inhibited in dorsomorphin or PTHrP treated pellets, collagen 
II production was allowed. C Gene expression of chondrogenic and hypertrophic markers in BMSC at 
day 35. Addition of both dorsomorphin and PTHrP allow expression of chondrogenic markers collagen II 
and SOX9. Dorsomorphin inhibits expression of hypertrophic markers MMP13, SSP1, ALPL, IBSP and 
VEGF, while PTHrP inhibits collagen X,SSP1 and IBSP. D To test ability to mineralize β-
glycerophosphate was added to the chondrogenic medium with or without dorsomorphin or PTHrP day 
35-49. Alizarine Red staining demonstrates inhibition of mineralization in dorsomorphin and PTHrP 
treated pellets.  Samples were harvested in triplets from three independent donors. (Immuno)-
histochemistry is shown of a representative pellet of one donor, while gene-expression is demonstrated 
of all three donors with triplicate samples per donor.  
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Effect of in-vitro culture conditions  
The above mentioned approaches to inhibit terminal differentiation in BMSC are not 
successful in inhibiting the expression of genes such as collagen X, ALPL and MMP13 to a 
level that resembles hyaline cartilage. Assuming that BMSC are theoretically able to 
generate hyaline cartilage, it is probable that the current in-vitro culture conditions are 
inducing terminal differentiation in a very early stage. In fact, we have previously 
demonstrated that, in contrast to embryonic endochondral ossification, the stage of early 
chondrogenic differentiation and the stage of hypertrophy are not clearly discernable in in-
vitro chondrogenic pellet cultures of BMSC where almost no interval exists between 
production of collagen II and X. Moreover, FGFR1 which is seen in embryonic endochondral 
ossification only during hypertrophy was already upregulated in BMSC producing collagen II 
before collagen X was observed (54).  
 
Expansion 
No definitive markers exist to select mesenchymal stem cells from a bone-marrow biopsy, 
therefore the cells are commonly selected by plastic adhesion. As a consequence a 
heterogeneous cell population is used for culturing. Osteogenic progenitor cells may well be 
present in the starting cell population. Medium used for expansion may also select these 
osteoprogenitor cells, or expansion may induce a more osteogenic phenotype. FGF2 is 
often added to the medium during expansion to accelerate population doublings and retain 
chondrogenic capacity (44; 167). However, this growth factor may select cells that are more 
driven towards the endochondral route. Nevertheless, hypertrophic cartilage formation by 
pig BMSCs was also observed when PDGF and EGF were added to the medium instead of 
FGF2 (168). Another factor that may play a role in selecting certain subpopulation is the use 
of fetal calf or bovine serum for colony formation and proliferation of BMSCs. Serum is a 
complex natural product that may vary from batch to batch even from a single manufacturer 
(169). The quality and concentration of both bulk and specific proteins can affect cell 
behavior and differentiation. A variation in chondrogenic potential due to the used serum is 
thus expected and indeed observed. However, it is likely that the different laboratories 
working on chondrogenic differentiation of BMSC use different serum batches and the 
induction of terminal differentiation of BMSC seems to be universally.  
 
Differentiation model 
To induce chondrogenic differentiation of BMSC a 3D culture system is typically used and 
the cells are cultured in specific differentiation medium. When studying gene expression of 
hypertrophic markers in time during chondrogenic differentiation in pellet culture it is clear 
that directly after expansion, before differentiation, Collagen X, MMP13 and IBSP are hardly 
expressed (fig. 4). ALPL gene expression on the other hand is high before chondrogenic 
differentiation, not unsurprisingly as ALPL is also a stem cell marker. ALPL is quickly 
downregulated during the first week of differentiation culture. Gene expression of ALPL, 
collagen X, MMP13 and IBSP are strongly upregulated during the second week of differen- 
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tiation, while CBFA1 and SSP1 expression increases more or less continuously during 
culture. This suggests that the current differentiation protocol and not the expansion induces 
the hypertrophic phenotype of BMSCs. Moreover, expression of these hypertrophic markers 
very quickly follows, almost overlaps, with the onset of chondrogenesis (expression of 
collagen II). This may even suggest a hypertrophic phenotype is prespecified when 
chondrogenic differentiation is still in its early stages. This may be an explanation why 
inhibiting terminal differentiation after the onset of chondrogenesis (i.e. with PTHrP or 
dorsomorphin) does not result in a truly stable hyaline phenotype although hypertrophic 
markers are reduced to some extent. 
 
Figure 4.  Gene expression of chondrogenic and hypertrophic markers during chondrogenic 
differentiation of BMSC. BMSC were chondrogenically differentiated for 35 days in pellet cultures. 
Data are shown of 6 samples from 2 donors. Expression of hypertrophic markers very quickly follows 
the onset of expression of collagen II. 
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 Pellet culture is a high cell-density model that is often used to study chondrogenic 
potential of BMSCs (33; 35; 44; 53; 101; 102; 135; 154). Therefore, the terminal 
differentiation may be associated with the high cell density or the direct cell-cell contact in 
this culture model. However, hypertrophic differentiation was also seen in polyglycolic acid 
(PGA) scaffolds (42; 101), fibrin-supported spheroids (168), and alginate beads (36). Direct 
comparison of pellet and alginate culture indicated expression of collagen II as well as 
collagen X at day 14, both somewhat higher in alginate culture (170). Validating these data, 
we have observed terminal differentiation of BMSC in both pellet and alginate models after 
14 and 35 days when using cells from the same donor (unpublished data). 
 
Differentiation medium 
From the above it does not seem likely that the choice of 3D model is associated with 
terminal differentiation. Therefore it may be the choice of differentiation medium that induces 
hypertrophy. This concept is supported by a study that demonstrated that while in-vitro 
cultured pig BMSC produced hypertrophic cartilage, in-vivo implantation of BMSC in a full-
thickness cartilage defect resulted in a spatially organized repair tissue (168). Hypertrophic 
cartilage was found in the deep zone in transition to subchondral bone and hyaline cartilage, 
rich in collagen II and proteoglycan but negative for collagen X, was found in the central 
region (168). However, in four out of six samples in which BMSC were not transplanted 
some chondrogenic repair tissue was also observed, mostly limited to the deep zone and 
thus possibly due to migration of local cells into the osteochondral defect. Moreover, it was 
not demonstrated whether or not the cartilage matrix lacking collagen X was produced by 
the implanted BMSC or by other cells that migrate into the defect, for example from the 
cartilage. However, these data are promising and suggest that the in-vitro microenvironment 
favors terminal differentiation and that BMSC might be capable of forming of stable cartilage. 
 Chondrogenic differentiation medium used in the above-mentioned publications 
evaluating terminal differentiation of human BMSCs contained TGF-β, ITS and 
dexamethasone (33; 36; 53; 101; 102; 135; 155; 164; 168), occasionally supplemented with 
IGF (42) or triiodothyronine (35). For the chondrogenic differentiation of AT-MSC BMP6 
(151; 155) or BMP7 (102) was additionally used. As these in-vitro chondrogenic 
differentiation media induce terminal differentiation of BMSCs, one of these factors or a 
combination thereof may be the trigger. Still, chondrocytes cultured in the same culture 
medium do not show signs of terminal differentiation as we have demonstrated earlier in this 
paper. Progenitor cells derived  from articular cartilage also form stable hyaline cartilage in a 
similar culture medium (171), indicating these progenitor cells have more tissue-specific 
(chondrogenic) properties and are less multi-potent than BMSC. Therefore, directly 
comparing these different cell types during culture, and studying for example their 
endogenous expression, may shed light into defining a better culture medium to create 
stable hyaline cartilage. 
 Also noteworthy is that the chondrogenic effect of these factors has been studied 
empirically by adding it throughout the culture period. In a recent paper by Lenas et al, the 
model of “developmental engineering” was put forward (172). Instead of investigating 
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empirically by trying various combinations of tools leading to a perpetual cycle of trial-and-
error attempts, a rational methodology should be followed based on a fundamental 
understanding of tissue development. To learn more about the fundamentals of normal 
differential development of hyaline and hypertrophic cartilage we should therefore review 
literature dealing with embryonic chondrogenesis.  
 
Induction of terminal differentiation versus hyaline chondrogenic differentiation: What 
can we learn from embryonic development? 
There is a traditional view that the development of articular hyaline cartilage is nothing more 
than the remnants of the embryonic epiphysis failing to go through endochondral 
ossification. Based on this view, the cartilage tissue-engineering field has used 
endochondral ossification during embryonic limb formation as a model for chondrogenesis 
and methods to inhibit terminal differentiation are often derived from research on the growth 
plate (5; 39; 173). However, chondrocytes in the growth plate are destined to become 
terminally differentiated and it therefore may not be the model of choice to study hyaline 
cartilage formation. Indeed, above-mentioned results in BMSC confirm that these cells are 
induced towards a terminally differentiated phenotype early on during their in-vitro 
differentiation and that inhibiting terminal differentiation is not sufficient to create true hyaline 
cartilage.  
 In fact, in developmental biology the idea that articular cartilage is a remnant of 
endochondral ossification is increasingly being challenged (174). The hypothesis that 
articular cartilage is derived from a distinct population of cells becomes more clear (174). 
This concept is also important for cartilage tissue engineering as it may mean inhibiting 
terminal differentiation may not result in stable hyaline cartilage. At a certain stage during 
limb development, a remodeling event takes place at the future joint location (called 
cavitation); the cells lose their round morphology and become elongated, accompanied by a 
loss of collagen II and an increase in collagen I expression. This zone is called the interzone 
and surgical removal of this zone results in fusion of the skeletal elements. The interzone 
consists of three cell layers; a dense intermediate cell layer and two outer cell layers each 
facing the epiphyseal end of the joint. The cells in the outer layers become chondrogenically 
differentiated early in embryogenesis and become incorporated in the epiphyses, while cells 
in the intermediate zone are responsible for the formation of hyaline articular cartilage (175).  
 The cells forming the interzone are not simply those cells that per chance occupied the 
future joint site. Instead peri-joint cells immediately adjacent to the future joint migrate into 
the site and participate in interzone formation (176). Whether or not the interzone is formed 
from a distinct subpopulations of cells or not is still under controversy, however it is clear 
that the development of the interzone and thus the articular cartilage is regulated apart from 
the transient cartilage template beginning during the prechondrogenic condensation. The 
formation of the interzone seems to be dependent upon blocking chondrogenic 
differentiation. One way through which this seems to be regulated is through BMP 
antagonism and thus blocking the function of chondrogenesis-promoting signals (174; 175). 
In noggin null mutant mice the mesenchymal condensations become much larger but joint 
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development is not initiated. Furthermore, at least two human syndromes characterized by 
multiple synostoses are due to mutations in noggin (174). 
 A central role in the formation of the interzone is also played by Wnt signaling. Ectopic 
expression of Wnt is sufficient to induce the formation of a three-layered interzone (177; 
178). Again, this effect seems to be based on blocking chondrogenic differentiation as 
Wnt14 overexpression in micromass culture resulted in severe inhibition of chondrogenesis 
(177). Besides Wnt14, the interzone also expresses Wnt4, Wnt16 and the canonical Wnt 
signaling mediator β-catenin (178). In the same way as Wnt14, ectopic expression of an 
activated form of beta-catenin induced ectopic joint formation while removal of β-catenin 
promoted chondrocyte differentiation and blocked the activity of Wnt14 in joint formation 
(178).  
 A marker often associated with the interzone is growth and differentiation factor 5 
(Gdf5), a member of the TGF-β superfamily, as it probably was the first recognized gene 
marker in the developing joint. In contrast to the above-mentioned proteins it does not 
induce joint formation, but stimulates chondrogenesis (174; 175). In culture of MSC from 
adipose tissue, GDF5 was described to increase chondrogenesis as well as collagen X 
expression (179).  
 An important concept in “developmental engineering” is that the multistage character of 
developmental processes allows high observability and controllability (172). In-vitro 
processes composed of distinct sequential steps that are characterized by markers 
expressed in a specific stage allow the possibility to intervene with additional factors to direct 
the cells at the appropriate stages. These data from embryonic development of the interzone 
suggest that to develop stable cartilage a subtle balance of chondrogenic stimulating as well 
as inhibiting signals is required, starting from the initial prechondrogenic differentiation, for 
instance FGF, TGF and Wnt. The timing and interactions of these signals may be the 
answer to develop stable hyaline cartilage. 
 
Conclusion 
We have demonstrated that terminal differentiation is a gradual progression of chondrogenic 
differentiation towards cartilage that can mineralize, and is thus best characterized with a set 
of markers indicative of this gradual progression. Although recently published methods to 
inhibit of terminal differentiation (through PTHrP, MMP13 or blocking phosphorylation of 
Smad1/5/8) resulted in cartilage formation with reduction of hypertrophic markers, this does 
not reach the low level of stable chondrocytes. As expression of hypertrophic markers 
almost overlaps with the onset of chondrogenesis, the hypertrophic phenotype may be 
prespecified when chondrogenic differentiation is still in its early stages in current culture 
conditions. These current culture conditions, and the rationale of inhibiting terminal 
differentiation, are derived from a traditional view that development of hyaline cartilage is 
nothing more than chondrocytes failing to go through endochondral ossification. However, 
chondrocytes in the growth plate are destined to become terminally differentiated and it 
therefore may not be the model of choice to study hyaline cartilage formation. Embryonic 
development of the interzone suggest that to develop stable cartilage a subtle balance of 
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chondrogenically stimulating as well as inhibitory signalling is required, starting from the 
initial prechondrogenic differentiation. For cartilage tissue engineering this may mean that 
inhibiting terminal differentiation may not result in stable hyaline cartilage, if the right balance 
of signals has not been created from the start of culture on. 
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ABSTRACT 
  
The use of bioengineered cell constructs for the treatment of bone defects has received a lot 
of attention of late. Often bone marrow stromal cells (BMSC) are used that are in-vitro 
stimulated towards the osteogenic lineage aiming at intramembranous bone formation. To 
date, the success of this approach is disappointing. A major concern in these constructs is 
core degradation and necrosis caused by a lack of vascularization. We hypothesize that 
stimulation of cells towards the endochondral ossification process would be more 
successful. In this study we test how in-vitro priming of human BMSC along osteogenic and 
chondrogenic lineages influences survival and osteogenesis in vivo. Scaffolds that were pre-
cultured on chondrogenic culture medium showed collagen II and collagen X production. 
Moreover, vessel ingrowth was observed. Priming along the osteogenic lineage led to a 
mineralized matrix of poor quality with few surviving cells and no vascularization. 
 We further characterised this process in vitro using pellet cultures. In vitro, pellets 
cultured in chondrogenic medium showed progressive production of collagen II and collagen 
X. In the culture medium of these chondrogenic cultured pellets VEGF release was 
observed at days 14, 21 and 35. When pellets were switched to culture medium containing 
β-glycerophosphate, independent of the presence or absence of TGF-β, mineralization was 
observed with a concomitant reduction in VEGF and MMP release. By showing that VEGF 
and MMPs are produced in chondrogenically differentiated BMSC in vitro we demonstrated 
that these cells produce factors that are known to be important for the induction of 
vascularization of the matrix. Inducing mineralization in this endochondral process does 
however severely diminish these capacities. Taken together, these data suggest that 
optimizing chondrogenic priming of BMSC may further improve vessel invasion in 
bioengineered constructs, thus leading to an alternative and superior approach to bone 
repair. 
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INTRODUCTION 
 
Treatment options for non-unions and large bone defects are plentiful. However, despite the 
use of external and internal fixation, autologous bone graft transplantation or biophysical 
stimuli, success rates vary and outcomes are unpredictable (180; 181; 182). Treatment of 
large bone defects is further complicated by the relatively small amount of available 
transplantable bone tissue further illustrating the need for alternative treatment options. 
 One of the strategies focuses on the use of human bone marrow stromal cells (BMSC), 
which can be harvested with relative ease and can be differentiated towards the 
chondrogenic and osteogenic lineages in vitro (183). Additionally, they can be transplanted 
autologously, which makes them suitable to use in transplantable bio-engineered cell 
constructs. However, to date, a vascularized, mechanically competent, osteoconductive 
construct that could be used to produce bone in vitro or cause complete osteogenesis in 
vivo remains to be developed. The issue of core degradation, arising from lack of nutrient 
delivery and waste removal from the centre of tissue engineered constructs is of major 
concern in the field of tissue engineering (184). This is caused by insufficient blood supply to 
the implanted tissue. Firstly, it takes time for blood vessels to invade a tissue and oxygenate 
it and provide it with nutrients. This is not an instantaneous process and usually occurs too 
slowly for cells to survive without nutrients. The second problem is that culture of a scaffold 
in vitro for several weeks can lead to formation of an extensive extracellular matrix which 
can prevent or seriously hamper blood vessel infiltration in vivo by sealing the pores of a 
scaffold. 
 The approach used for tissue engineering of bone using BMSC is usually similar in 
different laboratories and involves the induction of direct osteogenic differentiation in a 
manner akin to intramembranous ossification in vivo. As discussed the problem with this 
approach is the long term survival of these constructs, which is limited due to lack of 
vascularization. In this study we hypothesized that it might be preferable to induce bone 
formation in vivo via an endochondral ossification approach where hypertrophic 
chondrocytes, primed in vitro and derived from BMSC would be implanted. This priming of 
chondrogenic three-dimensional cellular constructs can be performed to different stages of 
the differentiation and maturation process, namely until a cartilaginous extracellular matrix 
has been formed or when the extracellular matrix is mineralized (185). Often this is seen as 
an obstacle to cartilage tissue engineering and is seen as something to be avoided (33). 
However, more recently the benefit of potentially using this phenomenon for bone tissue 
engineering has been realized (152). Because chondrocytes can survive in hypoxic 
environments (186) and because they produce anabolic and catabolic factors important for 
the conversion of an avascular tissue to a vascularized tissue, such constructs might 
stimulate vessel ingrowth and overcome the problem of core degradation. This approach 
has the benefits of both in vitro and in vivo vascularization strategies (187). In-vivo 
prevascularization of a construct in an ectopic site prior to its use has the benefit of creating 
a material that can be surgically connected to the host vasculature but requires a second 
surgery to relocate the construct to the implant site (188). In-vitro prevascularization avoids 
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this but still requires some time for anastamosis (189; 190) with the host during which time 
there will be a hypoxic period. The approach presented here combines the ease of in-vitro 
priming with the benefit of the ability to withstand the initial hypoxic conditions whilst 
performing in-vivo vascularization in the target site. Any undifferentiated BMSC at this stage 
would also stand a better chance of survival than differentiated cells as has also recently 
been shown (191).  
 In in-vivo endochondral ossification vascular endothelial growth factor (VEGF) is known 
to play a critical role in the establishment of vessel ingrowth by effecting angiogenesis, 
remodeling of extracellular matrix and ossification (146). Additionally, it has been shown that 
matrix metalloproteinases (MMP) are expressed by chondrocytes and hypertrophic 
chondrocytes. These molecules play an important role in the conversion of the non-
vascularized cartilaginous matrix to a vascularized mineralized tissue in both skeletal 
development and fracture healing (192; 193; 194; 195). Based on these facts and the lack of 
success of tissue engineering bone to date, it is more logical to use chondrocytes, which are 
less oxygen sensitive, to produce bone in vivo via the endochondral ossification route which 
will then naturally vascularize and mineralize in situ.  
  In vitro, pellet cultures of chondrogenic differentiated BMSC show a similarity to 
endochondral ossification; they progressively produce collagen II and collagen X, a protein 
specifically produced by hypertrophic chondrocytes (196; 197). When a phosphate donor is 
added to the culture medium mineralization can occur (198). Therefore this culture system 
offers a simple model for the development of in-vitro tissue engineering approaches for the 
creation of vascularized bone in vivo. This study aimed to assess the possible advantages of 
using an endochondral ossification model of bone formation for use in tissue engineering 
approaches. To that end, BMSC were seeded into highly biocompatible collagen 
glycosaminoglycan (Collagen GAG) scaffolds (199; 200; 201) and primed in vitro to progress 
along the osteogenic or chondrogenic routes prior to subcutaneous implantation into nude 
mice. In vitro, a simple model of endochondral ossification using pellet cultures enabled a 
further understanding of the process. 
 
MATERIALS AND METHODS 
 
Isolation and expansion of BMSC 
BMSC of three donors, all female, 33-60 years of age, were obtained during total hip 
arthroplasty after informed consent with approval of the local medical ethical committee 
(METC 2004-142). Bone-marrow aspirates were taken from the greater trochanter. 
Heparinized aspirates were seeded at a density of 30-90 x 106 nucleated cells per T175 
flask. After 24 hours non-adherent cells and cell debris were washed out. BMSC were 
further expanded in Dulbecco’s modified Eagles medium (DMEM), low-glucose with 10% 
fetal calf serum from a pre-selected batch to maintain the multi potential capacities of the 
cells, 50µg/ml gentamycin and 1.5µg/ml fungizone (all Invitrogen, Carlsbad, CA, USA), 
0.1mM L-ascorbic acid 2-phosphate and 1 ng/ml Fibroblast Growth Factor (Instruchemie 
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B.V., Delfzijl, the Netherlands). Cells were cultured at 37ºC under humidified conditions and 
5% carbon dioxide. Medium was changed twice a week. When cultures reached near 
confluence, they were trypsinized using 0.05 % trypsin and were replated at a density of 
2000 cells/cm2. Cells from the second to the fourth passage were used for the pellet 
cultures. BMSC purchased from Cambrex (Now Lonza,Verviers, Belgium) were used in the 
scaffold study. 
 
BMSC seeding onto collagen-GAG scaffold and subcutaneous implantation 
Cells were rinsed with phosphate-buffered saline (PBS, 100mM NaCl, 80mM Na2HPO4, 
20mM Na2H2PO4) and detached with trypsin-EDTA (Invitrogen). The resulting suspension 
was centrifuged (650g, 5min at 20°C), re-suspended in 2ml of control medium, and 
aspirated through a 20-gauge needle to obtain a single-cell suspension of 1.5 x106 cell/ml. 
Collagen-GAG scaffolds (8mm2 generously donated by MIT, Cambridge, MA), prepared by a 
freeze-drying method previously described (200), were seeded with 300,000 cells per 
scaffold as previously described with the exception that a smaller volume of 100µl of cell 
suspension per side was used (199). Seeding efficiency was estimated to be 50% according 
to recent experimental data using the same approach (202). These scaffolds are prepared 
from bovine collagen I and chondroitin sulphate in a freeze-drying process with 
dehydrothermal crosslinking. After seeding, 3 ml of supplemented DMEM was added to 
each well. After 2 days medium was replaced with chondrogenic (25µg/ml L-ascorbic acid 2-
phosphate, 100 mM sodium pyruvate (Invitrogen, Carlsbad, CA, USA), 1:100 ITS (BD 
Biosciences, Bedford, MA), 10ng/ml transforming growth factor beta-2 (TGF-β), (R&D 
Systems, UK,) and 100 nM dexamethasone (Sigma, St Louis, USA)) or osteogenic medium 
(25µg/ml L-ascorbic acid 2-phosphate, 10mM β-glycerophosphate (Sigma), 10-8M 
dexamethasone). Half of the medium was replaced every 3 days. Scaffolds were treated for 
21 days and were maintained in a humidified atmosphere of 95% air/ 5% CO2 at 37°C. At 
day 21, 5 scaffolds of each condition were harvested for histology and 5 scaffolds were 
implanted subcutaneously into the backs of nude mice. Two incisions were made along the 
central line of the spine, one at the shoulders and one at the hips. Two scaffolds were 
implanted at each point, one to the left and one to the right at random. Animals were allowed 
to recover and sacrificed 4 weeks later. This procedure was carried out with approval from 
the local animal ethical committee (EUR334). 
 
Chondrogenic differentiation in pellet cultures 
After detachment of the cells with 0.05% trypsin, 0.5 ml medium, containing 200,000 cells 
were put in polypropylene tubes. Tubes were then centrifuged for 8 minutes at 120g. To 
induce chondrogenic differentiation pellets were cultured for 21 days in DMEM High glucose 
medium containing 50µg/ml gentamycin and 1.5µg/ml fungizone (Invitrogen, Carlsbad, CA, 
USA), l-ascorbic acid 2-phosphate, 100mM sodium pyruvate (Sigma, St Louis, USA), 1:100 
ITS (BD Biosciences, Bedford, MA), 10ng/ml transforming growth factor beta-2 (TGF-β, R&D 
Systems, UK), and 100nM dexamethasone (Sigma, St Louis, USA). 
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 After 21 days of culture, three groups were made that were cultured for another two 
weeks in different media:  
1 Chondrogenic differentiation medium: this group was kept on the same medium 
2 Phosphate-containing chondrogenic medium: in this group 10 mM β-glycerophosphate 
(BGP) was added to the chondrogenic medium 
3 Osteogenic medium: this group was switched to medium with 10mM BGP and 10-8 M 
dexamethasone, without TGF-β 
 In order to induce mineralization of the extracellular matrix, pellets were switched to a 
phosphate-containing culture medium as in medium 2 above. As it has been shown that the 
presence of TGF-β in the culture medium might negatively influence hypertrophy (136), the 
induction of mineralization was also evaluated in pellet cultures switched to a culture 
medium more resembling an osteogenic differentiation medium (medium 3).  
 A pure osteogenic condition was not included in the pellet culture experiment based on 
the lack of sufficient bone formation in the in-vivo condition which we see as a non-viable 
option for bone repair in these settings. 
  
 
 
 
Table 1. Forward and reverse primers for genes of interest. 
Gene symbol Accession No.  Primer (5’-3’) 
ALPL NM_001127501 
NM_000478 
Fw 
FAM 
Rv 
GACCCTTGACCCCCACAAT 
TGGACTACCTATTGGGTCTCTTCGAGCCA 
GCTCGTACTGCATGTCCCCT 
COL2A NM_003150 
NM_001844 
Fw 
FAM  
Rv 
GGCAATAGCAGGTTCACGTACA 
CCGGTATGTTTCGTGCAGCCATCCT 
CGATAACAGTCTTGCCCCACTT 
COL10A1 NM_000493 Fw 
FAM  
Rv 
CAAGGCACCATCTCCAGGAA 
TCCAGCACGCAGAATCCATCTGA 
AAAGGGTATTTGTGGCAGCATATT 
RUNX2 NM_001024630 
NM_001015051 
NM_004348 
Fw 
FAM  
Rv 
GCCTTCAAGGTGGTAGCC 
CCACAGTCCCATCTGGTACCTCTCCG 
CGTTACCCGCCATGACAGTA 
SOX9 NM_000346 Fw 
FAM  
Rv 
CAACGCCGAGCTCAGCA 
TGGGCAAGCTCTGGAGACTTCTGAACG 
TCCACGAAGGGCCGC 
GAPDH NM_002046 Fw 
FAM  
Rv 
ATGGGGAAGGTGAAGGTCG 
CGCCCAATACGACCAAATCCGTTGAC 
TAAAAGCAGCCCTGGTGACC 
 
FW, forward; RV, reverse; FAM, FAM-labelled Taqman Probe. 
Using averages of triplicate samples for each donor. Due to insufficient RNA extracted from Donor C, 
PCR analysis could only be performed for RNA from pellets of donors A and B. 
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Gene expression analysis 
At harvesting pellet cultures were suspended in 300 μl RNA-Bee™ (TEL-TEST, 
Friendswood, TX, USA). To allow optimal suspension of all cells, pellets were disintegrated 
using a pestle and were subsequently flushed through a 28 gauge needle (Monoject, 
Sherwood Davis & Geck, St.Louis, MO, USA). For RNA precipitation a commercially 
available kit was used (Qiagen, Hilden, Germany). Reverse transcription in cDNA was 
performed on 200ng of total RNA using RevertAid™ First Strand cDNA Synthesis Kit (MBI 
Fermentas, St. Leon-Rot, Germany). Primers were designed using PrimerExpress 2.0 
software (Applied Biosystems, Foster City, CA, USA) to meet TaqMan® or SYBR®Green 
requirements and were designed to bind to separate exons to avoid co-amplification of 
genomic DNA. BLASTN ensured gene specificity of all primers. The following genes were 
analyzed: Sox-9 (SOX9), Collagen II (COL 2A1), Collagen X (COL10A1), RUNT-related 
transcription factor 2 (RUNX2/cbfα-1) and Alkaline Phosphatase (ALPL). 
Amplifications were performed as 25μl reactions using either TaqMan® Universal PCR 
MasterMix (ABI, Branchburg, New Jersey, USA) or qPCR™ Mastermix Plus for 
SYBR®Green I (Eurogentec, Nederland B.V., Maastricht, The Netherlands) according to the 
manufacturer's guidelines. Real-Time RT-PCR (QPCR) was done using an ABI PRISM® 
7000 with SDS software version 1.7. Data were normalized to GAPDH that was stably 
expressed across sample conditions (not shown). Relative expression was calculated 
according to the 2-∆CT formula 
 
Immunohistochemical and histochemical staining 
For immunohistochemistry pellets and scaffolds were fixed overnight in 4% phosphate-
buffered formalin and embedded in paraffin. 6μm sections were made, deparaffinized in 
xylene and rehydrated through graded ethanol. Three pellets of each condition were 
analyzed per donor. Five chondrogenically primed scaffolds and four osteogenically primed 
scaffolds were analyzed, sectioned at 10μm. One osteogenic scaffold could not be located 
and retrieved. As a control, scaffolds were also cultured in unconditioned medium and 
analyzed in the same manner (data not shown). 
Immunohistochemistry for collagen II and collagen X 
To analyze collagen II expression, sections were incubated with 0.1% pronase (Sigma, St 
Louis, MO) for antigen retrieval and 1% hyaluronidase (Sigma, St Louis, MO). Sections were 
incubated for 2h at room temperature with mouse monoclonal antibody against collagen II 
(II-II6B3 antibody, 1:100; Developmental Studies Hybridoma Bank, Iowa City, IA, under 
contract N01-HD-6-2915 from the NICHD). For collagen X, sections were incubated with 1% 
pepsin in 0.5 M Acetic Acid at pH 2.0 for 2 hours at 37°C (Sigma, St Louis, MO) and 30 
minutes in 1% hyaluronidase (Sigma). The sections were incubated overnight at 7°C with 
mouse monoclonal antibody against collagen X (1:30, X53, Quartett, Berlin, Germany).  
 For both staining procedures a biotin labeled secondary antibody was used (Biogenex 
HK-325, 1:100) followed by alkaline phosphatase conjugated streptavidin (Biogenex HK-
321-UK, 1:100). This alkaline phosphatase activity was demonstrated by incubation with a 
new fuchsine substrate (Chroma, Kongen, Germany). Control for all antibodies was 
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performed by using an isotype IgG1 monoclonal antibody. Counterstaining was performed 
with Gill's haematoxilin (Sigma, St Louis, MO).  
 Quantification was determined by multiplying the intensity of the staining (ranging from 
1 to 3, where 1 is light positive staining and 3 intense) by the fraction of stained area over 
the pellet area, resulting in a maximum score of 300 (3 x 100%). Scores of three sections 
were averaged. These scorings were performed blind by 2 independent observers. 
  With regard to our choice of markers, Collagen II is the definitive chondrogenic marker 
and collagen X is also the most widely accepted marker of chondrocyte hypertrophy/ 
terminal differentiation. For gene expression analyses discussed below we also examined 
classical markers of chondrogenesis and hypertrophy/osteogenesis, namely the 
chondrogenesis transcription factor, Sox 9, the osteogenic marker alkaline phosphatase and 
the early osteogenic/hypertrophic transcription factor cbfα-1/runx2 (203). 
Von Kossa/Thionine staining 
For evaluation of mineralization, slides were immersed in 5% silver nitrate solution (Sigma, 
St Louis, MO) for 10 minutes, rinsed in ultra pure water and exposed to light for 10 minutes. 
Excess silver nitrate was removed with 5% sodium-thiosulphate (Sigma, St Louis, MO) and 
cells were rinsed in distilled water. For evaluation of proteoglycan content paraffin sections 
were counterstained with 0.4% thionine in 0.01 M aqueous sodium acetate, pH 4.5 for 5 min. 
Thionine stains GAG as can be seen in the chondrogenic conditions (204). 
 Positive calcium phosphate surface over the pellet surface resulted in the fraction of 
mineralized area. Averaged results of three sections per pellet were used for further 
analysis. 
 
VEGF expression and MMP release 
Culture medium of day 14, 21 and 35 were collected from each condition. Immediately after 
collection the medium was centrifuged at 1000g for 10 minutes at 4˚C, and stored at –80˚C 
until further use. 
VEGF 
Expression of VEGF was analyzed on 24-hour conditioned culture medium of day 14, 21, 
35. For each condition, medium of three pellets was analyzed in triplicate using a 
commercially available sandwich ELISA kit (R&D systems, Abingdon, UK) according to the 
manufacturer’s protocol. 
MMP release 
Release of MMPs was determined by concentrating 100μl of the conditioned culture medium 
by ultra-filtration (YM-30, Millipore, Billerica, MA, USA), leaving a sample volume of 
approximately 15μl. Sample loading buffer (Biorad zymogram buffer, BioRad, Hercules, CA, 
USA) was added to the samples (2:1), and were incubated for 10 minutes at 37°C. 
Electrophoresis in a gelatin gel (BioRad, Hercules, CA, USA) was performed, at 100V and 
25mA, together with a marker (BioRad, Hercules, CA, USA). Thereafter gels were incubated 
for 2 hours in a renaturing buffer, containing 2.5% Triton X-100 (Sigma, St Louis, MO) in 25 
mM Tris-HCl (pH 7.4) followed by incubation for 72 hours in an activation buffer (2mM 
calcium chloride, 5µm zinc chloride, 25 mM Tris-HCl, pH 7.5, Fluka). Gels were stained 
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using coomassie brilliant blue and were destained with roti destain (both Carl Roth, 
Karlsruhe, Germany). Areas of proteolytic activity appeared as translucent halos against a 
blue background of stained, non-degraded gelatin. Gels were scanned using a Kodak IS 
scanner. 
Statistics 
Analyzes of immunohistochemistry and VEGF-expression were performed on three pellets of 
each of the three donors for all conditions. An ANOVA test and post-hoc Bonferroni test of the 
means between culture days and between different culture media on day 35 were performed. 
p<0.05 was considered to indicate statistically significant differences. Statistical analysis was 
performed on averages of triplicate samples per pellet using Graph Pad Prism 5.00 for 
Windows (GraphPad Software, San Diego California USA).  
 
 
 
 
 
 
 
 
 
 
Figure 1. Von Kossa staining with thionine of primed scaffolds. GAG production (thionine staining, 
white arrrows) in chondrogenically primed scaffolds after 3 weeks in vitro (A) which is further developed 
after 4 weeks in vivo (C) into a cartilage-like matrix with individual cells surrounded by matrix. No 
mineralization was observed. Following 3 weeks of osteogenic stimulation, mineralized matrix was 
observed both in vitro (B) and after subsequent implantation in vivo (D) with a similar progressive 
increase in matrix production. This matrix however did not resemble native bone nor did it contain many 
viable cells. 
B A 
C D 
Chapter 7 
 
120 
RESULTS 
 
Priming of BMSC in vitro and subsequent in-vivo implantation 
Following 3 weeks in-vitro priming, chondrogenic scaffolds were positive for GAGs and 
negative for mineralization (fig. 1A) whereas osteogenically primed scaffolds were 
mineralized throughout (fig. 1B). Following implantation, the osteogenic scaffolds continued 
to differentiate along the osteogenic route however producing an inferior matrix with 
questionable levels of cell survival 4 weeks after implantation as evidenced by reduced cell 
number within the mineralized portions (fig. 1D). In the chondrogenic condition, despite cell 
survival and a formation of a cartilage like matrix with some hypertrophic cells visible, no 
osteogenesis was observed (fig. 1C). No appreciable matrix formation of either kind was 
observed in control unprimed control conditions (cultured on expansion medium, data not 
shown) showing the promise and importance of the initial in vitro culture period and the 
possible benefits of well timed implantation. 
 Collagen X immunostaining of chondrogenically primed implanted scaffolds showed 
positive staining for in 5 out of 5 of the retrieved scaffolds (fig. 2A). Osteogenically primed 
scaffolds showed only very weak positive staining in 1 of 4 scaffolds (fig. 2B).  
 Importantly, in the chondrogenic scaffolds mature blood vessels were visible in all 
implanted scaffolds (fig. 2). In 3 out of 5 the scaffolds, blood vessels contained erythrocytes, 
in the 2 other scaffolds we found what appeared to be blood vessels without red blood cells. 
This shows not only good cell survival of chondrogenically primed cells but also good host 
integration and suggests progression along the endochondral ossification route. Conversely, 
no vascularization was visible in the osteogenically treated scaffolds, possibly due to too 
much matrix deposition or a lack of release of inductive factors. This lack of vascularization 
in the osteogenically primed constructs might explain the lack of cells in the scaffolds due to 
cell death.  
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Collagen X staining of implanted scaffolds. Following implantation of primed scaffolds, 
immunostaining for collagen X showed that all chondrogenically primed scaffolds were positive for 
collagen X (A) (black arrows) and all osteogenically primed scaffolds were negative (B). More 
importantly, blood vessels containing erythrocytes were visible (see inset, white arrow indicates 
erythrocytes). In contrast, no blood vessels were visible in any of the osteogenically primed scaffolds. 
A B 
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Figure 3. Gene-expression analysis of pellets. Gene-expression analysis of markers of 
chondrogenesis, hypertrophy and osteogenesis showed a steady increase in time in expression of all 
markers cultured in chondrogenic medium. Switching to either of the two mineralizing media for 14 days 
did not lead to significant differences in gene expression of any of the markers. Data represents 3 
pellets per donor for Donors A and B only. 
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Figure 4. Collagen II immunohistochemistry and scoring of pellets. To some extent, positive 
collagen II staining (red) was observed in all pellets in a donor-dependent manner, as is often seen. 
Upon addition of a phosphate donor for 14 days, collagen II expression was vastly reduced in all 3 
donors. 3 sections per pellet with 3 pellets per donor were analyzed to score the amount of staining (1 
way ANOVA; *= P<0.05). Representative images of the chondrogenic condition are displayed for each 
donor respectively. 
 
 
In vitro pellet culture system 
 
Gene expression 
All genes were observed to increase in expression over time upon addition of chondrogenic 
factors. At day 35 comparison of expressions in the mineralizing conditions which had been 
switched 14 days previously was unchanged for Sox 9, cbfα-1/runx2 and alkaline 
phosphatase. There was a decrease in expression of collagen II and X upon the addition of 
phosphate, however this decrease was not observed in the osteogenic condition and in no 
instances was it significantly different from the chondrogenic condition (fig. 3). 
 In vitro, collagen II positive staining was found in chondrogenically differentiated pellets 
of all donors at day 35 (fig. 4A). Although they all showed positive staining, variation in 
stained area and intensity was high, ranging from a score of 57 to the maximum score of 
300. This variation was donor dependent. Collagen II expression was mainly seen in the 
center of the pellets (fig. 4B). 
 Collagen X expression was found in all patients at day 35. This expression was again 
donor dependent and only highly expressed in donor A who also produced more collagen II. 
Collagen X and II expressions were reduced in both conditions switched to mineralizing 
media (fig. 5).  
* 
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 Von Kossa staining showed calcium-phosphate depositions in pellets that were 
switched to phosphate-containing medium after being cultured on chondrogenic 
differentiation medium for 21 days. Mineralization was found in two out of three donors (A 
and B) in both the chondrogenic + phosphate switched condition and in the condition 
switched to osteogenic medium, with no mineralization observed in the chondrogenic 
condition. The mineralized area was found in the core of the pellet cultures and covered 
approximately half of the pellet area. Few viable cells were visible in the mineralized 
portions. In non-mineralized tissue this lack of cells was not seen. No difference was found 
between the chondrogenic condition containing BGP (culture medium 2) and the osteogenic 
condition (culture medium 3) (fig. 6).  
 When pellets were cultured on chondrogenic differentiation medium for 49 days 
collagen II and X further increased (data not shown). When cultures were switched after 35 
days on chondrogenic differentiation medium, the incidence and amount of mineralization 
was not different to those conditions switched after 21 days. Mineralization again occurred in 
two out of three donors.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Collagen X immunostaining and scoring of pellets. Staining of pellets for collagen X 
showed a similar pattern of expression to collagen II with a donor related variation in expression levels 
with decrease expression in the presence of a phosphate donor. Again sections were scored in triplicate 
with 3 pellets per donor (1 way ANOVA; *= significant difference from chondrogenic + phosphate and 
osteogenically switched conditions P<0.05). Representative images show collagen X expression in the 
chondrogenic condition following 35 days culture.  
* 
Chapter 7 
 
124 
 
Figure 6. Von Kossa staining of in-vitro cultured pellets. Culture of pellets for 35 days on 
chondrogenic medium resulted in no mineralization in any pellet form any donor as evidenced by the 
zero scores for the chondrogenic group. When a source of phosphate was added, mineralization was 
observed in all pellets in 2 of 3 donors with no difference between the chondrogenic + phosphate and 
osteogenic conditions. Despite the presence of cells within the pellets, donor C demonstrated no 
mineralization capability. Representative images of stained pellets show mineralization when phosphate 
was added to the chondrogenic medium (black stain). 
 
VEGF expression 
VEGF was present in medium of pellets on chondrogenic medium on day 14, 21 and 35 
except for one donor, which showed VEGF release at day 14 but little thereafter. This donor, 
Donor C also showed little collagen II and X expression and insufficient RNA was available 
for gene expression analysis. When pellets were switched to the culture medium containing 
BGP, independent of the presence of TGF-β2 or the concentration of dexamethasone, 
VEGF expression was considerably lower than the chondrogenic condition (fig. 7). Also, the 
conditions that were switched after 35 days of culture showed no reduced VEGF expression 
(data not shown). Although some variation between donors was found, the overall effect on 
VEGF production was the same. 
 
MMP-release 
Gelatin zymography demonstrated MMPs present in the culture medium collected at day 35 
from all cultured pellets. A steady increase in release from day 14 was also observed in the 
chondrogenic condition (data not shown). The two bands with high activity showed up 
around 62 kDa, and around 59 kDa. A third activity band was seen around 50 kDa. Analysis 
of culture medium collected from pellet cultures that were switched to phosphate containing 
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culture medium demonstrated far less activity at 62 kDa and no activity at 59 and 48 kDa, 
both at day 35 and day 49 (not shown) of culture (fig. 7B).  
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
Figure 7. Release of factors related to endochondral ossification. Release of VEGF from pellets 
was measured over time. As was seen with collagen II and collagen X, release of VEGF from pellets 
was abrogated following addition of a phosphate donor for 14 days after 21 days in chondrogenic 
medium (A). It is important to note that VEGF was released continuously until day 35 in the 
chondrogenic condition with almost no VEGF release 14 days after addition of BGP and pellet 
mineralization. VEGF levels at days 14 and 21 are for chondrogenic condition only (1 way ANOVA n=3 
per donor; *= significant difference from chondrogenic + phosphate and osteogenic conditions P<0.05). 
There was also a concomitant reduction in MMP release in these samples at day 35 suggestive of an 
inhibition of the remodeling processes associated with endochondral ossification (B). 
  
B 
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DISCUSSION 
 
In this article we assessed the possibility for in-vitro chondrogenically primed BMSC to offer 
a better repair option for bone tissue engineering approaches. In vivo we demonstrated 
improved cell survival following chondrogenic priming of BMSC in vitro, with significant blood 
vessel invasion after 4 weeks in vivo, although no bone formation was observed, possibly 
due to insufficient time allowed. We hypothesized that in-vitro priming of BMSC along the 
chondrogenic lineage would prompt the release of factors leading to tissue vascularization 
and bone formation in vivo. Here we demonstrate that mineralization of cartilage tissue can 
be induced in vitro but that this inhibits the angiogenic and remodeling properties of 
chondrogenically differentiated pellet cultures. Crucially, in a model of endochondral 
ossification we show that pellet cultures of chondrogenically differentiated BMSC express 
collagen II and collagen X, produce VEGF and increased amounts of MMPs and that all of 
these qualities are quickly reduced following mineralization in a model of endochondral 
ossification as was initially hypothesized. This might suggest that mineralized pellet cultures 
do not possess the same angiogenic and remodeling properties that can stimulate graft-host 
integration in vivo and that compared to chondrogenically differentiated pellet cultures the 
chance to obtain a bony union in bone defects might therefore be reduced. 
 Progressive production of collagen II and subsequent collagen X, suggests that 
differentiated BMSC in pellet culture resemble chondrogenic differentiation and hypertrophy, 
as seen in the growth plate during longitudinal growth. Lack of phosphate in the 
chondrogenic culture medium does however prevent further resemblance to endochondral 
ossification because the formation of calcium-phosphate depositions is inhibited. In order to 
examine if pellet cultures only need the presence of phosphate in the culture medium to 
mineralize the extracellular matrix or that they must be cultured in a more osteogenic with a 
lower concentration of dexamethasone and in the absence of TGF β, we evaluated the 
mineralization of chondrogenic differentiated pellet cultures that were switched after 21 days 
to these two phosphate containing culture media. 14 days after switching, abundant 
amounts of mineralization were seen in the core of the pellets at the same area as the 
cartilaginous tissue production was found, suggesting that this is indeed possible also in 
vitro given the correct signals and timing. Patterns of VEGF release, collagen expression 
and MMP release were similar between this condition and a standard osteogenic condition 
switched from chondrogenic culture at the same timepoint. The spatial production of 
collagen II, collagen X and mineralization as seen in subsequent sections suggests 
endochondral ossification had occurred. This is line with published data by Mueller and 
Tuan, however they observed the requirement for the removal of TGFβ for mineralization to 
occur (35). Gene expression of markers of chondrogenesis and hypertrophy/osteogenesis 
was also seen to increase over time as has been demonstrated in the past (33; 35; 196).  
VEGF, which is produced by hypertrophic chondrocytes, is known to have distinctive roles in 
endochondral ossification. First, it is an important mediator in angiogenesis. Blocking the 
activity of VEGF inhibits blood vessel formation in the hypertrophic zone (146). Furthermore, 
it has been shown that VEGF has chemoattractant effects on mesenchymal progenitor cells 
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and osteoblasts and influences osteoblast proliferation and differentiation (205; 206). Cells 
of the monocyte-macrophage lineage are also affected; chondroclasts are less present 
when VEGF activity is blocked (146; 207; 208). Analysis of VEGF on the culture medium of 
chondrogenically differentiated pellet cultures showed a considerable production of VEGF at 
14 days of culture. In two donors the expression remained stable during the five-week 
culture period. This suggests that these pellet cultures have potential to stimulate 
incorporation in vivo after transplantation. Most importantly, amounts of VEGF release 
appeared related to collagen II and X expression and were almost completely inhibited by 
matrix mineralization. This is very much in line with the in-vivo findings showing no 
vascularization of the osteogenically primed scaffolds and some vasculature connected to 
the host within the chondrogenically primed scaffolds. It will be important to elucidate the 
timing of these events in the future along with cell-death events to understand the role of cell 
death in this process. The type of cell death undergone by hypertrophic chondrocytes is a 
continuing debate (209; 210; 211) and warrants investigation, however it is beyond scope of 
this article.  
 To further evaluate the angiogenic and remodeling activities of the cell constructs we 
performed gelatin zymography to analyze the relative amounts of total MMPs released by 
the various pellets. In the conditioned medium of chondrogenically differentiated pellet 
cultures, three bands were found, one around 62 kDa, one around 59 kDa and a third 
around 50 kDa, the approximate weights of several MMPs including but not exclusively 
MMP-2, pro-MMP-13 and MMP-13 respectively. What is important to note is that many of 
these MMPs play an important role in the remodeling of the cartilaginous extracellular matrix 
during endochondral ossification by breaking down collagen 2 and non-collagenous matrix 
proteins such as aggrecan to allow vessel in-growth (192; 193; 194; 195; 212; 213). 
Reduced levels of MMPs in the mineralizing samples are in agreement with the in vivo 
findings where no blood vessel invasion was observed in the osteogenic condition. 
 It is clear that there was a large inter-donor variability in this study. We show relatively 
little variation within pellets from the same donors. Often in this research field donors are 
pre-screened and those that do not “perform” well are not included in experiments. We 
believe however it is just these donors who will most likely require treatment in the future 
and it is therefore relevant to examine how they respond to this type of stimulation and to 
present this data. Donor C produced collagen II and no collagen X and subsequently no 
VEGF. Having performed all experiments on multiple pellets of each donor we are confident 
of our results. From this data we conclude that chondrogenic priming of BMSCs will lead to 
increased VEGF release with a concomitant increase in blood-vessel invasion in vivo. 
Induction of mineralization in pellets or scaffolds prevents this release of VEGF and leads to 
inferior mineralized matrix production in vivo with no blood supply and non-viable cells. The 
poor performance of Donor C in all respects confirms that this is not simply a standard 
response of BMSC in pellet culture and that this approach requires further investigation and 
optimization. This is not the first article to illustrate large variation between donors. 
Scharstuhl et al (214) demonstrated as much as 1000 fold differences in expression of 
chondrogenic markers between patients and it is important not to overlook this variability 
Chapter 7 
 
128 
and to use it as a means to develop better treatments and approaches to regenerative 
medicine.  
 Also of interest is the better control of this process that could be garnered through 
further understanding of how it works. Endochondral ossification is tightly controlled by a 
host of intra and extracellular signaling molecules including but not exclusively, insulin like 
growth factors (IGF), members of the fibroblast growth factor (FGF) family and the Wnt 
signaling pathway. It is conceivable that tailored addition of growth factors or agonists at 
temporally distinct periods in the differentiation process could vastly improve the efficacy of 
such an approach, particularly for those donors that do not respond well to the standard 
cocktail of growth factors. This also would apply to attraction of vessels in vivo, determining 
the correct combination to lead to optimum vessel/osteoblast/osteoclast attraction upon 
implantation. 
 This study contributes to the view that chondrogenically differentiated pellet cultures of 
BMSC resembles endochondral ossification, the more so as we demonstrated that 
mineralization of the extracellular matrix can occur when a phosphate donor is present. 
More importantly we demonstrate for the first time the critical relationship between VEGF 
release, MMP release and matrix mineralization that can have huge effects on the success 
of implanted tissue engineered constructs. While we are aware of the limitations of using an 
immunocompromised animal in this model we felt it was important to assess the potential of 
human cells and this was the best model to do so. We demonstrate that induction of 
mineralization prior to transplantation might have severe effects on the angiogenic and 
remodeling properties, suggesting that transplantation of chondrogenically primed tissue at 
the correct stage of differentiation, and prior to mineralization, might prove much more 
successful than fully differentiated tissue. Finally we show that chondrogenically primed 
BMSC are capable of expressing the hypertrophic marker collagen X, attracting the host 
vasculature and surviving long term in vivo. While this pattern was observed in all samples, 
it should be noted that this was performed on commercially provided cells from a single 
donor. Our data suggest that determination of the optimal time of implantation of these 
primed cells, combined with a longer in vivo period, will lead to successful bone formation in 
vivo via the more common route of endochondral ossification. 
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Cartilage has a very poor capacity for regeneration in vivo. In otorhinolaryngology cartilage 
defects are usually reconstructed with autologous cartilage from for instance the external ear 
or the ribs. Cartilage tissue engineering may be a promising alternative to supply tissue for 
cartilage reconstructions in otorhinolaryngology as well as in plastic surgery and 
orthopaedics. Different cell sources could be used to tissue engineer cartilage. In this thesis 
we studied expanded chondrocytes and adult bone-marrow derived mesenchymal stem 
cells (BMSC). The aim of this thesis was to find new tools by which cartilage tissue 
engineering can be better controlled, focusing on the generation of cartilage that does not 
mineralize when implanted in vivo. We hypothesize that new insights to control cartilage 
tissue engineering can be gained by studying in-vivo chondrogenesis during embryonic 
development. 
 
In chapter 2 we evaluated the potential of culture-expanded auricular and nasoseptal 
chondrocytes as cell sources for generation of stable cartilage. Auricular chondrocytes 
produced larger cartilage-like constructs than nasoseptal chondrocytes. The matrix formed 
by auricular and nasoseptal chondrocytes contained collagen X, a marker for hypertrophic 
differentiation. However, the cartilage constructs did not mineralize in an in-vitro model, nor 
after in-vivo subcutaneous implantation for 6 weeks. Next, a DNA-microarray study on 
expanded auricular and nasoseptal was performed to analyze the differences in gene-
expression profile of expanded chondrocytes from these specific locations and revealed 
1090 differentially expressed genes. No difference was observed in the expression of known 
markers of chondrogenic capacity (e.g. collagen II, FGFR3, BMP2 and ALK1). The most 
striking differences were that the auricular chondrocytes had a higher expression of anabolic 
growth factors BMP5 and IGF1, while matrix-degrading enzymes MMP13 and ADAMTS5 
were higher expressed in nasoseptal chondrocytes. This might offer a possible explanation 
for the observed higher matrix production by auricular chondrocytes. Moreover, 
chondrocytes from different donor sites seemed to express specific molecular characteristics 
even after expansion. These specific molecular characteristics were not restricted to known 
characterization of donor-site subtype (e.g. elastic), but were also related to developmental 
processes. Therefore, our data indicate that using expanded chondrocytes from a donor-site 
that is not directly related to the host tissue, may result in cartilage with a different molecular 
character.  
 In the next chapters we focused on the potential of BMSC for cartilage tissue 
engineering. It is known that chondrogenically differentiated BMSC display signs of 
chondrocyte hypertrophy and mineralize in vivo (33). It has been said that this terminal 
differentiation and mineralization of BMSC resembles in-vivo endochondral ossification of 
the limbs. Therefore, in chapter 3 we compared embryonic chondrogenesis to in-vitro 
chondrogenic differentiation of BMSC. In both models three sequential stages were 
discriminated, condensation, differentiation, and hypertrophy, respectively characterized by 
N-cadherin, collagen II, and collagen X expression. However, a difference in these models is 
seen when the relative length of these stages is considered. For example while in embryonic 
development a differentiation stage is clearly discernable, in in-vitro chondrogenic pellet 
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cultures of BMSC almost no interval exists between production of collagen II and X. Next, 
we related the expression of different Fibroblast Growth Factor Receptors (FGFR) subtypes 
to the differentiation stage in in-vitro differentiation and in-vivo embryonic limb development. 
In both models FGFR2 is clearly expressed by cells in the condensation phase. No FGFR 
expression was observed in differentiating and mature hyaline chondrocytes, while 
hypertrophic chondrocytes stained strongly for all FGFR. To evaluate whether stage-specific 
modulation of chondrogenic differentiation in BMSC is possible with different subtypes of 
FGF, FGF2 and FGF9 were added to the chondrogenic medium during different stages in 
the culture process (early or late). In general, addition of FGF to the medium had a negative 
effect on chondrogenesis. However we did show that the effect of an FGF ligand is 
dependent upon the FGFR subtype to which it preferentially binds, thereby offering clues to 
subtype specific functions of FGFR. Moreover, we demonstrated that the effect of a growth 
factor depends on the stage in which it is added in the medium. This is in accordance with 
embryonic development. While FGF9 has an inhibitory effect when added throughout 
culture, or during hypertrophy, it does not have a negative effect when given during early 
differentiation and shows a trend towards stimulatory when given at the right time interval. 
Therefore, a more specific stimulation of FGFR2 activation during condensation may be 
interesting for cartilage tissue engineering. Since the effects of growth factors and 
modulation of intracellular signaling are mostly studied throughout culture, these results 
indicate that more attention to stage-specific effects may be warranted. 
 The concept of stage-specific modulation of chondrogenesis was continued in    
chapter 4. To induce chondrogenic differentiation of BMSC TGF-β is commonly used (31) 
and intracellular signaling of members of the TGF-β superfamily involves phosphorylation of 
Smads (104). Therefore we investigated the roles of Smad2/3 and Smad1/5/8 
phosphorylation in chondrogenic and hypertrophic differentiation and assessed whether 
specific targeting of the Smad signaling pathways offers possibilities to prevent terminal 
differentiation and mineralization of chondrogenically differentiated BMSC. First, we 
evaluated whether Smad2/3 and Smad1/5/8 pathways are phosphorylated in hypertrophic 
and hyaline cartilage. Terminally differentiated chondrocytes in cartilage produced in vitro by 
chondrogenic differentiation of BMSC or studied ex vivo during murine embryonic limb 
formation, stained positive for both Smad2/3P and Smad1/5/8P. On the other hand, hyaline-
like cartilage lacking expression for MMP13 and collagen X only expressed Smad2/3P. 
When either Smad2/3 or Smad1/5/8 phosphorylation was blocked by addition of SB-505124 
or dorsomorphin throughout culture, no collagen II expression was observed, indicating that 
both pathways are involved in early chondrogenesis. Distinct functions for these pathways 
were demonstrated when Smad signaling was blocked after the onset of chondrogenesis. 
Blocking Smad2/3P after the onset of chondrogenesis resulted in a halt in collagen II 
production. On the other hand, blocking Smad1/5/8P during this time period resulted in 
decreased expression of MMP13, collagen X and alkaline phosphatase while allowing 
collagen II production. Moreover, blocking Smad1/5/8P prevented mineralization. This 
indicates that while Smad2/3P is important for continuation of collagen II deposition, 
Smad1/5/8 phosphorylation is associated with terminal differentiation and mineralization. 
Summary 
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 Three mammalian subtypes of TGF-β (TGF-β1, TGF-β2 and TGF-β3) are commonly 
used to induce chondrogenic differentiation of BMSC in different laboratories (31; 35; 41; 
129). In our laboratory we are accustomed to use TGF- β2. In literature, results with one 
TGF-β subtype are often extrapolated to the other subtypes. As results in literature suggest 
that these subtypes actually may provoke certain subtype-specific activities, the choice of 
TGF-β subtype to induce chondrogenesis may attribute to contradictory results in different 
studies regarding chondrogenic differentiation of BMSC. Therefore, we compared the three 
TGF-β subtypes in chapter 5 for their capacity to induce chondrogenesis in BMSC, 
concentrating on the amount of produced cartilage as well as the degree of terminal 
differentiation and capacity to mineralize. Although no significant differences were found 
between TGF-β1, -β2 and -β3 cultured pellets in the quantity of cartilage production or in the 
expression of hypertrophic markers, the presence of mineralization was significantly higher 
when TGF-β3 was used, compared to TGF-β1. For future studies TGF-β1 is therefore 
preferred for use in cartilage tissue engineering. Since TGF-β3, and to a lesser extent TGF-
β2 show signs of matrix-mineralization, those subtypes might be better to tissue engineer 
bone through endochondral ossification. 
  Although the studies in chapter 4 demonstrated that blocking phosphorylation of 
Smad1/5/8 resulted in cartilage formation with reduction of hypertrophic markers, this did not 
reach the low level of stable chondrocytes. This was also the case for other recently 
published methods to inhibit terminal differentiation, through PTHrP (101; 102; 154) or 
blocking MMP13 (155). Therefore in chapter 6 we aimed to review the literature 
supplemented with own data to answer the question: Is it possible to generate stable hyaline 
cartilage from adult mesenchymal stem cells? First, we characterized terminal differentiation 
more precisely as a gradual progression of chondrogenic differentiation towards cartilage 
that can mineralize. As expression of hypertrophic markers almost overlaps with the onset of 
chondrogenesis, the hypertrophic phenotype may be predetermined when chondrogenic 
differentiation is still in its early stages in current culture conditions. These current culture 
conditions, and the rationale of inhibiting terminal differentiation, are derived from a 
traditional view that development of hyaline cartilage is nothing more than chondrocytes 
failing to go through endochondral ossification. However, chondrocytes in the growth plate 
are destined to become terminally differentiated and it therefore may not be the model of 
choice to study hyaline cartilage formation. Embryonic development of the interzone suggest 
that to develop stable cartilage a subtle balance of chondrogenic stimulating as well as 
inhibiting signal is required, starting from the initial prechondrogenic differentiation. For 
cartilage tissue engineering this may mean that inhibiting terminal differentiation may not 
result in stable hyaline cartilage, if the right balance of signals has not been created from the 
start of culture on. 
 While the terminal differentiation and mineralization seen in chondrogenically 
differentiated BMSC is negative for cartilage tissue engineering, it may offer a new route to 
engineer bone. Often  BMSC are in vitro stimulated toward the osteogenic lineage, thereby 
aiming at intramembranous bone formation (183). However, results of this approach have 
been disappointing due to core degradation and necrosis of the construct as a result of lack 
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of vascularization (184). Therefore, in chapter 7 we studied the possibility of tissue 
engineering bone through endochondral ossification as an alternative approach. Scaffolds 
seeded with BMSC were cultured in vitro on either osteogenic or chondrogenic medium 
before they were implanted in a nude mouse, and survival and osteogenesis in vivo were 
evaluated. Scaffolds that were pre-cultured on chondrogenic culture medium showed 
collagen type II and collagen type X production after implantation. Moreover, vessel in 
growth was observed. In contrast, scaffolds that were osteogenically pre-cultured 
demonstrated a mineralized matrix of poor quality, with few surviving cells and no 
vascularization. This process was further characterized in vitro using pellet cultures. Pellets 
cultured in chondrogenic medium showed progressive production of collagen type II and 
collagen type X, so a hypertrophic cartilage construct was formed. Moreover, in the culture 
medium VEGF release and MMP activity were observed, two factors that are known to be 
important for the induction of vascularization of the matrix. We therefore conclude that 
chondrogenically differentiated BMSC produce hypertrophic cartilage that supplies 
vascularization stimulating factors, which may be essential to prevent core degradation and 
necrosis of the tissue-engineered construct. These data suggest that optimizing the 
hypertrophic differentiation of BMSCs may further improve vessel invasion in bioengineered 
constructs and longer implantation may lead to viable bone turnover of the hypertrophic 
cartilage construct. 
 
Concluding, in this thesis we have demonstrated that expanded auricular and nasoseptal 
chondrocytes produce cartilage that does not mineralize, and therefore offer great promise 
for clinical application in cartilage tissue engineering. In contrast, chondrogenically 
differentiated BMSC become terminally differentiated and mineralize. While this offers a new 
route to tissue engineer bone, it is disadvantageous for cartilage tissue engineering as 
stable cartilage is essential for clinical cartilage reconstructions. The chondrogenic 
differentiation of BMSC is a multi-stage process (condensation, differentiation and 
hypertrophy) that resembles endochondral ossification during embryology. Therefore, a 
stage-specific modulation of chondrogenic differentiation seems a promising way to control 
cartilage formation by BMSC. However, current concepts to control chondrogenic 
differentiation of BMSC have arisen from developmental research of the growth plate. Since 
chondrocytes in the growth plate are destined to become terminally differentiated, it may not 
be the model of choice to study hyaline cartilage formation. Embryonic development of the 
interzone suggest that to develop stable cartilage a subtle balance of chondrogenic 
stimulating as well as inhibiting signals is required, starting from the initial prechondrogenic 
differentiation. For cartilage tissue engineering this may mean that inhibiting terminal 
differentiation may not result in stable hyaline cartilage, if the right balance of signals has not 
been created from the start of culture on. 
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Embryology as a model for tissue-engineering  
Formation of cartilage is only seen during embryonic development (215). The rationale of 
comparing tissue engineering and embryonic development is that these processes may 
involve similar pathways, and that understanding these common pathways may lead to 
advances in tissue engineering. Therefore we compared differentiation of BMSC with 
embryonic endochondral ossification of the limbs in chapter 3 and 4. When trying to relate 
the in-vitro differentiation of BMSCs to embryonic chondrogenesis, it is important to take into 
account the fundamental differences in these models. Most importantly, chondrogenically 
differentiating cells in the embryonic limb bud get signals from other cell types surrounding 
these cells, such as in the future perichondrium and the loose mesenchyme (4), whereas 
BMSC get signals mainly from components added in the medium. The signals to these cells 
are hugely complex and not only involve growth factors such as TGF-β and FGF, but include 
pathways such as BMP, IHh, PTHrP, Wnt/ β-catenin (4). In this thesis we have compared 
these models to obtain more knowledge about the FGF and TGF-β pathways to enhance the 
tissue engineering process to better control chondrogenic differentiation.  
Stage-specific modulation of chondrogenesis 
The effects of growth factors and modulation of intracellular signaling are mostly studied 
throughout culture. We have demonstrated in chapter 3 and 4 that more attention to stage-
specific effects may lead to a better control over chondrogenesis. In a recent paper by 
Lenas et al (216), the model of “developmental engineering” was put forward. Instead of 
investigating empirically by trying various combinations of tools leading to a perpetual cycle 
of trial-and-error attempts, a rational methodology should be followed based on a 
fundamental understanding of tissue development. An important concept in “developmental 
engineering” is that the multistage character of developmental processes allows high 
observability and controllability. In-vitro processes composed of distinct sequential steps that 
are characterized by markers expressed in a specific stage allow the possibility to intervene 
with additional factors to direct the cells at the appropriate stages. This thesis has made a 
first attempt to define chondrogenic differentiation of BMSC as a gradual progression of 
steps in need of specific stimuli.  
 
Expanded auricular and nasoseptal chondrocytes for cartilage tissue engineering 
In this thesis we have demonstrated that both expanded auricular and nasoseptal 
chondrocytes produce cartilage that is stable and does not mineralize in vivo (chapter 2) in 
contrast to BMSCs (chapter 3-7). Moreover, while a huge inter-donor variability is seen in 
chondrogenic capacity of BMSC, in our experience chondrocytes (and especially auricular 
chondrocytes) seem to be more predictable and have less donor variability. Thus, although 
BMSC are generally considered a popular cell source for tissue engineering, in the near 
future chondrocytes seem to be a more likely cell source for successful clinical application of 
cartilage tissue engineering than BMSCs.  
 Although tissue-engineered cartilage constructs from auricular and nasoseptal 
chondrocytes are stable and do not mineralize, both cells sources produce a collagen X rich 
matrix indicating a progression towards terminal differentiation. This may be due to 
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progenitor cells in the cambium layer of the perichondrium (6; 8; 28). Still, no mineralization 
was observed after 6 weeks subcutaneous implantation. Another study on rabbit 
chondrocytes (20) did demonstrate mineralization after 10 weeks of implantation. These 
contradictory result may be explained by the different sites of implantation. Tissue-
engineered constructs were implanted in the trachea of rabbits in that study, while we 
implanted the cartilage constructs ectopically in the subcutis of the back of nude mice. 
Ectopic implantation in the back is often performed in similar studies (33; 34; 55) with small 
animals, such as nude mice, but may influence the stability of the construct. The 
subcutaneous fat tissue of the back is completely sterile and not highly vascularized. In 
contrast, the region of the head and neck is highly vascularized and the tissue aligning the 
airways has a high immune activity to protect it from the exterior. The combination of these 
factors in the head and neck region may cause a more active reaction to a tissue-
engineered cartilage construct, leading to for instance mineralization or resorption of the 
construct (21; 23). Therefore, more research is warranted on long-term stability upon 
implantation of the cartilage construct derived from human chondrocytes in specific 
orthotopic locations such as the trachea, nose or auricle. 
 Auricular chondrocytes especially seem attractive for translation to clinical practice, as 
these chondrocytes seem to produce more cartilage-like matrix (chapter 2). Furthermore, 
auricular cartilage can be harvested in a minimally invasive procedure. A higher cartilage-
matrix production in auricular chondrocytes was also seen in previous studies (50; 51). 
Nevertheless, our study is the first to directly compare auricular and nasoseptal 
chondrocytes from the same human donors. What is more, our microarray study did offer a 
possible explanation for the observed higher matrix production by auricular chondrocytes, as 
anabolic growth factors BMP5 and IGF1, were significantly higher expressed in auricular 
chondrocytes while matrix degradation enzymes MMP13 and ADAMTS5 were expressed 
significantly higher in nasoseptal chondrocytes. These data also highlight the importance in 
tissue-engineering of not only adding needed growth factors or signaling molecules to the 
culture medium, but the need to increase knowledge of and to control cellular behavior and 
production of signaling molecules by the cells themselves. The importance of these 
endogenously produced factors for cartilage tissue engineering should be further studied.  
 Even after extended expansion chondrocytes seem to retain some characteristics of 
their native donor site (chapter 2). This was indicated by elastin production in vivo and gene 
expression of Fibrillin 2 and elastin by auricular chondrocytes as well as more subtle 
differences in gene expression between auricular and nasoseptal chondrocytes mostly in the 
field of developmental processes. Therefore, using expanded chondrocytes from a donor-
site that is not directly related to the host tissue, may result in cartilage regeneration of a 
different molecular character. This does not seem to be a vital clinical problem, as it is 
common practice in head and neck surgery to use hyaline costal cartilage for auricular 
reconstructions (217) or auricular elastic cartilage to repair hyaline cartilage defects of the 
nose (14). However, more knowledge about the differential developmental processes of the 
different cartilage subtypes may reveal clues to tissue engineer cartilage with a more 
specific character adapted to local circumstances, such as mechanical characteristics or the 
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presence of elastin, that may improve long-term results. This may prove to be essential 
especially in paediatric patients, as long-term functionality as well as further development 
and adaptation of the cartilage construct may be important during growth.  
 The function of elastin is to maintain shape and flexibility of the cartilage matrix, for 
instance in the auricle (218). Currently, auricular reconstruction is a multistep procedure 
using costal hyaline cartilage lacking elastin (217). These procedures result in somewhat 
unsatisfactory results, but this may be due to the fact that fully matured cartilage is used and 
formed into shape and may not be caused by the lack of elastin. We were not able to tissue 
engineer cartilage constructs in vitro from auricular chondrocytes that contained elastin. 
However, upon 6 weeks of in-vivo implantation elastin was produced and thus the cartilage 
was transformed in elastic cartilage. Nevertheless, whether presence of elastin is necessary 
to create a cartilage construct that is suitable for reconstruction of for instance auricular 
cartilage is not known. Perhaps, before attempting to tissue engineer cartilage of a specific 
molecular phenotype more knowledge is warranted on the characteristics and mechanical 
properties, and demands, of the original cartilage in the transplant site. For instance, in case 
of auricular reconstruction one should know which characteristics of the auricular cartilage 
are essential to make it both aesthetically acceptable as well as functional in the day-to-day 
use. 
 Before translation to the clinic, research in this field should be focused on generating 
cartilage of a sufficient size and form to be adequate for reconstruction. It is likely that 
scaffolds will be necessary to achieve this, as is discussed later on in this chapter. 
Moreover, the cartilage construct should have sufficient mechanical properties. Large animal 
studies focusing on reconstruction of nasal, auricular or tracheal defects with tissue-
engineered cartilage seem feasible on the short term.  
 In conclusion, especially auricular chondrocytes have great potential for cartilage tissue 
engineering as these cells produce abundant cartilage matrix, the cartilage construct is 
stable and does not mineralize, and the cells can be harvested with minimally invasive 
techniques. Although upon expansion the cells retain characteristics of their donor-site, 
clinically this may not be relevant and tissue-engineered auricular cartilage constructs may 
be used without difficulties for cartilage reconstruction elsewhere in the body.  
 
BMSC for cartilage tissue engineering 
In chapter 6 we have discussed the significance and problems associated with the terminal 
differentiation of chondrogenically differentiated BMSCs, making these cells not appropriate 
for clinical application of cartilage tissue engineering in the near future. In this thesis we 
have described two methods (addition of  dorsomorphin or PTHrP) to inhibit terminal 
differentiation of BMSCs. Especially dorsomorphin led to a significant reduction of a large 
variety of hypertrophic markers. In contrast to other studies on inhibition of terminal 
differentiation of BMSC (101; 102; 154; 155), in this thesis we compared gene expression of 
BMSCs with stable hyaline cartilage produced by articular chondrocytes. Because of this 
comparison, we consider the significant reduction of hypertrophic markers as promising but 
insufficient as it did not reach the low level of stable hyaline cartilage produced by articular 
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chondrocytes. Nevertheless the inhibiting effect of dorsomorphin on terminal differentiation 
as well as mineralization, by inhibiting Smad1/5/8 phosphorylation, seems to indicate an 
important role of this TGF-β signaling pathway. Perhaps by targeting this pathway more 
upstream, the specific ALK receptors that bind to TGF-β rather than the intra-cellular Smad 
signaling molecules, the signal can be balanced more subtle and a better control over 
terminal differentiation of BMSC can be attained. Another approach to inhibit terminal 
differentiation of BMSCs could be to affect different pathways simultaneously, for instance 
combining addition of PTHrP and dorsomorphin. Still, one must keep in mind that although a 
reduction in mineralization was observed in the presence of the inhibitor in vitro, that the 
inhibition of terminal differentiation may be only temporarily during the presence of the 
inhibitor. The cartilage construct may become terminally differentiated and mineralized when 
implanted in vivo without the inhibitor. As a consequence, for future studies on inhibition of 
terminal differentiation and mineralization of BMSC long-term in-vivo experiments are 
essential.  
 We have seen in chapter 5 that although the choice of TGF-β subtype did not have a 
clear effect on collagen X or VEGF, significantly less matrix mineralization was seen in the 
presence of TGF-β1 than TGF-β3. However, this was tested in our in vitro mineralization 
model, and should be repeated in in-vivo experiments. Still, this suggests that subtle 
differences in TGF-β subtype specific signaling pathways may play a role in terminal 
differentiation and mineralization. Therefore, gaining more insight into these TGF- β  
subtype-specific signaling pathways may reveal clues to inhibit terminal differentiation and 
mineralization. 
 We have demonstrated in chapter 6 that terminal differentiation is a gradual 
progression of chondrogenic differentiation towards cartilage that can mineralize, and is thus 
best characterized with a set of markers indicative of this gradual progression. As 
expression of hypertrophic markers almost overlaps with the onset of chondrogenesis, the 
hypertrophic phenotype may be predetermined when chondrogenic differentiation is still in 
its early stages in current culture conditions. These current culture conditions, and the 
rationale of inhibiting terminal differentiation, are derived from a traditional view that 
development of hyaline cartilage is nothing more than chondrocytes failing to go through 
endochondral ossification (5; 39; 173). However, chondrocytes in the growth plate are 
destined to become terminally differentiated and it therefore may not be the model of choice 
to study hyaline cartilage formation. Embryonic development of the interzone (174) suggest 
that to develop stable cartilage a subtle balance of chondrogenic stimulating as well as 
inhibiting signal is required, starting from the initial prechondrogenic differentiation. For 
cartilage tissue engineering this may mean that inhibiting terminal differentiation may not 
result in stable hyaline cartilage, if the right balance of signals has not been created from the 
start of culture on. 
 Therefore, clinical application in head and neck surgery of cartilage tissue engineering 
with BMSC seems to be out of reach in the near future. Instead, it looks as if the research 
field should go back to the beginning; what determines the hyaline or hypertrophic 
chondrogenic faith of undifferentiated stem cells during early development. Unless a better 
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control over chondrogenic differentiation of BMSC is achieved and a long-term stable 
cartilage construct can be guaranteed, clinical application of tissue-engineered cartilage 
constructs from BMSC is not recommended in head and neck surgery.  
 
BMSC for bone tissue engineering 
This inclination of BMSC to become terminally differentiated can be advantageous for bone 
tissue-engineering by generating bone through the endochondral route in contrast to direct 
intramembranous bone formation. Clinically, autologous bone grafts are frequently used to 
heal large bone defect but this has some major disadvantages (219). First, it requires the 
generation of a second surgical site with significant donor site morbidity. Secondly, the 
availability of autologous bone is limited (219). For this reason, a huge interest has emerged 
to generate autologous bone through tissue engineering. In contrast to bone, cartilage can 
survive in a defect area without direct connection to a vasculature. Additionally, hypertrophic 
cartilage produces growth factors to stimulates the in growth of new blood vessels (4). 
Therefore, taking advantage of the tendency of BMSCs to become terminally differentiated 
to generate bone via the endochondral route, seems a more promising approach than 
inducing BMSC directly into the bone lineage. This leads to a potential clinical approach for 
bone replacement by inducing BMSCs to form a hypertrophic cartilage construct in vitro 
which upon implantation in vivo is transformed into bone. 
 We have seen in chapter 7 that the tissue-engineered hypertrophic cartilage indeed 
excretes VEGF and active MMP, both important to induce vascularization. Moreover, 
significant vessel formation was observed after 4 weeks in-vivo implantation. However, no 
mineralization or bone formation was observed, possibly because of insufficient time allowed 
in vivo to remodel. Therefore, further experiments were warranted to optimize the in-vitro 
differentiation of BMSC and study the most favorable timing to implant the tissue-engineered 
constructs to generate bone in vivo through endochondral ossification. Indeed, additional 
experiments performed by our research group have demonstrated that prolonging the 
implantation period not only resulted in mineralization of the hypertrophic cartilage construct 
but that the construct was truly transformed into bone, including bone marrow (220). This 
endochondral ossification of in-vivo implanted hypertrophic cartilage constructs was also 
demonstrated in studies from other research groups using BMSC from human (221) or 
murine (222; 223) origin. The in-vitro terminal differentiation of BMSC could perhaps be 
further enhanced. For instance, in chapter 7 we have used TGF-β2 while we have observed 
in chapter 5 that TGF-β3 induces cartilage formation that is driven more towards 
endochondral ossification. A role may also be played in this fashion by FGF9, by stimulating 
matrix remodeling upon implantation as we have seen in chapter 3. Furthermore, future 
experiments should be conducted to increase the size of the tissue-engineered constructs 
as this is necessary for clinical application.  
 After optimization of the culture protocol, a large animal model could be used to test 
safety and efficacy of this novel clinical approach to tissue engineer autologous bone. Next, 
a clinical trial seems feasible on patients that have intra-oral defects that need bone 
reconstruction to allow dental implant placement. This defect is the perfect candidate to test 
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the tissue engineered constructs since it is, although challenging, small in size and because 
a biopsy is part of the routine procedure to generate space to place the implant. This allows 
histological evaluation of the newly formed tissue.  
 In conclusion, the hypertrophic differentiation of chondrogenically differentiated BMSC 
is generally considered as a problem for cartilage tissue engineering in this thesis. However, 
the hypertrophic cartilage that is the product of the current chondrogenic culture conditions 
for BMSC may actually be the optimal construct for bone tissue engineering. Although 
optimization of the current procedure is advisable, the clinical application of bone tissue 
engineering via endochondral ossification and the chondrogenic differentiation of BMSC 
seems feasible in the near future. 
 
Important general issues for clinical translation of tissue-engineering 
 
Inter-donor variability 
In the experiments throughout this thesis we encountered a problem with inter-donor 
variability with BMSC, while only little variation was seen within pellets from the same donor. 
Furthermore, when BMSCs are used from the same donor in a later experiment, even when 
used in another passage number, the chondrogenic capacity is predictable in our 
experience. Inter-donor variability is often seen in other research groups as well (41; 224). In 
fact, often in this research field, donors are pre-screened and those that do not ‘‘perform’’ 
well are not included in the experiments. However, this poses a huge problem for further 
advances in tissue engineering and especially in clinical application as results from patient 
to patient may differ due to the chondrogenic capacity of their BMSCs. Moreover, the 
chondrogenic capacity cannot be predicted from for instance age, osteoarthritis etiology, 
BMSC yield or cell size (41). Therefore, further studies are necessary to understand and 
control inter-donor variability in chondrogenic differentiation potential.  
 Perhaps the condensation phase may play a role in inter-donor variability as the size of 
the condensation determines the size of the cartilage template (225). In embryology the 
mesenchymal condensation results from an active cell movement towards the centre of the 
outgrowing limb bud and is characterized by expression of adhesion molecules, such as N-
cadherin (38; 225). In fact, during limb development functional N-cadherin is required for 
normal mesenchymal  condensation to occur, as well as chondrogenesis, and its expression 
should be strictly regulated in both a quantitatively and temporally specific manner (38). 
Although we did not see an evident difference in immunohistochemical staining for N-
cadherin during condensation between donors with different chondrogenic differentiation 
capacity (unpublished data), we have seen that FGFR2  is expressed during condensation 
and that addition of FGF9 (with a high binding affinity for FGFR2) during early differentiation 
results in a somewhat increased matrix production. As FGFR2 was indicated as a positive 
regulator in embryonic chondrogenesis, by influencing the size of the cartilage templates 
(96) it may indicate that a more precise control over FGF signaling may lead to more control 
over and predictability of cartilage formation by BMSC of different donors. Moreover, 
addition of FGF2 during expansion not only increased the proliferation rate but also delayed 
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loss of chondrogenic potential upon expansion (44). Therefore, the role of intrinsic FGF 
signaling in inter-donor variability and the interactions between TGF-β and FGF signaling 
would be interesting to study.  
 
External control and observation of differentiation process 
This thesis has made a first attempt to define chondrogenic differentiation of BMSCs as a 
gradual progression of steps in need of specific stimuli. However, for this approach to tissue-
engineering it is essential to know during culturing how far the cells have progressed into 
their differentiation and thus which stimuli should be added. For the experiments in this 
thesis we decided beforehand at which time-intervals we would add certain growth factors or 
inhibitors, but did encounter differing results in outcome due to variability in the progress of 
differentiation of the BMSC from different donors. Therefore, more research is warranted to 
study markers, for instance in the medium, that can be used during culturing to define the 
progress of differentiation. BMSC during differentiation produce all kinds of endogenous 
signals, some of which are secreted in the medium. More knowledge of stage-specific 
production of these proteins may lead to a method in which one can predict during culturing 
from a sample of the medium how far the BMSC have progressed in their differentiation and 
thus which exogenous factors should be added. This would enhance the possibilities of 
stage-specific modulation of chondrogenic differentiation of BMSC and enable the concept 
of “developmental engineering” that was put forward by Lenas et al (216) and discussed 
earlier in this chapter.  
 
Use of scaffold material 
Traditionally tissue engineering is performed using bio-degradable scaffolds.  However, the 
well-vascularized subcutaneous transplant site in head and neck surgery in combination of 
the high immune activity of the airways induces the risk of a strong inflammatory response to 
the scaffold and resorption of the construct (21). Indeed, in the head and neck region the 
use of (degradable) scaffolds to create a tissue-engineered cartilage construct has proved 
unsuccessful (23; 24). Therefore we have performed most of the experiments in this thesis 
without the use of scaffolds. However, for clinical application this means that one should 
tissue engineer a cartilage construct in vitro consisting of only cells and their ECM that has 
sufficient mechanical properties to perform its function from the moment of implantation on. 
In addition, creating a cartilage construct in a specific predefined shape and form (such as 
for regeneration of the auricle) could be facilitated by using a scaffold. Therefore, more 
research is warranted for cartilage tissue engineering in the head and neck region to design 
a flexible scaffold, that can be shaped into a prespecified form with long-term durability and 
that does not induce an inflammatory response. One must keep in mind for further studies 
that the potential benefits and limitations of a scaffold may depend on the site of 
transplantation. 
 Recently, clinical application of a tissue-engineered trachea in a 30 year old woman 
with end-stage bronchomalacia has made headlines (47). For this approach a decellularized 
trachea was used from a human donor as a scaffold and seeded with BMSC-derived 
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autologous chondrocytes externally and autologous epithelial cells internally. Research on 
pigs has demonstrated that this decellularized cartilage matrix is not sufficient on its own to 
reconstruct the matrix and that autologous cells are necessary for optimal graft survival 
(226). Although there were no clinical (47), immunological, or histological (226) signs of 
rejection despite the lack of immune suppression, this tissue-engineering approach relies on 
a allograft material as a scaffold. Therefore, patients reserving such transplants should be 
critically monitored and long-term follow-up is required before this approach can be 
implemented on a larger scale. 
 
Regulatory and ethical issues  
Strict regulation of any emerging biotechnology is required to protect patients. Until recently, 
medical products were regulated in the European Union either as medicinal products (such 
as drugs), or medical devices (such as pacemakers). Tissue-engineered products fell 
between these two categories. Therefore a new class of medicinal products has been 
defined in 2007: Advanced Therapy Medicinal Products (ATMP).  
 To ensure safety and efficacy the production of tissue engineered products for clinical 
application requires good manufacturing practice (GMP)-protocols focusing on for instance 
sterility, identity and purity. Therefore, it is important already in the current not-clinical 
research setting to start to develop rapid in-process characterization and controls of the 
product and to aim at reproducibility of the tissue-engineering process. Another requirement 
for ATMP is absolute traceability, not only of the original cells and the end product but also 
of all the substances that have come in contact with the cell during the manufacturing 
procedure.  
 Characterization of the cells and the end-product is especially important since 
pluripotent cell theoretically have the risk of ectopic differentiation or tumor production. 
Although with adult stem cells this appears not to be a problem in animal models, the human 
situation is more complex and may be different and the long-term effects of tissue-
engineered products in humans are not yet known (227). For example, tumor formation may 
be more likely in patients that become immunodeficient in the long run. 
 In this thesis cartilage tissue engineering was studied from the perspective of future 
autologous application of the cells. In this approach the delay from harvesting of the stem 
cells to the implantation of the tissue may become an issue. As a consequence a broad 
interest has emerged in tissue engineering of-the-shelve products derived form allogenic 
stem cells (227). Moreover, the use of characterized allogenic stem cells would facilitate 
regulatory issues as described above and improve reproducibility and traceability. However, 
although it has been reported that some populations of stem cells have a low 
immunogenicity (228), it seems that differentiated cells display all the immunogenic 
characteristics of the cells in question, thereby inducing a potential immune reaction to a 
tissue-engineered allogenic off-the-shelve product (227).  
 An important hurdle in clinical translation of cartilage tissue engineering is the use of 
animal-derived components. For the experiments in this thesis chondrocytes and BMSC 
were expanded in fetal calf serum. This is routinely done nowadays, even for clinical 
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applications. However, fetal calf serum is prone for transmission of viral and prion related 
material and could also theoretically cause an immune response (229). Therefore, new rules 
and guidelines ATMPs have stated that xenogeny product free cultures are preferred. A 
good alternative in clinical application may be the use of autologous serum derived from 
peripheral blood. Although it has been demonstrated that autologous serum is not inferior to 
fetal calf serum (229), a minimum concentration of 10% is needed (230; 231). As a 
consequence, the use of autologous serum seems feasible only in a clinical setting where 
low numbers of BMSC are needed. When vast numbers of BMSC are needed, such as to 
tissue engineer a cartilage construct for reconstruction, in current protocols large amounts of 
culture media are needed and sufficiently large volumes of peripheral blood cannot be 
obtained from the patient. Furthermore, serum is a complex natural product that may vary 
from individual to individual thereby introducing an unpredictable variable in the culturing 
process (169). The same is true for the application of platelet-rich plasma (PRP) to the 
culture system (232). Therefore further research on defining optimal culture conditions, 
preferably serum-free, is necessary for clinical application of BMSC.  
 With respect to the ethics of tissue engineering, it has been suggested that one can 
roughly distinguish two perspectives (233). On the one hand, this technology could be 
considered morally good because it mimics nature. On the other hand, tissue engineering 
could be considered morally dangerous because it defies nature; bodies or organs 
constructed in the laboratory are seen as unnatural. Nevertheless, tissue engineering with 
BMSC or chondrocytes does not evoke the same ethical concerns as with embryonic stem 
cells. Generally there seems to be no discussion in the media about so-called adult stem 
cells, since the potential benefit appears to be very high and the utilization of the patient's 
own cells poses no serious ethical conflict (234). Still two issues remain to be discussed. 
First,  animal experimentation seems necessary for future development and clinical 
translation of tissue engineering to study safety and efficacy of the procedure before clinical 
trials. Then again, research with (adult) stem cells may lead to organotypic models that may 
be able to replace animal models in some areas of research. Secondly, the development of 
tissue engineering techniques requires tremendous funding and potential future clinical 
applications will most probably be expensive. This may cause a serious public debate, 
especially when not-lifesaving or esthetical procedures are considered.  
 There is no doubt that numerous scientific developments have transformed our lives in 
a way that would have been unthinkable of just a century ago. Whether tissue engineering 
research will have the same impact as other scientific achievements cannot be foreseen, but 
the promise seems so great that it seems wise to consider seriously how best to proceed 
research in a manner that is perceptive to any ethical objections. 
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Kraakbeen heeft een unieke weefselopbouw in die zin dat het geen zenuwen, bloed- of 
lymfevaten bevat en slechts uit één celsoort bestaat: de kraakbeencel oftewel chondrocyt. 
Kraakbeencellen maken in totaal slechts 1-5% van het kraakbeen uit, omdat ze zijn ingebed 
in een grote hoeveelheid tussenstof of extracellulaire matrix (ECM). Deze extracellulaire 
matrix wordt door de kraakbeencellen wordt geproduceerd en bepaalt de eigenschappen 
van kraakbeen. Een belangrijk eiwit in deze extracellulaire matrix is collageen II; het geeft 
het kraakbeen zijn trekkracht geeft. Proteoglycanen, hydrofiele moleculen die water 
aantrekken in de matrix, zorgen voor de drukkracht van kraakbeen. Op basis van de 
moleculaire compositie van deze extracellulaire matrix wordt kraakbeen klassiek ingedeeld 
in 3 subtypes: hyalien (gewricht, neus), elastisch (oorschelp, strottenklepje) en fibreus 
(meniscus, tussenwervelschijven). Een vierde subtype kraakbeen kan ook gedefinieerd 
worden, hoewel het bestaan hiervan tijdelijk is: hypertroof of terminaal gedifferentieerd 
kraakbeen. Dit type kraakbeen is als het ware een tussenstation in een proces dat 
endochondrale verbening wordt genoemd; hierbij wordt kraakbeen omgezet in bot, 
bijvoorbeeld in de groeischijf. Alle lange beenderen in ons lichaam worden op deze manier 
gevormd tijdens de embryologie. Hierbij wordt aanvankelijk kraakbeen gemaakt, waarna de 
kraakbeencellen zich verder differentiëren (doorontwikkelen) tot hypertrofe kraakbeencellen. 
Hypertrofe kraakbeencellen produceren andere eiwitten (collageen X, VEGF en MMP13) 
dan gewone kraakbeencellen. Dat leidt tot mineralisatie, ingroei van bloedvaten en 
uiteindelijk tot de omzetting van het kraakbeen in bot. 
 Kraakbeen wordt in principe alleen tijdens de embryologie gevormd en het kan zich in 
het lichaam niet herstellen of regenereren. Kraakbenige defecten worden in de keel-, neus-, 
en oorheelkunde (KNO) daarom gereconstrueerd met lichaamseigen oftewel autoloog 
kraakbeen. Zo kan een neus gereconstrueerd worden met kraakbeen uit de oorschelp, of 
wordt een nieuwe oorschelp gemaakt met behulp van ribkraakbeen. Maar zeker bij grote of 
herhaalde ingrepen is de beschikbaarheid van autoloog kraakbeen beperkt. Tissue-
engineering van autoloog kraakbeen, oftewel het in een laboratorium maken van kraakbeen 
van lichaamseigen cellen, zou daarvoor een goed alternatief kunnen zijn.  
 Verschillende cellen kunnen hiervoor gebruikt worden. De meest voor de hand 
liggende keuze is de kraakbeencel zelf. Nadat deze cellen uit het kraakbeen worden 
geïsoleerd, bijvoorbeeld uit de neus of het oor, kunnen ze in het laboratorium gestimuleerd 
worden om zich te vermeerderen (expanderen) totdat een voldoende groot celaantal wordt 
bereikt. Deze geëxpandeerde chondrocyten hebben echter hun kraakbenige eigenschappen 
verloren en kunnen geen goede kraakbenige extracellulaire matrix meer produceren. 
Daarom moeten ze eerst opnieuw worden gestimuleerd (bijvoorbeeld met groeifactoren) om 
te redifferentiëren, om met andere woorden opnieuw “echte” kraakbeencellen te worden.  
 Een andere celsoort die gebruikt kan worden voor het tissue-engineering van 
kraakbeen is de volwassen stamcel die uit verschillende weefsels kan worden geïsoleerd. 
Omdat deze cellen geoogst kunnen worden zonder een (nieuw) kraakbenig defect te maken 
en omdat zij zeer uitgebreid kunnen expanderen worden volwassen stamcellen als een zeer 
veelbelovende celsoort voor tissue-engineering gezien. Ten behoeve van dit proefschrift 
werden uit het beenmerg geïsoleerde volwassen mesenchymale stam cellen (BMSC) 
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bestudeerd. Bij de start van dit promotie onderzoek was reeds bekend hoe deze cellen 
gestimuleerd konden worden om kraakbeen te maken. Echter, het kraakbeen dat hierbij 
gevormd wordt is van het hypertrofe subtype en mineraliseert wanneer het in het lichaam 
wordt geïmplanteerd, waardoor het niet geschikt is voor kraakbenige reconstructies.  
 Het doel van het onderzoek was om meer controle te krijgen over het proces van 
kraakbeen tissue-engineering met als uiteindelijk doel het maken van hyalien kraakbeen dat 
niet mineraliseert wanneer het in het lichaam wordt geïmplanteerd. De achterliggende 
gedachte van dit promotie onderzoek is dat door bestudering van de ontwikkeling van 
kraakbeen in de embryologie, nieuwe inzichten verkregen kunnen worden die leiden tot 
meer controle over kraakbeen tissue-engineering.      
 
In hoofdstuk 2 wordt het onderzoek beschreven naar het gebruik van geëxpandeerde oor- 
en neuskraakbeencellen voor kraakbeen tissue-engineering. Zowel oor- als 
neuskraakbeencellen produceerden kraakbeen met collageen X, een teken van hypertrofie. 
Hoewel hypertrofie van kraakbeen kan leiden tot mineralisatie en verbening van het 
kraakbeen, mineraliseerden de verkregen kraakbenige constructen van oor- en 
neuskraakbeencellen niet. Dit werd getest in een in-vitro model en door de constructen in-
vivo in een muis te implanteren. Vervolgens werd een zogenoemde “DNA-microarray” 
uitgevoerd op beide celsoorten. Hierbij kunnen genen tegelijkertijd worden bestudeerd en 
wordt gemeten welke actief tot expressie komen. Dit geeft aan welke processen in de cel 
actief zijn. Door genen te bestuderen die significant verschillend tot expressie komen tussen 
oor- en neuskraakbeencellen komen we meer te weten over het fundamentele verschil 
tussen deze cellen. Er bleek geen verschil te zijn in expressie van genen waarvan reeds 
bekend was dat ze bepalen hoe goed een cel kraakbeen kan maken (collageen II, FGFR3, 
BMP2, ALK1). Desondanks viel wel iets anders op dat kan verklaren waarom 
oorkraakbeencellen meer kraakbeen kan maken dan neuskraakbeencellen. In 
oorkraakbeencellen is namelijk meer activiteit van de genen voor BMP5 en IGF1, 
groeifactoren met een stimulerende werking op kraakbeen, en minder activiteit van de 
genen voor MMP13 en ADAMTS5, enzymen die juist kraakbeen afbreken. Verder bleek dat 
ook geëxpandeerde chondrocyten, die de mogelijkheid kwijt zijn om uit zichzelf kraakbeen te 
maken, toch nog veel karakteristieken te hebben behouden van het kraakbenige subtype 
waaruit ze ooit zijn geoogst. Dit betekent dat wanneer voor het kweken van kraakbeen 
geëxpandeerde kraakbeencellen worden gebruikt van een donor-site van een ander 
kraakbenig subtype, het gekweekte kraakbeen ook moleculair zal verschillen van het 
kraakbeen wat gereconstrueerd moet worden. 
 In de volgende hoofdstukken is het onderzoek gericht op de uit het beenmerg 
geïsoleerde volwassen mesenchymale stamcellen (BMSC). Zoals eerder gezegd was reeds 
bekend dat in de huidige kraakbenige kweekprotocollen deze stamcellen hypertroof 
kraakbeen vormen en dat dit kraakbeen na implantatie in het lichaam mineraliseert. Dit 
proces van hypertrofie en mineralisatie van volwassen stamcellen wordt in de literatuur ook 
wel vergeleken met het proces van embryonale endochondrale verbening van de ledematen 
waarin hypertroof kraakbeen wordt omgezet in bot. Daarom worden in hoofdstuk 3 deze 
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processen met elkaar vergeleken. In beide processen bleken drie achtereenvolgende stadia 
van kraakbeenontwikkeling aangetoond te kunnen worden: condensatie, differentiatie en 
hypertrofie. Vervolgens werd gekeken naar de aanwezigheid van de 3 verschillende 
subtypen fibroblast groei factor receptoren (FGFR). Deze receptoren op de celmembraan 
kunnen geactiveerd worden door groeifactoren waarna ze bepaalde processen in de cel 
aansturen. Juist deze FGFR werden bestudeerd, omdat bekend is dat mutaties in de 
onderliggende genen kunnen zorgen voor ernstige afwijkingen in de endochondrale 
verbening van de lange beenderen, wat kan leiden tot o.a. dwerggroei. Er bleek in beide 
processen een duidelijke stadiumspecifieke expressie van deze receptoren te zijn. 
Stimulering met groeifactoren van deze verschillende receptoren  bleek in het algemeen een 
negatief effect te hebben op kraakbeenvorming van volwassen stamcellen. Het effect was 
echter wel afhankelijk van het subtype receptor dat werd gestimuleerd en in welke fase 
(condensatie, differentiatie of hypertrofie) dit precies gebeurde. Echter, een meer specifieke 
stimulatie van alleen FGFR2 beperkt tot de condensatiefase zou zelfs mogelijk stimulerend 
kunnen zijn voor de kraakbeenproductie. Hoewel men in tissue-engineering gewend is het 
effect van een stof gedurende de hele kweek te bestuderen, lijken de resultaten uit deze 
studie aan te tonen dat een meer stadiumspecifieke benadering aandacht behoeft omdat het 
de kans op succes vergroot. 
  In hoofdstuk 4 hebben we deze stadiumspecifieke benadering daarom voortgezet. Dit 
keer werd het effect van TGF-β bestudeerd, de groeifactor die wordt gebruikt om volwassen 
stamcellen te stimuleren tot kraakbeenproductie. TGF- β kan via twee verschillende signaal-
routes de cel stimuleren. In deze studie werd aangetoond dat in hyalien kraakbeen de 
signalering beperkt blijft tot de Smad2/3 route, terwijl in hypertroof kraakbeen signalering 
plaatsvindt via zowel de Smad2/3 als de Smad1/5/8 route. Door stadiumspecifiek de 
Smad2/3 en Smad1/5/8 route te remmen, kwamen we tot de conclusie dat beide routes in 
de vroege kraakbeenontwikkeling noodzakelijk zijn. In de late kraakbeenontwikkeling bleken 
deze routes echter verschillende functies te hebben. Door Smad2/3 te remmen werd 
verdere kraakbeenproductie geremd. Door Smad1/5/8 te remmen in de late 
kraakbeenontwikkeling werd de hypertrofie van volwassen stamcellen onderdrukt en werd er 
wel een kraakbenige extracellulaire matrix werd geproduceerd. Bovendien bleek ook dat de 
mineralisatie werd geremd in een in-vitro model.  
 Er bestaan 3 verschillende subtypes van TGF-β (TGF-β1, TGF-β2 and TGF-β3). Zoals 
eerder vermeld wordt TGF-β gebruikt om volwassen stamcellen te stimuleren tot 
kraakbeenvorming. In verschillende laboratoria worden echter verschillende subtypes 
gebruikt. Bovendien wordt in de literatuur vaak geen onderscheid gemaakt tussen deze 
subtypes wanneer resultaten van verschillende studies worden vergeleken. Daarom worden 
in hoofstuk 5 de verschillende TGF-β subtypes direct met elkaar vergeleken, waarbij de 
hoeveelheid kraakbeenproductie en de mate van hypertrofie en mineralisatie onderzocht 
werd. De keuze voor TGF-β subtype bleek niet bepalend voor de hoeveelheid 
kraakbeenproductie en er werd geen verschil gezien in de expressie van hypertrofie 
markers. Er werd wel een verschil gezien in de mate van mineralisatie; toediening van TGF-
β1 leidde tot significant minder mineralisatie dan TGF-β3. Daarom lijkt voor verdere 
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experimenten TGF-β1 het meest geschikt voor tissue-engineering van kraakbeen, terwijl 
TGF-β3 meer geschikt is voor tissue-engineering van bot. 
 In hoofdstuk 6 wordt een uitgebreide literatuurstudie beschreven, aangevuld met 
eigen data, om de vraag te beantwoorden of het sowieso mogelijk is om stabiel hyalien 
kraakbeen te maken uit volwassen stamcellen. Allereerst werd onderzoek gedaan naar 
hypertrofie en werd gezien dat dit in feite een gradueel proces is waarin kraakbeen zich in 
verschillende stappen ontwikkelt tot kraakbeen dat kan mineraliseren. In de huidige 
kraakbenige kweekprotocollen van volwassen stamcellen worden hypertrofie markers al 
gemeten voordat kraakbeenproductie heeft plaatsgevonden. Dit zou kunnen betekenen dat 
de uiteindelijke hypertrofie van volwassen stamcellen al in een zeer vroege fase wordt 
bepaald. De huidige kweekprotocollen en de methodes om hypertrofie te remmen komen 
voort uit kennis van endochondrale verbening van de lange beenderen. Het lot van deze 
kraakbeencellen is echter hypertrofie  en mineralisatie. Daarom lijkt dit minder geschikt om 
de ontwikkeling van hyalien kraakbeen te bestuderen. Onderzoek naar de embryonale 
ontwikkeling van hyalien gewrichtskraakbeen laat zien dat al in een zeer vroege fase een 
subtiele balans nodig is van stimulerende en remmende factoren. Voor kraakbeen tissue-
engineering zou dit kunnen betekenen dat het remmen van hypertrofie niet voldoende is om 
hyalien kraakbeen te maken, wanneer niet vanaf het begin van de kweek de juiste balans 
aan signalen wordt gegeven.  
 Hoewel de hypertrofie en daarmee de endochondrale verbening van volwassen 
stamcellen als nadelig wordt gezien in kraakbeen onderzoek, zou dit een alternatieve 
methode kunnen zijn om bot te maken. Bij bot tissue-engineering worden volwassen 
stamcellen in het algemeen direct gestimuleerd tot botvorming (intramembraneuze 
botvorming). Echter, in tegenstelling tot kraakbeen heeft bot behoefte aan bloedvoorziening 
en de resultaten van bot tissue-engineering zijn hierdoor teleurstellend. In hoofdstuk 7 
hebben we daarom bestudeerd of het mogelijk is om bot te maken van volwassen 
stamcellen via endochondrale verbening. Dit zou kunnen leiden tot een nieuwe aanpak van 
bot tissue-engineering, waarbij hypertroof kraakbeen in het lab gevormd wordt, wat 
vervolgens in het lichaam wordt geïmplanteerd waar het ter plaatse op een natuurlijke 
manier wordt omgezet tot bot. In tegenstelling tot de volwassen stamcellen die direct tot bot 
werden gestimuleerd, produceerden de stamcellen die kraakbenig werden gestimuleerd 
verschillende moleculen die stimulerend zijn voor de vorming van bloedvaten. Volwassen 
stamcellen die direct tot bot werden gestimuleerd vormden een gemineraliseerd construct, 
echter de cellen in het construct overleefden implantatie in een muis niet. Volwassen 
stamcellen die kraakbenig werden gestimuleerd vormden hypertroof kraakbeen dat na 
implantatie in een muis vitaal bleef en waarin bloedvaten werden gezien. Er werd geen 
mineralisatie of botvorming in deze constructen gezien, waarschijnlijk omdat het kraakbeen 
niet voldoende lang geïmplanteerd was. Deze gegevens laten echter wel zien dat hypertroof 
kraakbeen gevormd uit volwassen stamcellen in-vivo bloedvaten aantrekt waardoor het 
beter kan overleven. Inmiddels heeft vervolgonderzoek van onze onderzoeksgroep 
aangetoond dat langere in-vivo implantatie leidt tot daadwerkelijke omzetting van dit 
kraakbeen in bot.  
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Conclusie 
In dit proefschrift wordt aangetoond dat geëxpandeerde oor- en neuskraakbeencellen 
kraakbeen vormen dat niet mineraliseert. Daarom zijn deze cellen veelbelovend voor de 
klinische toepassing van kraakbeen tissue-engineering. Dit in tegenstelling tot volwassen 
stamcellen die hypertroof kraakbeen maken dat na implantatie mineraliseert. Hoewel dit kan 
leiden tot een nieuwe aanpak voor tissue-engineering van bot, is de resulterende hypertrofie 
nadelig voor kraakbeen tissue-engineering. De kraakbeenontwikkeling van volwassen 
stamcellen verloopt via verschillende stadia (condensatie, differentiatie en hypertrofie) en 
lijkt op endochondrale verbening van de ledematen tijdens de embryologie. Daarom is een 
stadiumspecifieke benadering nodig om meer controle te krijgen over de kraakbeenvorming 
van volwassen stamcellen. De huidige kweekprotocollen en methodes om hypertrofie te 
remmen komen voort uit kennis van de ontwikkeling van de lange beenderen. Maar het lot 
van deze kraakbeencellen is hypertrofie en mineralisatie. Daarom lijkt dit eigenlijk geen 
geschikt model om de ontwikkeling van hyalien kraakbeen te bestuderen. Onderzoek naar 
de embryonale ontwikkeling van hyalien gewrichtskaakbeen laat zien dat al in een zeer 
vroege fase een subtiele balans nodig is van stimulerende en remmende factoren. Voor 
kraakbeen tissue-engineering zou dit kunnen betekenen dat het remmen van hypertrofie niet 
voldoende is om hyalien kraakbeen te maken, indien niet vanaf het begin van de kweek de 
juiste balans aan signalen wordt gegeven.  
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om te broeden op een geniale inval, of juist een duwtje in de rug. In elk geval heb je mij altijd 
weten te stimuleren er net nog iets extra’s uit te halen en door te gaan. Bedankt voor je 
enthousiasme en je steun in de afgelopen jaren! 
 
Alle co-auteurs wil ik bedanken voor een productieve en plezierige samenwerking. In het 
bijzonder wil ik noemen Peter van der Kraan, Esmeralda Blaney Davidson, Dorothy Frenz 
en Eugène Verwiel. Daarnaast wil ik alle KNO-artsen, orthopeden en plastisch chirurgen 
bedanken voor hun essentiële bijdrage aan mijn boekje met kraakbeen en beenmerg. 
 
Prof. dr. Verwoerd en mw. Verwoerd, bedankt voor uw interesse in en enthousiasme voor 
mijn promotie onderzoek. Al heeft het (nog) niet tot een publicatie geleid, samen achter de 
microscoop naar embryo’s kijken heeft mij niet alleen een beter inzicht gegeven in de 
ontwikkeling en anatomie van het KNO gebied, maar was ook zeer belangrijk als 
achtergrond voor mijn onderzoek naar tissue engineering. 
  
Collega’s van de kliniek en het lab: bedankt voor alle gezelligheid en goede samenwerking 
over de jaren heen. 
 
Froukje en Inez, ik heb enorm geboft dat ik twee studenten mocht begeleiden die zo 
enthousiast en hardwerkend waren! Jullie mogen trots zijn op de publicaties die zijn 
voortgevloeid uit jullie wetenschapsstage. Geen wonder dat jullie inmiddels zelf een 
promotieplek hebben gevonden en het zal niet lang meer duren voor jullie in mijn schoenen 
staan! 
 
Wendy, jouw bijdrage aan dit boekje is enorm en je naam staat niet voor niets op elke 
publicatie! Kweken met jou was niet alleen altijd gezellig, maar leidde ook steeds tot 
hernieuwd enthousiasme in het onderzoek. Wij hebben dit onderzoek samen verricht, en ik 
zal me een stuk geruster voelen met jou naast me wanneer ik dit proefschrift zal verdedigen.  
 
Dankwoord 
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Karin, bedankt voor de prachtige omslag! Wat fijn dat jij naast mij zal staan op deze 
bijzondere dag. Ik weet dat wij als “Las Catharinas” namelijk elk avontuur aankunnen!  
 
Susanne, lieve Suus, bedankt voor je hulp om deze dag echt tot een feest te maken! 
 
Lieve Guus, wat bof ik met jou in mijn leven! 
 
Lieve oma, bedankt dat jij en opa ons hebben laten opgroeien met het vertrouwen dat we 
alles kunnen bereiken waar we ons hoofd toe zetten! 
 
Lieve pap en mam, bedankt voor jullie onuitputtelijke liefde, steun en vertrouwen! 
 
 
 
Als je vrienden aanvoelen als familie en je familie je beste vrienden zijn, dan heb je 
een zeer rijk leven. Bedankt dat jullie er altijd voor me zijn! 
 
 
  
 
